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 i 
Abstract 
Non-competitive antagonists of the glutamate N-methyl-D-aspartate receptor 
(NMDAR) induce a broad range of schizophrenia-like symptoms in humans. 
Consequently hypothesis has emerged suggesting that glutamate or NMDAR 
hypofunction may occur in schizophrenia. The NMDAR is localised at dendritic spines 
of neurons and is embedded in a multi-protein complex called the post-synaptic 
density (PSD). The biochemical composition of the postsynaptic membrane and the 
structure of dendritic spines are continuously modulated by glutamatergic synaptic 
activity. The activity-dependent interaction between glutamate receptors and proteins 
of the PSD stimulate intracellular signalling pathways underlying learning and memory 
processes. These may be disturbed in schizophrenia.  
In the present study we hypothesised that molecules of the PSD may be disturbed in 
expression in the premotor cortex of patients with schizophrenia. Postmortem 
premotor cortex from patients with schizophrenia, major depressive disorder, bipolar 
disorder and healthy controls were processed for PSD extraction and purification. 
Protein expression of the PSD fraction was assessed using co-immunoprecipitation (co-
IP) and Western blotting (WB) methods. The expression of NMDAR subunit NR2A, PSD-
95, Ca2+/calmodulin-dependent protein kinase II subunit β (CaMKIIβ) and truncated 
isoform of the tropomyosin receptor kinase type B (TrkB-T1) were significantly reduced 
in schizophrenia. A significant decrease in the expression of NR2A was also observed in 
patients with major depressive disorder relative to controls. 
A decrease in the abundance of key PSD proteins in schizophrenia provides strong 
evidence that PSD function and possibly synaptic plasticity may be disturbed in the 
premotor cortex in the disease. There may also be more subtle disturbances in PSD 
function in major depressive disorder. 
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1.1 Schizophrenia 
Schizophrenia is a grave psychiatric disorder of thought and sense of self, which 
generally appears soon after adolescence. Because of its early onset, schizophrenia 
poses a great burden on emotional, social and economic aspects within a society. 
Furthermore, deficiencies in sociability during the illness lead to earlier death by 
natural causes (poor diet, little exercise, obesity, and smoking) or by suicide (van Os 
and Kapur, 2009). The prevalence of this illness is approximately one percent of the 
world population and its incidence is higher in men (McGrath, 2006). This disease of 
the brain is known to affect emotional behaviours to a higher degree than mood 
disorders. Furthermore, although cognitive functions such as memory, language and 
attention are affected to a lesser degree than in dementia, they are still severely 
disabling in affected individuals. 
 
 
Figure 1-1: Environmental factors and associated genes risk hypothesis for the aetiology of 
schizophrenia. Taken from (Horváth and Mirnics, 2009). 
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In contrast to neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease or Huntington’s disease, characteristic pathological hallmarks for schizophrenia 
have not been established. Multiple factors seem to be at the origin of this complex 
illness. The most probable hypothesis is that individuals carrying a genetic vulnerability 
develop schizophrenia according to environmental factors (see Figure 1-1). 
Schizophrenia has a significant genetic component since the heritability of 
schizophrenia reaches up to 80% among monozygotic twins (Sullivan et al., 2003). The 
environmental factors implicated in the aetiology of schizophrenia include abuse of 
drugs such as amphetamine, LSD (lyserge saüre diäthylamid) or cannabinoids, which 
can induce similar symptoms as those found in schizophrenia and constitute to risk 
(Demily and Thibaut, 2008). Furthermore, numerous studies have shown that more 
schizophrenic patients are born during the winter-spring months (Torrey et al., 1997), 
which may be due to infection or nutritional deficiencies. Other retrospective studies 
have found a link between obstetric complications such as bleeding, congenital 
malformation, or asphyxia and the development of schizophrenia in offspring (Cannon 
and Clarke, 2005). 
 
1.1.1 Symptoms 
The term schizophrenia (schizo: “to split”; phrenia: “though”) was introduced by Eugen 
Bleuler in the article entitled “Dementia praecox or the group of schizophrenias” in 
Aschaffenburg’s Handbook of Psychiatry of 1911 (Stotz-Ingenlath, 2000). For Bleuler, 
Kraepelin’s “dementia praecox” designation was not appropriate for patients showing 
split personality as a first symptom (Tandon et al., 2009). However, Bleuler did not 
consider delusions and hallucinations which are now currently admitted as principal 
features of the disease. Although this appellation continues to be used to date, 
progress in diagnosis and description of the illness seem to lead to a new definition of 
schizophrenia. In Japan schizophrenia has already be renamed “integration-
dysregulation syndrome” (van Os and Kapur, 2009). 
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Currently the diagnosis of schizophrenia is carried out by psychiatrists using either ICD-
10 or DSM-IV-TR criteria (Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision). Diagnosis is based on the concomitant occurrence of at least 
two of the following symptoms each one representing a significant position of time 
within a six month period: delusions, hallucinations, disorganized speech, excessively 
disorganized behaviour, and the negative symptoms (American psychiatric Association, 
2000). Symptoms can be broadly separated into three categories: positive, negative 
and cognitive symptoms (see Table 1-1). Positive symptoms, also called psychotic 
symptoms, include delusions, hallucinations, disorganized speech and disorganized 
behaviour. The deficit symptoms currently defined as negative symptoms include 
blunted emotion, anergia, alogia, poor sociability and anhedonia. The cognitive 
symptoms in schizophrenia are in particular related to disorders of abstraction, 
attention, working memory, language and executive functions (Frankle et al., 2003). 
 
Table 1-1: Symptoms of schizophrenia are categorized into three broad subgroups: positive, 
negative, and cognitive symptoms. 
Positive symptoms Negative symptoms Cognitive symptoms 
Hallucinations 
Delusions 
Disorganised speech 
Disorganised behaviour 
Alogia 
Anhedonia 
Poor sociability 
Psychomotor poverty 
Blunted emotions 
Disturbances in: 
Abstraction 
Memory 
Attention 
Language 
Executive functions 
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The loss of contact with reality is characteristic of the positive symptoms. These 
implicate high brain functions and manifest as abnormalities in perception (auditory 
hallucinations), inferential thinking (delusions), language (disorganised speech) and 
behavioural monitoring and control (disorganised behaviour), in which normal brain 
functions are disturbed or exacerbated (Andreasen, 2000). Functional magnetic 
resonance imaging (fMRI) studies have shown that frontal cortex areas such as inferior 
frontal gyri, including the Broca’s language region, are activated during hallucinations 
in schizophrenic patients. Furthermore, other cortical structures such as ventral 
striatum, the auditory cortex, the right posterior temporal lobe, and the cingulate 
cortex are also implicated (Raij et al., 2009). 
In contrast to the episodic feature of positive symptoms, longitudinal stability 
characterises negative symptoms of schizophrenia which are present during as well as 
between episodes of positive symptom exacerbation. The definition of these 
symptoms is the absence or diminution of normal behaviours and functions which lead 
to alogia (literally “without speech”), anhedonia (literally “without pleasure”), poor 
sociability, psychomotor poverty and blunted emotions (Buchanan, 2007). Functional 
imaging studies have led to the identification of particular cerebral regions implicated 
in negative symptoms. These studies showed a decrease in activity of the prefrontal 
cortex and parietal cortex while activity was increased in the caudate nuclei bilaterally 
characterising psychomotor poverty (Liddle, 1996). 
Contrary to positive and negative symptoms, cognitive disturbances are not incuded as 
part of the criteria to establish schizophrenia diagnosis. However, these symptoms are 
integrally part of the illness and are found in 94% of schizophrenic patients (Waldo et 
al., 1994). Neuropsychological studies of cognitive symptoms highlighted dysfunction 
in capacity of abstraction, memory, attention, language and executive functions 
(Kurachi, 2003). Frontal lobe dysfunction and deficits in cognitive function are 
evaluated using neuropsychological test such as Wisconsin Card Sorting Test which 
assesses executive functions and the Stroop test which measure attention during tasks 
with distraction interferences (Goldberg and Bougakov, 2005). Furthermore, a 
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quantitative meta-analysis of functional imaging studies showed a correlation between 
decreased activation of the dorsolateral/ventrolateral prefrontal cortex and 
impairments in episodic memory tasks in affected individuals (Ragland et al., 2009). 
 
1.1.2 Treatments 
At the beginning of the 20th century, the use of barbiturates, coma by insulin injection, 
electro-convulsive therapy and frontal leucotomy were used as treatments for 
schizophrenia. In the mid fifties, a synthesized compound, chlorpromazine, initially 
utilised for anaesthesia and surgery was identified as a dopamine receptor antagonist 
and gave rise to the pharmaceutical management of schizophrenia (Stip, 2002). Since 
that time, numerous types of antipsychotics have been developed. Chlorpromazine 
and haloperidol are classed as “typical” antipsychotics, while clozapine and quetiapine, 
the second generation of antipsychotic, are termed “atypical” by contrast to “typical” 
antipsychotics which induce movement disorder side-effects. The use of animals 
treated with Phencyclidine (PCP) or Ketamine as a model of schizophrenia have led to 
a better understanding of mechanisms of action and side effects of these compounds. 
Chlorpromazine, the first compound qualified as antipsychotic, was used to treat 
schizophrenia in the late 1970s. Its introduction led to deinstitutionalization of 
psychiatric patients and their social reinsertion, reducing at the same time the stigma 
associated with schizophrenia (López-Muñoz et al., 2005). In addition, during the same 
period another compound named haloperidol was synthesized. Used to treat 
schizophrenia, this compound showed a great effect on positive symptoms of the 
disease, particularly on hallucinations and delusions (Granger and Albu, 2005). 
However, from the first clinical trials, it was obvious that both chlorpromazine and 
haloperidol induced extrapyramidal side effects, characterized by tardive dyskinesia, 
parkinsonism, dystonias and akathisia (Shen, 1999). These side effects have been 
attributed as result of D2 dopamine receptor blockade in the basal ganglia (Kuperberg 
et al., 2002). 
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The second generation of antipsychotics termed “atypical” are represented by 
clozapine. This compound showed a decreased effect on the dopamine D2 compared 
to older antipsychotics, and instead affected other neuroreceptors, such as dopamine 
D1, histamine H1, serotonin 5-HT2 and muscarinic M1 receptors. Studies 
demonstrated a better efficacy of clozapine and a diminution of extrapyramidal side 
effects relative to chlorpromazine and haloperidol treatment. Furthermore, clinical 
trials highlighted that some negative symptoms were ameliorated in schizophrenic 
patients treated with clozapine (Kapur and Mamo, 2003). However, in spite of the 
beneficial effects of these compounds on positive and negative symptoms of 
schizophrenia, their exact mechanisms of action remain speculative. A newer second 
generation of “atypical” antipsychotics is represented by drugs such as olanzapine, 
quetiapine, risperidone and amisulpride. These compounds have equal or better 
efficacy than clozapine on acute schizophrenia, on positive and negative symptoms 
and induce less motor side-effects. For instance, olanzapine enhance benefit for 
psychosis and negative symptoms with very few extrapyramidal side effects. However, 
this compound induces other side effects such as weight gain and, in some patients, 
hyperlipidaemia, hyperglycaemia and diabetes (Lambert and Castle, 2003). 
Nevertheless, the second generation of “atypical” antipsychotics is now widely used to 
treat schizophrenia. Moreover, studies have shown that these new drugs reduce 
suicide attempts among patients affected by schizophrenia compared to haloperidol-
treated patients (Meltzer and Okayli, 1995; Glazer and Dickson, 1998). 
Mood stabilisers and antidepressants drugs are often added to the treatment regime 
for schizophrenia patients to prevent affective syndromes, such as mania, 
characterised by period excitement and agitation, and depression which occur 
commonly during the course of illness. Studies have demonstrated that the co-
administration of antidepressants and mood stabilisers such as imipramine and lithium 
respectively lead to improvements of depressive symptoms (Escamilla, 2001). Mood 
stabilizers and antidepressants such as sodium valproate and benzodiazepines are 
usually used to treat schizophrenic patients with anxiety and sleep disturbance. 
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However, the fact that mood symptoms appear generally after typical and atypical 
antipsychotic drugs treatment and not in all patients suggest that optimisation of 
antipsychotic treatment should be attempted instead of multiple drugs treatment 
(Levinson et al., 1999). 
“Typical” antipsychotics are effective only for positive symptoms, whilst “atypical” 
antipsychotics show efficacy for both positive and negative symptoms. Both types of 
antipsychotic have various side effects and can lead to secondary symptoms such as 
depression. Also, these drugs do not have efficacy for treating cognitive symptoms of 
schizophrenia. New strategies of treatment are needed to treat all symptoms of the 
disease and avoid drugs side effects. Two projects, the Measurement and Treatment 
Research to Improve Cognition in Schizophrenia (MATRICS) and the Treatment Units 
for Research on Neurocognition and Schizophrenia (TURNS), were setup respectively 
for the discovery and validity of new therapeutic targets. The MATRICS project, 
involved in the research of new targets highlighted cholinergic, dopaminergic, and 
glutamatergic systems as potentially effective to treat cognitive symptoms of 
schizophrenia. These findings led to the development of cholinergic, dopaminergic, 
and glutamatergic drugs which are currently in early stages of pharmacological and 
pharmaceutical testing (Buchanan et al., 2007). 
 
1.2 Pathophysiology of schizophrenia 
1.2.1 Genes involved in schizophrenia 
Evidence for the genetic aetiological component of schizophrenia comes from results 
of numerous family, twin, and adoption studies. These studies showed that disease risk 
is dramatically increased among the relatives of schizophrenic patients. More recent 
studies have demonstrated that the heritability of schizophrenia reaches 41 to 65% in 
monozygotic twins, and 0 to 28% in dizygotic twins. Although these results highlight a 
high heritability of the illness in twins, environmental factors remain implicated due to 
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a broadly heritability (85%) inferior to 100% (Cardno and Gottesman, 2000). 
Association studies implicate several loci in schizophrenia, such as 6p24–22, 1q21–22, 
13q32–34, 8p21–22, 6q16–25, 22q11–12, 5q21–q33, 10p15–p11, and 1q42, including 
neuregulin (NRG1), dysbindin (DTNBP1), disrupted in schizophrenia (DISC1), D-amino 
acid oxydase activator DAOA (G72), D-amino acid oxydase (DAO), metabotropic 
Glutamate Receptor 3 (GluR3) and regulator G protein signaling 4 (RGS4) genes 
(Craddock et al., 2005). Most of these genes encode proteins acting at the 
glutamatergic synapse (see Figure 1-2). 
 
 
Figure 1-2: The glutamate synapse and associated susceptibility genes in schizophrenia. 
 
Evidence for a disturbance in the genes coding for subunits of the NMDA receptor in 
schizophrenia is equivocal (Kristiansen et al., 2007a). However, evidence is stronger for 
dysbindin which is present at the synaptic bouton of glutamate synapses and 
modulates vesicular glutamate release (Numakawa et al., 2004). This protein is widely 
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expressed in the human brain and seems to play an important part in cognitive 
function and memory (Owen et al., 2004). Postmortem studies suggest that dysbindin 
concentrations are reduced in schizophrenic patient brains (Weickert et al., 2004), in 
particular in the prefrontal cortex and the hippocampus (Talbot et al., 2004). Straub et 
al. 2002 showed, using a family-based association analysis, that SNPs within the 
DTNBP1 gene (locus 6p22.3) were strongly implicated in schizophrenia (Straub et al., 
2002). Another genetic study demonstrated that haplotype variation of DTNBP1 was 
associated with negative symptoms of schizophrenia, this finding led the authors to 
suggest that dysbindin was implicated in mechanisms that give rise to negative 
symptoms via a glutamate receptor activity (DeRosse et al., 2006).  
Other proteins present at the glutamate synapse such as NRG1 and its receptor V-erb-
a erythroblastic leukemia viral oncogene homolog 4 (ErbB4) have also been shown to 
be associated with schizophrenia in many studies (Petryshen et al., 2005). Genetic 
studies have shown that several haplotypes of NRG1 are associated with schizophrenia 
particularly on glutamatergic synapses (Stefansson et al., 2002). Concerning the ERBB4 
gene, a study identified 3 SNPs in exon 3 associated with schizophrenia, and using RT-
PCR, showed that ERBB4 isoforms were increased in patients affected by the illness. 
 At the post-synaptic level of glutamatergic synapse, activation of the G-coupled 
receptor mGluR3 (GRM3) is known to result in decreased glutamate release into the 
synapse and was identified as a potential genetic risk factor for schizophrenia (Fujii et 
al., 2003). Also, the RGS4 protein which negatively controls the Gi/o subunits and Gq of 
the G-coupled receptor was implied in genetic studies as a likely candidate gene in 
schizophrenia (Ding and Hegde, 2009). Association and linkage studies showed that 4 
SNPs within RGS4 gene were linked to schizophrenia (Morris et al., 2004). 
Glycine and D-serine released from unsheathing astrocytes, are NMDA receptor 
activators via the co-agonist binding site. D-serine is synthesised from L-serine in local 
astrocytes via the action of serine racemase. Another enzyme, DAOA, which degrade 
D-serine has been associated with the risk of schizophrenia in several studies (Corvin et 
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al., 2007). Moreover, serine racemase, has also been implicated in schizophrenia 
(Morita et al., 2007). Meta-analysis studies have demonstrated that two loci 13q32-
q33 and 22q11 were associated with schizophrenia (Badner and Gershon, 2002), and in 
postmortem dorsolateral prefrontal cortex samples DAOA was found over-expressed 
in patients with schizophrenia (Korostishevsky et al., 2006). 
 
1.2.2 Brain regions involved in schizophrenia 
Evidence from neuropsychological, post-mortem and neuroimaging studies suggest 
that symptoms of schizophrenia arise from neuro-physiological disturbances in all 
major brain areas and neuronal circuits. These observations are in concordance with 
multiple different forms and symptoms of schizophrenia. Concerning structural brain 
changes, the most consistent findings from post-mortem and imaging studies are an 
enlargement of lateral ventricular size, a loss of grey matter and a reduction in brain 
volume, all potentially leading to a cortical surface mis-folding. Considering circuit 
abnormalities, studies implicate and involvement of circuits between the prefrontal 
cortex, basal ganglia, thalamus, hippocampus and medial temporal lobe in patients 
with schizophrenia (Fallon et al., 2003). Although many different cerebral structures 
are involved in the pathology of schizophrenia, the prefrontal cortex (PFC) and the 
temporal lobe seem to be particularly implicated in the disease (Kawada et al., 2009). 
The prefrontal cortex play a critical role in complex functions of the brain, such as 
planning, attention, language, working memory and emotion. It can be divided into 
dorsal, dorsolateral, lateral, orbital and parietal prefrontal cortices, which are all 
connected with sub-cortical areas. The dorsolateral prefrontal (DLPFC) cortex has been 
widely studied. This part of the PFC is known to be associated with working memory, 
which is disturbed in patients with schizophrenia. Recently, a study showed, using 
cognitive tests and magnetic resonance imaging (MRI), a correlation between reduced 
DLPFC volume and executive functions impairment in patients with schizophrenia 
(Kawada et al., 2009). Furthermore, the importance of PFC function during memory 
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tasks was demonstrated in a study using the Wisconsin Card Sorting Test and positron 
emission tomography (PET) in schizophrenic patients (Bertolino et al., 2000). 
The hippocampus, situated in the temporal lobe, is part of the limbic system and is 
involved in memory and learning. Evidence for the involvement of the hippocampus in 
schizophrenia stems from multiple research disciplines. In vivo studies showed that 
hippocampus volume is reduced in brain of schizophrenic patients, even in early onset 
of the illness, which means that reduced volume isn’t due to the disease or medication 
(Velakoulis et al., 2006). In addition, PET and fMRI studies have reported respectively 
abnormalities in neuronal metabolism and decreased N-acetyl aspartate in 
hippocampus of affected individuals (Harrison, 2004). Moreover, post-mortem studies 
highlighted dysfunction of numerous neuroreceptors, such as glutamate receptors, 
GABA receptors, nicotinic receptors and serotonin receptors in patients with 
schizophrenia (Harrison, 2004). 
Although these findings implicate the PFC and hippocampus in the pathology of 
schizophrenia, an involvement of other structures such as cerebellum, cingulate cortex 
and thalamus was also reported. It is well known that all these regions of the brain are 
interconnected via neuronal circuitry and this connectivity has been suggested to be 
disturbed in schizophrenia (Bertolino et al., 2000). 
 
1.2.3 Dysconnection in schizophrenia 
The idea that schizophrenia could be due to dysconnection between regions of the 
brain was introduced by Wernicke and Bleuler at the early beginning of the twentieth 
century. They proposed that schizophrenia was not only a disease involving several 
regions of the brain, but also a disease of the connection of these regions. The 
hypothesis is that disturbances within neural network of brain regions and 
dysfunctional connectivity between these regions give rise to symptoms of 
schizophrenia, such as auditory hallucination and cognitive impairment (Stephan et al., 
2006). The use of techniques such as PET and fMRI during the last three decades have 
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led to a better understanding of disturbed activity and functional connectivity of brain 
regions implied in schizophrenia (Liang et al., 2006). A recent study showed using fMRI 
showed that connectivity between insula, temporal lobe, prefrontal cortex and basal 
ganglia was disturbed in patients with schizophrenia (Stephan et al., 2006; Liang et al., 
2006). Another fMRI study showed disconnection between DLPFC and hippocampus in 
subjects with schizophrenia during working memory activation (Meyer-Lindenberg et 
al., 2005). In addition a PET study demonstrated that cooperative activity between PFC 
and temporal lobe was disrupted in schizophrenia (Meyer-Lindenberg et al., 2001). 
Despite evidence of dysconnection in schizophrenia the mechanisms that underlie its 
occurrence are still unclear. Two possible explanations may explain dysconnectivity, 
one is based on disturbances of neurodevelopment, the other on impairments in 
neuroplasticity, or even perhaps both occur. To consolidate the first hypothesis, a 
study showed that loss of neuronal connections in DLPFC which occur in normal 
teenagers is increased in patients with early onset of schizophrenia (Glantz and Lewis, 
2000). The second theory is supported by the involvement of NMDAR and its neuro-
modulators, such as dopamine, serotonin, or acethylcholine in learning processes such 
as long term potentiation (LTP). Long term potentiation plays a critical role in the 
survival of dendritic synapses and disturbed LTP may explain abnormal connectivity in 
patients with schizophrenia. Studies of post-mortem brains have highlighted a 
decreased dendritic field size and dendritic spines in patients affected by schizophrenia 
(Garey et al., 1998), suggesting a reduction in afferent connections. 
 
1.3 Developmental theories of schizophrenia 
1.3.1 Neurodevelopment 
The idea that schizophrenia may be a disease of neurodevelopment arises from 
numerous studies of environmental factors affecting foetal or postnatal brain 
development as a risk to develop schizophrenia. Environmental factors such as 
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asphyxia or virus infection can interfere in the functioning of critical 
neurodevelopment processes such as proliferation, migration, differentiation, 
synaptogenesis, myelination or apoptosis and lead to disturbed brain functions. A 
study demonstrated that, during the 1957 type A2 influenza pandemic, the risk of 
developing schizophrenia in later life was significantly increased when foetuses were 
exposed to the virus during the second trimester of development compared to non-
affected subjects (Mednick et al., 1988). In addition, seasonal birth studies have shown 
5 to 8% excess of schizophrenia births in the winter-spring months (Torrey et al., 
1997). The period of gestation for winter-spring birth is the most vulnerable period for 
virus infections, and migration of embryonic neurons during human 
neurodevelopment occurs in the second trimester of pregnancy. It is well known that 
neuronal migration via radial glia during neurodevelopment forms the cytoarchitecture 
of the cortex. Several studies have detected cytoarchitectural alterations in particular 
in the medial temporal cortex and hippocampal formation in patients with 
schizophrenia (Harrison, 1999). 
After birth and during adolescence, the human brain continues its development and 
maturation in processes such as axonal elimination and synaptic pruning (Gogtay et al., 
2004). Studies showed that in early onset schizophrenia the brain undergoes excessive 
synaptic elimination which may lead to the illness (Innocenti et al., 2003) (see Figure 
1-3). In addition, another study demonstrated that mRNA levels of the synaptic protein 
synaptophysin, which plays an important role in the establishment of new synapses, 
was down-expressed in the medial temporal lobe in patients with schizophrenia 
(Eastwood and Harrison, 1995). 
 
The glutamate post-synaptic density in schizophrenia 
14 
 
 
Figure 1-3: Neurodevelopmental model of schizophrenia. 
(a) Diagram of proliferation, migration, arborisation and myelination in prefrontal and 
changes in brain grey matter volume in healthy subjects. (b) Comparison of brain 
neurodevelopment between healthy subjects and schizophrenic patients. Patient with 
schizophrenia show excessive excitatory pruning, reduced interneuron activity and deficient 
myelination during neurodevelopment. Taken from (Insel, 2010). 
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All these findings suggest neurodevelopmental alterations in the pathology of 
schizophrenia. However, after adolescence, the adult brain still undergoes 
neurogenesis and neuroplasticity to produce new neurons and new neuronal 
connections. These mechanisms may also be implicated in schizophrenia. 
1.3.2 Neurogenesis 
There are several evidences that early onset of schizophrenia is associated with 
reduction of the hippocampus and an increase of ventricles volume (McDonald et al., 
2002; Pantelis et al., 2003). The hippocampus, the subventricular zone (SVZ) and the 
olfactory bulb are well known to house adult neurogenesis (Kornack and Rakic, 2001). 
Adulthood neurogenesis is known to be implicated in learning processes in the 
hippocampus and in olfactory tissue regeneration. Although disturbance of adult 
neurogenesis has not yet been demonstrated, several clues suggest that it may be 
involved in schizophrenia. Olfactory impairments have been reported in patients with 
schizophrenia (Rupp et al., 2005). Furthermore, cultured olfactory cells from 
schizophrenic patients showed differential expression of cell surface molecules 
regulating cell proliferation, differentiation and death compared to healthy individuals 
(F ron et al., 1999). During development of the central nervous system the Wnt-
dependent signaling pathway regulates cell adhesion, proliferation and differentiation 
(Dale, 1998). Briefly, Wnt interacts with ‘frizzled’ receptors which activate disheveled 
and lead to the degradation of β-catenin via glycogen synthase kinase 3β (GSK-3β). 
This signaling pathway might be implicated in neurogenesis mechanisms and disturbed 
in schizophrenia. A post-mortem study demonstrated that GSK-3β mRNA was 
significantly decreased in hippocampus of patients with schizophrenia (Nadri et al., 
2004). In addition, a decrease of β-catenin and γ-catenin was found in hippocampus of 
schizophrenic patients (Cotter et al., 1998). A recent study using gene knockdown in 
mice showed that adult neurogenesis in hippocampus is regulated by Wnt signaling 
pathway via DISC1 (Mao et al., 2009). Other factors implicated in neurodevelopment 
may play a role in adult neurogenesis and be disturbed in patients with schizophrenia. 
Neurotrophins, neuregulins, reelin, and retinoid are factors which could be involved in 
The glutamate post-synaptic density in schizophrenia 
16 
 
dysfunction of the neurogenesis in schizophrenic patients and could be investigated 
for a better understanding of the mechanisms of the illness (Toro and Deakin, 2007). 
Regarding functional impairment and reduced volume of the hippocampus observed in 
early episode of schizophrenia, these findings highlight an involvement of 
neurodevelopment factors in the mechanism of neurogenesis in adulthood which 
could be investigated to find new pharmaceutical targets to cure the illness. 
 
1.4 Neurochemical theories of schizophrenia 
1.4.1 Dopaminergic theory 
Arvid Carlsson and Paul Greengard obtained the Nobel Prize of Physiology and 
Medicine in 2000 for the discovery of the dopamine and Arvid Carlsson was the first to 
provide evidence that chlorpromazine functions by blocking dopamine receptors 
(Iversen and Iversen, 2007). The hyperdopaminergic theory of schizophrenia stemmed 
from the finding that administration of D-amphetamine, a drug of abuse known to be a 
dopamine agonist mimics positive symptoms of schizophrenia in healthy individuals. 
Moreover, recent studies based on cerebral imaging showed that the administration of 
this drug in small amounts causes a larger release of dopamine in the brains of the 
schizophrenic patients compared to controls (Iversen and Iversen, 2007). 
Dopamine is a neurotransmitter that belong to the catecholamine family and acts at 
two distinct metabotropic G-coupled receptor families. The D1 (including D1 and D5 
receptors) and D2 (including D2, D3, and D4 receptors) receptor families activate and 
inhibit postsynaptic adenylyl cyclase respectively at the dopamine synapse (Emilien et 
al., 1999). It is well accepted today that antipsychotic drugs are antagonists of the 
dopaminergic receptors, in particular D2 (Kapur and Mamo, 2003). Dopamine is known 
to modulate the glutmatergic system in many regions of the brain such as PFC and 
hippocampus. Hyperdopaminergy that occurs in schizophrenia and symptoms which 
ensue from could be explained either by excess of dopamine itself or by an increase of 
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its receptors. All these data contribute to the hyperdopaminergic theory of 
schizophrenia. Despite the fact that much evidence implicates dopamine in the 
neuropathology of schizophrenia, attempts to explain this disease solely in terms of 
dopaminergic system impairment leaves many aspects unsolved. 
 
1.4.2 Serotonergic theory 
The serotonergic theory originally arose from findings of the effect of a drug of abuse, 
LSD, which is a 5-hydroxytryptamine (5-HT2A) agonist and induces hallucinations in 
healthy individuals. LSD activates specifically 5-HT2A receptors situated on neocortical 
pyramidal cells, leading to increased level of glutamate in the cortex. The use of LSD 
has led to a better understanding of the 5-HT2A receptor which is implicated in 
cognitive processing such as working memory. Furthermore, brain imaging in humans 
has shown that hallucinogens increase prefrontal cortical metabolism (Nichols, 2004). 
In addition, “atypical” antipsychotics such as clozapine, olanzapine, and quetiapine, are 
known to antagonize 5-HT2A receptor more than dopamine D2 antagonists. These 
antipsychotics have effect on both positive and negative symptoms of schizophrenia 
suggesting a role of 5-HT2A receptor in the therapeutic action of these drugs. 
Equivocal findings regarding the possible involvement of serotonergic systems in 
schizophrenia, however, have been reported. A brain imaging study using PET showed 
no changes in number of 5-HT receptors in schizophrenic patients (Trichard et al., 
1998), whilst two other studies using post-mortem 5-HT binding found an increase 
(Hashimoto et al., 1991) and a decrease number of receptors compared to healthy 
controls (Burnet et al., 1996). Neuropharmacological evidence suggests that 
serotonergic system is implied in some aspects of schizophrenia, however the causes 
of cognitive symptoms in the illness and a possible role of 5-HT2A receptors remains 
widely unclear and requires further study. 
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1.4.3 Glutamatergic theory 
Glutamate (L-glutamic acid) is a neurotransmitter present in the central nervous 
system (CNS). It belongs to the amino-acid neurotransmitter family and it is considered 
as the principal excitatory neurotransmitter in the brain. There are two families of 
glutamate receptors, the ionotropic receptors which include the N-methyl-D-aspartate 
receptor (NMDAR), the α-amino-3-hydroxy-5-methyl-D-aspartate receptor (AMPAR) 
and kainate receptors; and glutamate metabotropic receptors.  Both families have 
been implicated in the pathophysiology of schizophrenia. 
Pharmacological and in-vivo imaging studies have highlighted that antagonists of 
NMDAR (e.g. ketamine, Phencyclidine [PCP]) reproduce negative, positive symptoms, 
and cognitive deficits related to schizophrenia in healthy volunteers (Krystal et al., 
1994). Moreover, some suggest that this effect is more transparent than for any other 
known drug (Parwani et al., 2005). Ketamine administration induces an increase in 
blood flow in the prefrontal cortex (Lahti et al., 1995), increases quantity of glutamate 
released in the prefrontal cortex in normal volunteers (Moghaddam et al., 1997) and 
strongly worsens symptoms in schizophrenic patients (Javitt and Zukin, 1991). These 
observations contributed to the establishment of the glutamate NMDA receptor 
hypofunction theory of schizophrenia. 
 
1.5 NMDA receptor and schizophrenia 
1.5.1 Structure and function 
Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. Most 
brain neurons express at least one class of glutamate receptors. The NMDAR (see 
Figure 1-4) is a tetrameric channel which is triggered by the glutamate and co-agonist 
binding; leading to calcium entry at the postsynaptic membrane. This mechanism is 
voltage depend, magnesium ions block the channel whilst the postsynaptic membrane 
remains polarised. The NMDAR is composed of three different subunits, NR1 (GRIN1), 
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NR2 (GRIN2-A, -B, -C nd -D) and NR3 (GRIN3). The NR1 subunit contains a binding site 
for glycine and D-serine co-agonists whilst the NR2 subunits contain the binding site 
for glutamate (Lei and McBain, 2002). 
 
 
Figure 1-4: The NMDA receptor. 
The NMDAR is composed of four or five subunits including at least one copy of the NR1 
subunit. The glutamate binding site is on the NR2 subunit, while the Glycine/D-Serine 
binding site is on the NR1 subunit. The NR2 subunit can be phosphorylated. Opening of the 
NMDAR channel depends on binding of glutamate and co-agonist (glycine/D-serine) and 
depolarising excitatory post-synaptic current leading to magnesium release and calcium 
entry into the post-synaptic dendrite. 
 
The NMDAR is implicated in several neurobiologic mechanisms such as 
neurodevelopment, cerebral plasticity and excitotoxicity, all of which could play a 
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major part in schizophrenia pathophysiology. Indeed, schizophrenia is a disease which 
appears only after adolescence and it was shown that among newly-diagnosed 
schizophrenic patients, the normal loss of neuronal connections observed in normal 
individuals is exacerbated by an additional 30% in patients (Bennett, 2008). Moreover 
the increase in glutamate release in the prefrontal cortex of schizophrenia patients 
could induce excitotoxic mechanisms (e.g. apoptosis and inflammation) and would 
explain the loss of cerebral volume observed in this disease. 
In order to determine the involvement of NMDA receptors in schizophrenia, a study 
using genetic methods to induce NMDA hypofunction in rodents showed that a 
genetically induced reduction of the NR1 subunit NR1 of NMDARs results in deficits in 
attention, social behaviour and cognitive symptoms (Mohn et al., 1999). Similar results 
were obtained by changing the co-agonist glycine binding site on NR1 subunit (Ballard 
et al., 2002). However post-mortem studies have not conclusively shown differences in 
NMDA subunits expression between schizophrenic patients and controls (Kristiansen 
et al., 2007a). 
 
1.5.2 NMDAR hypofunction 
The NMDAR hypofunction theory is based on the observation that NMDAR antagonists 
(PCP, MK801 and ketamine) induce schizophrenia symptoms in normal volunteers 
(Javitt and Zukin, 1991). NMDAR hypofunction theory suggests that co-agonists such as 
glycine/D-serine should be therapeutically beneficial in schizophrenia. The use of D-
cycloserine, a partial NMDAR glycine-site agonist, may improve cognitive functions in 
schizophrenia (Javitt, 2012). Studies using functional magnetic resonance imaging have 
made it possible to highlight disturbed brain function in schizophrenic patients. 
Abnormalities have been observed in cortical and subcortical structures such as the 
prefrontal cortex, hippocampus, temporal lobe, cingulate gyrus, thalamus and 
cerebellum (Liddle, 2001). All of these structures are known to have a broad 
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glutamatergic component. An emerging hypothesis is that dopaminergic dysfunction in 
schizophrenia is secondary to a fundamental glutamatergic dysfunction. 
A particularly interesting study correlates the status of ErbB4 receptor function and 
NMDA hypofunction in schizophrenia (Hahn et al., 2006). In this study, addition of 
NRG1 to human brain slices induced phosphorylation (activation) of its ErbB4 receptor 
leading to decreased NR2A subunit phosphorylation. A decrease in NR2A 
phosphorylation was exacerbated in hippocampus samples from schizophrenia 
patients. Furthermore, the interaction between scaffolding protein, post synaptic 
protein 95 (PSD-95), NMDAR and ErbB4 was increased, leading to a greater reduction 
in NMDAR phosphorylation in response to NRG1. There was an absence of changes in 
PSD-95 or ErbB4 protein levels, suggesting that protein-protein interactions in the PSD 
are responsible for NMDA receptor hypofunction in schizophrenia (Hahn et al., 2006). 
Glutamate synapses in the central nervous system are characterised by electron-dense 
zones under the postsynaptic membrane; called postsynaptic densities (PSD). PSDs are 
composed of a dense network several hundred proteins, such as receptors, ion-
channels, scaffolding proteins, and enzymes such as kinases and phosphatases (Collins 
et al., 2006a). The study of PSD proteins in schizophrenia is important, especially in 
light of the findings by Hahn et al., 2006 suggesting that NMDAR hypofunction could 
be related to abnormal protein-protein interactions within the PSD. 
1.6 Post synaptic density 
1.6.1 Structure and function of the post synaptic density 
The post synaptic density is a dense network of proteins localized along the glutamate 
post synaptic membrane within dendritic spines (see Figure 1-5). The PSD forms a 
macromolecular complex that plays an essential role in synaptic signaling pathways, 
receptor trafficking and synaptic plasticity. The whole complex of proteins forms a 
band of 30 to 40 nanometres thick with a diameter of a few hundred nanometres. 
Various studies have isolated the PSD using differential centrifugation methods and 
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have determined that the PSD appears as disc-shaped organelles using electronic 
microscopy (Ziff, 1997).  
Glutamate receptors such as AMPAR, NMDAR and metabotropic receptors are 
embedded in the PSD and linked to specific clusters of proteins (Mayer and Armstrong, 
2004). To identify each of the different receptor-associated protein complexes, 
proteomic studies were carried out and three protein complexes defined; the NMDAR 
associated complex (NRC) also called Membranes Associated Guanylate Kinases 
(MAGUK)-Associated Signalling Complex (MASC), the AMPAR complex (ARC) and the 
mGluR complex (mGC) (Farr et al., 2004). 
 
 
Figure 1-5: Electronic microphotographs of the glutamatergic synapses. 
(A) Electron micrograph from the adult hippocampal CA1 region. (B) Synaptic junction 
formed between a Purkinje cell dendritic spine and a parallel fiber axon in the murine 
cerebellar cortex. Arrowhead indicates the PSD of the synapses. Taken from (Ziff, 1997). 
Within the PSD more than one thousand proteins have been identified and about five 
hundred have been detected in two or more high-throughput proteomic studies (such 
as using two dimensional gel electrophoresis followed by liquid chromatography 
coupled with tandem mass spectrometry (2D LC-MS/MS)) of the PSD (Collins et al., 
2006a). PSD proteins have been categorized into functional groups including ion 
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channel receptors, receptors, cell adhesion and cell-cell interaction proteins, scaffold 
proteins and signal transduction proteins, amongst many others (Yoshimura et al., 
2004a). Amongst these complexes, scaffold proteins such as PSD-95 (Cho et al., 1992a), 
signalling molecules such as calmodulin and calcium calmodulin dependent protein 
kinase II (CaMKII) and proteins of the cytoskeleton such as actin and tubulin play a 
prominent role in synapse formation and function (Kennedy et al., 1983). 
Recent studies using comparative proteomics and genomics highlighted the origin of 
the pro-PSD structure in unicellular organisms and suggested that it plays a role in cell-
cell communication, calcium signalling and cytoskeleton regulation (Alié and Manuël, 
2010). Moreover a study showed the presence of PSD and MASC orthologs in yeast 
which regulate structural functions. In this study they also compared PSD composition 
in different organisms such as unicellular, invertebrate and vertebrate. They showed 
an increase in structural complexity of the PSD, particularly marked by an expansion of 
receptors, scaffolding and cytoskeletal proteins which correlated with organism 
complexity. They also showed differential organisation of the PSD depending on brain 
localisation in complex organism such as vertebrates (Emes et al., 2008).  
In dendritic spines of neurons, the PSD is a dynamic structure which functions as a 
bridge that constantly reacts to intra- and extracellular signals. A study showed that 
the PSD thickness increases around two-fold following potassium stimulation in rat 
cultured neurons and hippocampal slices, due to accumulation of CaMKII within the 
PSD (Dosemeci et al., 2001). The PSD can be considered as a specialised organelle 
within the dendrite spine that regulates synaptic interaction between the pre-synaptic 
terminal and post-synaptic dendrites of neurons. 
Modulation of the PSD is essential during neurodevelopment, and allows maintenance 
and plasticity of spines during adulthood. Neurotrophic factors, cell adhesion proteins 
and neurotransmitters act on their receptors which are embedded within the PSD to 
modulate protein-protein interactions between scaffolding proteins within the PSD 
which trigger molecular mechanisms implicated in the regulation of receptors 
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trafficking, intracellular cytoskeleton rearrangements, and the strength of the synapse 
in response to specific activity. The PSD also plays an important role in synaptogenesis 
and synaptic plasticity. These unique functions of the PSD suggest a central role in 
disturbances of LTP and LTD and hence learning and memory (Boeckers, 2006). 
1.6.2 Receptors within the PSD 
Trans-membrane receptors and cell adhesion molecules (CAMs) are embedded within 
the PSD and regulate synapse formation and maintenance via their interaction with 
scaffolding and signalling proteins of the PSD. 
At glutamate post-synaptic dendrites, NMDAR and AMPAR are the most represented 
glutamate receptors within the PSD whilst mGluRs (mGluR1/5) are present at a lower 
concentration (Mayer and Armstrong, 2004). Within the PSD, these receptors are 
associated with specific proteins to form protein complexes NRC-MASC, ARC, mGC 
which respectively correspond to NMDAR, AMPAR and mGluR binding complexes. 
NR1, NR2A-B and NR3 NMDAR subunits are highly expressed at the dendritic 
membrane, and their surface trafficking is regulated by their interactions with proteins 
of the PSD. NR2A subunit interacts with PSD-95/Discs-large/ZO-1 homology (PDZ) 
domain of scaffold proteins via its C terminus and this interaction is disturbed in 
experiments using competitive peptide mimicking the NR2A C terminus. The 
scaffolding proteins PSD-95 and PSD-93 were identified as essential for NR2A 
membrane surface trafficking (Delint-Ramirez et al., 2010). Both C termini of NR2A and 
NR2B subunits bind PSD-95 scaffold protein within the PSD. They also bind CaMKII 
which regulate their interaction with PSD-95 via specific phosphorylation sites (e.g. 
PDZ1 of PSD-95) (Gardoni et al., 2006). NR1 and NR3 NMDAR subunits interact with 
the NR2 subunits. NR1 is essential for NMDAR function and localisation at the post-
synaptic membrane as it carries the co-agonist binding site. This is exemplified in NR1 
knock-down studies, where the NR2A and NR2B subunits no longer localise at the 
postsynaptic membrane but instead remain in the endoplasmic reticulum (ER) (Forrest 
et al., 1994; Fukaya et al., 2003). 
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A study using co-immunoprecipitaion and bioluminescence resonance energy transfert 
(BRET) demonstrated that NMDAR NR1 subunit interacts with the dopamine D1 
receptor within the PSD. They also showed using co-transfection of dopamine D1 
receptor and NR1 subunit that NR2B is necessary for the translocation of D1/NR1 
complex to the post-synaptic dendrite membrane (Fiorentini et al., 2003). However 
there is no evidence that NR1 and NR3 interact directly with scaffold proteins of the 
PSD. 
The second most abundant glutamate receptor subtype at glutamate post-synaptic 
dendrites is the AMPAR which forms ARC complex with proteins of the PSD. The 
AMPAR is an ionotropic receptor composed of four tetrameric heteromeric subunits 
termed GluR1, GluR2, GluR3 and GluR4. The C termini of AMPAR GluR2/3/4 subunits 
interact with the scaffold proteins glutamate receptor-interacting protein 1/2 also 
called AMPA-receptor-binding protein (GRIP1/2 - ABP) and the protein interacting with 
C kinase (PICK1) via their PDZ domain (Dong et al., 1997; Nishimune et al., 1998; Xia et 
al., 1999). In addition, the N-ethylmaleimide sensitive factor (NSF) a protein implicated 
in vesicular membrane fusion is also a partner of AMPAR GluR2 subunits within the 
PSD (Dong et al., 1997; Nishimune et al., 1998). The GluR1 subunit binds the PDZ of the 
scaffolding protein Synaptic Associated Protein 97 (SAP-97) (Leonard et al., 1998; 
Rumbaugh et al., 2003). Although these proteins interact with AMPAR via their PDZ 
domain, their role within the PSD is AMPAR trafficking and recycling at the post-
synaptic membrane. AMPARs can also be associated with proSAP/Shank proteins 
which are one of the main component of the PSD and act to dock the AMPAR complex 
at the PSD (Uchino et al., 2006). 
Metabotropic GluR receptors (mGluRs) have also been reported to be enriched within 
the PSD, particularly the mGluR1 family which includes mGluR1 and mGluR5 (Mayer 
and Armstrong, 2004). These two metabotropic receptors interact with PSD scaffolding 
protein, Homer, an immediate early gene, which codes a protein with PDZ-like domain, 
Enabled /VASP homology-1 (EVH1) domain and a C-terminal coiled coil (CC) 
multimerisation motif that lead to Homer dimerisation (Brakeman et al., 1997). Homer 
The glutamate post-synaptic density in schizophrenia 
26 
 
binds the mGluRs carboxy-terminal intracellular domains and regulates their activity. 
Disrupted interaction between Homer and mGluRs lead to constitutive activation of 
mGluRs highlighting that their activation is modulated by intracellular proteins as well 
as by glutamate binding (Ango et al., 2001). Moreover, Homer also interacts directly or 
indirectly with other proteins of the PSD such as Shank, PSD-95 and GKAP, linking them 
with the PSD complex (Tu et al., 1999). 
Most dopaminergic neurons are localized in two regions of the brain: the substantia 
nigra pars compacta (SNc) and the ventral tegmental area (VTA). These neurons 
project their outputs to the striatum, nucleus accumbens, hippocampus and 
neocortex. In these latter brain regions, dopaminergic and glutamatergic systems 
interact at the post-synaptic dendritic spine. Both dopamine D1 (D1/D5) and D2 
receptors (D2, D3 and D4) are enriched within the PSD (Yao et al., 2008). Confocal live 
cell imaging has shown that the D1 dopamine receptor family localises at the head of 
dendritic spines whereas D5 dopamine receptors concentrate at the neck. 
Furthermore, NMDAR-triggered stimulation leads to an increase of D1 receptor 
positive spine heads, possibly due to an interaction between D1/PSD-95/NMDAR 
(Kruusmägi et al., 2009). A study using co-transfection of D1 or D2 receptors with PSD-
95 in HEK-293 cells highlighted an interaction between PSD-95 and D1/D2 receptors. 
Using functional assays they showed that the PSD-95/D1 complex is disturbed after 
dopamine stimulation. They also demonstrated the important role of PSD-95 in D1 
resensitisation which is accelerated in the presence of PSD-95 (Sun et al., 2009).  
PSD-95 interacts with the carboxyl-terminal tail of dopamine D1 receptor via its NH2 
terminus domain. The interaction between PSD-95 and D1 plays an important role in 
internalisation of D1. In the absence of stimulation by D1 receptor agonist, the PSD-
95/D1 receptor complex inhibits D1 signalling pathway due to an increased 
internalisation process via PSD-95 (Zhang et al., 2007). A study reported that PSD-95 
stabilise interaction between dopamine D1 receptor and NMDAR which can induce cell 
death when both receptors are over activated. In this study they also showed that 
PSD-95 inhibits dopamine D1 receptor-NMDAR NR1 subunit association and NMDAR-
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dependent activation of dopamine D1 receptor recycling. Dopamine D1 
receptor/NMDAR/PSD-95 complex plays critical role in molecular mechanism 
underlying neuronal cell survival and neuroplasticity (Zhang et al., 2009). To highlight 
the role of PSD-95 in the regulation of dopamine D1 receptor induced NMDAR Ca2+ 
release, a study was carried out using co-transfected HEK 293 cells with PSD-
95/D1/NR1-NR2B complex. They showed that treatment with dopamine increased 
NMDAR activity in dose-dependent manner whereas no difference was observed in 
their controls without co-transfected PSD-95. This study suggests a pivotal role of PSD-
95 in dopamine D1 receptor triggered NMDAR activity and LTP (Gu et al., 2007). 
Treatment with dopamine D1 receptor agonist leads to AMPAR GluR1 subunit 
phosphorylation which increase the number of GluR1 subunits at the dendritic spine. 
Mutation experiments of scaffolding proteins of the PSD such as A-kinase anchoring 
protein (AKAP79/150) and PSD-95 disturb this molecular mechanism. These results 
show the involvement of the proteins of the PSD in AMPAR receptor trafficking via 
dopamine D1 receptor modulation which may have an important role in synaptic 
plasticity (Swayze et al., 2004). The D2 dopamine receptors family also interacts with 
the PSD, a study highlighted the role of the interaction between D2 dopamine receptor 
and NMDAR NR2B subunit in vivo. They showed that recruitment of CaMKII by NR2 
subunit phosphrylation site within the PSD is disturbed after dopamine stimulation. In 
consequence, phosphorylation of the NR2 subunit is reduced which lead to a 
hypoactivity of the NMDAR (Liu et al., 2006). These studies highlight the importance of 
PSD proteins such as PSD-95, in mechanisms that regulate dopamine receptor and 
NMDAR interactions with a potentially important role in dendritic spine plasticity, 
molecular mechanisms of memory and possibly schizophrenia pathophysiology. 
Trophic factors such as Neuregulins (NRG), ephrins and neurotrophins are involved in 
neuronal development and synaptic plasticity. These factors interact with receptor 
tyrosine kinases (RTKs) which are embedded within the PSD. 
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Amongst the six existing subtypes of receptor tyrosine kinases, ErbB (generated by 
alternative splicing of the gene ERBB and activated by NRG1), ErbB2, ErbB3 and ErbB4 
are the three subtypes present at the glutamatergic synapse and interact with 
scaffolding proteins of the PSD (Bublil and Yarden, 2007). PSD-95 interacts with ErbB4-
ErbB4 homodimer and indirectly with ErbB2-ErbB3 heterodimer via erbin, a protein 
that contains multiple leucine-rich domains and a PDZ domain (Huang et al., 2000; 
Huang et al., 2001).  
Another type of RTKs are the Eph receptors which are activated by cell-surface ligands 
called Ephrins (Klein, 2004). There are two main types of Eph receptors; EphA (EphA1–
8) and EphB (EphB1–4, EphB6) which respectively bind ephrin A (A1-A5) and ephrin B 
(B1-B3) transmembrane ligands (Kullander and Klein, 2002). EphB2 and EphB4 are 
present at the post-synaptic dendrites (Dalva et al., 2000). Furthermore, a study 
highlighted the involvement of the scaffolding protein SAP 97 in a transsynaptic 
signalling implicated in synaptic plasticity which functions via EphB receptor/ephrinB 
suggesting interaction between EphB and SAP-97 (Regalado et al., 2006).  
The third group of TRKs, activated by neurotrophins consist of two classes of receptors; 
the tropomyosin-related kinase (Trk) family of receptors and the p75 a member of the 
tumour necrosis factor family. The neurotrophins nerve growth factor (NGF), brain 
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and NT-4/5 bind the Trk 
family (TrkA/B/C) whereas pro-neurotrophins (neurotrophin precursors) bind to p75 
(Reichardt, 2006a). Studies have shown that both TrkB and p75 interact with PSD-95 
(Sandoval et al., 2007; Yoshii and Constantine-Paton, 2007a). 
Synaptic cell adhesion molecules (synCAMs) are transmembrane receptors implicated 
in cell-cell interactions. These transmembrane receptors contain typically an intra-, a 
trans- and an extra-cellular domain. The extracellular domain interacts with either the 
same kind of CAMs (homophilic binding) or other kind of CAMs (heterophilic binding). 
The synCAMs transmembrane receptors regroup four classes of proteins; the 
cadherin–catenin, the cadherin-like and cadherin-related neuronal receptor (CNR), the 
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immunoglobulin-like (Ig) superfamily, and the neurexin–neuroligin. These receptors 
are enriched at the post-synaptic dendrites and most of them contain specific domains 
such as PDZ to interact with proteins of the PSD. For instance, a study showed that 
postsynaptic CAMs such as netrin-G ligand (NGL) and netrin-G (NG) interact with PSD-
95 via their cytosolic domain in cultured rat neurons. They also showed that 
modulation of the expression of these receptors regulate the abundance of PSD-95 
leading to a regulation of dendrite spine formation. This study suggests that CAMs are 
important for the recruitment of PSD-95 during synapse formation and could be 
implicated in plasticity (Kim et al., 2006). In a more recent study, the CAMs NGL-3 was 
also identified as an interacting receptor with PSD-95. This CAMs interacts with 
leukocyte common antigen-related (LAR) which modulate synapse formation and 
maturation (Woo et al., 2009). 
 
1.6.3 Protein-protein interactions within the PSD 
The PSD can be defined as a cluster of specific protein complexes. As mentioned above 
(see section 1.6.1) glutamate receptors NMDAR, AMPAR and mGluR form protein 
complex with associated scaffolding proteins called NRC, ARC and mGC respectively. 
These protein complexes are linked via another molecular structure called Pro-
SAP/Shank platform (PSP) which is associated with the cytoskeleton and smooth 
endoplasmic reticulum (SER) within the dendrite spine (Boeckers, 2006). Scaffolding 
proteins are characterised by specific protein-protein interacting domains such PDZ 
(PSD-95/ Discs large/Zona occludens 1), SH3 (src-homology 3), GK (guanylate kinase), 
EVH1 (N-terminal Ena/VASP Homology 1), CC (coiled-coil) and SAM (sterile alpha motif) 
domains.  
Among scaffolding proteins of the PSD, the Membranes Associated Guanylate Kinases 
(MAGUKs) proteins play an important role in the regulation of the intracellular traffic 
and the synaptic localization of the ionotropic glutamate receptors. Four homologues 
have been described; the synapse-associated proteins (SAP) 90/PSD-95, SAP102, 
The glutamate post-synaptic density in schizophrenia 
30 
 
SAP97 and chapsyn-110/PSD-93, all localised at the glutamate synapses of the CNS 
(Aoki et al., 2001). All of these MAGUK proteins contain three PDZ domains at the N-
terminus, a SH3 domain and a C-terminal guanylate kinase GK domain. These domains 
play a key role in protein-protein interactions between receptors of the post-synaptic 
dendrite, MAGUK proteins, scaffolding proteins of the PSD and signalling proteins 
implicated in synaptic plasticity (Elias and Nicoll, 2007; Lau and Zukin, 2007).  
SAP/PSD-95 was the first scaffolding protein identified within the PSD and studies 
showed that first and second PDZ domains interact with the NR2 subunit of the 
NMDAR (Cho et al., 1992a; Kistner et al., 1993; Niethammer et al., 1996). It is well 
known now that PSD-95 regulates synaptic activity organizing the glutamate ionotropic 
receptors and their signalling associated proteins in the PSD. PSD-95 interacts also with 
AMPAR indirectly via stargazin/TARPs which contain the C-terminal PDZ binding motif 
and play a crucial role in AMPAR trafficking at the glutamate synapse (Schnell et al., 
2002). A study also reported that the MAGUK protein SAP-97 could play the same role 
as stargazin/TARPs allowing interaction between AMPAR and NMDAR/PSD-95 (Chen et 
al., 2000; El-Husseini et al., 2002). SAP-97 was also identified as partner of NMDAR via 
NR2A subunit (Gardoni et al., 2003; Mauceri et al., 2007). The scaffolding protein 
MAGUK SAP102 interacts with NR2B NMDAR subunit and its role is to deliver the 
subunit to the synaptic membrane (Sans et al., 2003). In addition, studies have 
highlighted two more binding partners neuroligin and ErbB4 which interact with the 
third PDZ domain of PSD-95 (Huang et al., 2000; Irie et al., 1997; Song et al., 1999; 
Naisbitt et al., 1999; Garcia et al., 2000). These studies show the important role of 
MAGUKs scaffolding proteins in receptor clustering and trafficking at post-synaptic 
membrane. Furthermore they also have a role in protein-protein interactions with 
other scaffolding protein of the PSD and signalling proteins implicated in synaptic 
plasticity. 
The other main types of scaffolding proteins within the PSD are the pro-SAP/Shank 
proteins. All family members are from splice variant of three genes named Shank1/2/3 
(Naisbitt et al., 1999; Lim et al., 1999). Typically, proteins coded by these genes contain 
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six protein-protein interaction domains namely N-terminal ankyrin (ANK) repeats SH3 
(Src homology 3) and PDZ domains, several proline-rich clusters (PRC), a cortactin 
binding domain (ppI) and a SAM domain at C-terminal. The PDZ domain of Pro-
SAP/Shank binds the C-terminus of GKAP scaffolding protein which interacts with PSD-
95/NMDAR complex (Naisbitt et al., 1999). The N-terminal ankyrin repeats of Shank 
are only present in Shank 1 and pro-SAP2/Shank 3 scaffolding proteins which interact 
with α-fodrin a protein interacting with actin filament and Sharpin a protein implicated 
in oligomerisation of ProSAP (Lim et al., 2001). 
ProSAP/Shank scaffolding proteins were also identified as partners of Homer, another 
type of scaffolding protein present within the PSD. The proline-rich clusters of Pro-
SAP/Shank interacts with the EVH1 domain of Homer which links mGluR1 and mGluR5 
with inositol 1,4,5-trisphosphate (IP3) receptors and Shank/GKAP/PSD-95/NMDAR 
complex (Tu et al., 1999; Tu et al., 1998). These protein-protein binding domains are 
also implicated in pro-SAP/Shank – cytoskeleton interaction as they allows interaction 
with cortactin and actin binding protein (Abp1) which regulate actin polymerization 
(Kim and Sheng, 2004; Qualmann et al., 2004). The SAM domain at C terminus of pro-
SAP/Shank was identified as the molecular structure which allows Pro-SAP/Shank – 
Pro-SAP/Shank binding and give rise to the particular platform within the PSD; PSP 
(Naisbitt et al., 1999). 
As mentioned above (see section1.6.2) the Homer gene was first identified as an IEG 
which encodes two specific protein-protein interactions domains, EVH1 and CC 
(Brakeman et al., 1997). A study showed that three Homer genes encode Homer 1/2/3 
proteins and generate splice variants Homer 1a/b/c and Homer 2a/b (Xiao et al., 
1998). All of these splice variants carry the EVH1 domain which interacts with 
mGluR1/5, pro-SAP/Shank scaffolding proteins and inositol 1,4,5-trisphosphate (IP3) 
receptors as mentioned above (Tu et al., 1999; Tu et al., 1998). A study also showed 
that EVH1 binding partner dynamin III allows the localization of the clathrin endocytic 
machinery near the PSD through its interaction with Homer and is implicated in 
AMPAR recycling at post-synaptic membrane (Lu et al., 2007). At the C-terminus the 
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protein-protein interactions CC domain is known to allow the dimerization of Homer 
proteins (Xiao et al., 1998).  
The GKAP/SAPAP (guanylate kinase-associated protein/synapse-associated protein-
associated protein) family of proteins is composed of four isoforms (SAPAP1-4), each 
containing a C-terminus with a PDZ-binding motifs and a 14-amino acid repeats 
domain which interacts with GK domain (Takeuchi et al., 1997). Temporal and spatial 
expression of these proteins varies during brain development (Kindler et al., 2004). 
GKAP1/SAPAP1 plays a central role in connecting PSD-95 scaffolding proteins of the 
Pro-SAP/Shank family. The 14-amino acid repeats domain anchors the PSD-95 
Guanylate Kinase (GK) domain (Kim et al., 1997) and the synaptic scaffolding molecule 
(S-SCAM) (Hirao et al., 1998) and the PDZ-binding motifs binds to the PDZ domain of 
Pro-SAP/Shank molecules (Naisbitt et al., 1999). In addition, a study using 
immunoprecipitation experiments showed that GKAP/SAPAP protein family can 
interact with proteins associated with cell-cell adhesion molecules such as 
adenomatous polyposis coli (APC), beta-catenin (Akiyama, 1997) and nArg BP2 
(Kawabe et al., 1999). GKAP/SAPAP also interacts with proteins of the cytoskeleton and 
associated proteins. Studies have also highlighted GKAP/SAPAP interaction with 
neurofilament (Hirao et al., 2000) and motor proteins such as myosin Va and dynein 
(Naisbitt et al., 2000). Thus the GKAP/SAPAP protein family plays central role in 
protein-protein interactions within the PSD as it links the three complexes NRC-
MASC/ARC/mGC to the PSP. 
 
1.6.4 The PSD and its possible role in schizophrenia 
Since NMDA receptor hypofunction is implied in the pathophysiology of schizophrenia, 
it has been suggested that disturbed PSD-95 function may be associated with 
schizophrenia. However, it does not appear that the NMDA receptor hypofunction is 
directly related to the level of PSD-95 expression (Tsai et al., 2007). Despite this, a 
study demonstrated an increase in ErbB4-PSD95 interactions in postmortem tissue 
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slices of prefrontal cortex obtained from patients with schizophrenia. This study 
showed significantly increased NRG1-induced activation of ErbB4 compared to controls 
where protein levels of both proteins remained unchanged. Also NRG1-induced 
hypophosphorylation of NR2A subunit led to inhibition of NMDAR receptor activation 
which was more pronounced in schizophrenia subjects compared to controls (Hahn et 
al., 2006). These findings are the first consistent results which indicate that NMDAR 
hypofunction may be relevant to explain part of symptoms of schizophrenia.  
Another study showed that transcription of DLGAP1 (gene coding for GKAP1) is up-
regulated in the nucleus acumbens of rats treated with phencyclidine (a model for 
schizophrenia). This study also showed an up-regulation of DLGAP1 protein in the 
same brain area in untreated patients with schizophrenia (Kajimoto et al., 2003). A 
cytogenetic study showed that GKAP1 is implicated in families with schizophrenia 
(Pickard et al., 2005). Also, changes in gene copy number (Friedman et al., 2008) and 
reduced mRNA levels for this gene were associated with schizophrenia (Toro and 
Deakin, 2008 ; unpublished findings). In addition, a study showed that GKAP1 can 
potentiate the ionotropic activity of the NMDAR via PSD-95 (Yamada et al., 1999). 
Furthermore, GKAP1 co-immunoprecipitates with the NR2A subunit of the NMDAR and 
also with β-catenin (Akiyama, 1997). All of these findings suggest a potential role of 
GKAP1 as a modulator of the NMDAR and may play a role in NMDAR hypofunction in 
patients affected with schizophrenia. As previously mentioned, PSD-95 and the 
scaffolding protein ProSAP/Shank interact via GKAP1 in the PSD. As Shank plays an 
essential role in the maintenance of the dendritic spines and synapses in cultured 
hippocampus (Roussignol et al., 2005) and is also known to connect to Homer, a 
protein linked to mGluRs (see Figure 1-6), these proteins could be investigated as 
potential modulators of NMDAR function. 
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Figure 1-6: Protein-protein interactions at the postsynaptic density.  
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1.7 Hypothesis and aims 
The preceding sections describe the pathophysiology of schizophrenia and some of the 
most convincing developmental and neurochemical theories of this illness. There is a 
focus on glutamatergic PSD neurotransmission in schizophrenia and in particular the 
glutamate NMDAR and associated proteins. Possible aberrations in expression of 
NMDARs and associated proteins in the brain in schizophrenia may contribute to many 
of the theories put forward in the present work. 
 
Hypothesis 
There is an alteration in the expression of proteins involved in synaptic plasticity within 
the PSD of premotor cortex from schizophrenics in comparison to major depressive 
disorder, bipolar disorder and healthy controls. 
 
Aims 
1. To optimise and characterise a method for the extraction/purification of the 
PSD from human premotor cortex. 
2. To determine the protein expression of the NMDAR subunit NR2A and 
associated proteins PSD-95, CaMKIIα, CaMKIIβ and NSF in the PSD of the premotor 
cortex in schizophrenia compared to major depressive disorder, bipolar disorder and 
healthy controls. 
3. To determine the expression of the neurotrophin receptors TrkB, truncated 
TrkB T1-TrkB and p75 that regulate synaptic strength and plasticity, in the PSD of the 
premotor cortex in schizophrenia compared to major depressive disorder, bipolar 
disorder and healthy controls. 
  
2 Materials and methods 
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2.1 Human brain samples 
Postmortem brain tissue from patients with schizophrenia, major depressive disorder, 
bipolar disorder and a non-psychiatrically ill comparison group was obtained from the 
Stanley Consortium postmortem brain collection. The four groups were matched by 
age, sex, race, postmortem interval, pH, and side of brain. Diagnosis was effectuated 
according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision (DSM IV-TR) and clinical, demographic and perimortem data were 
reported (see Table 2-1).  
Table 2-1: Clinical and demographical data for Stanley Foundation Neuropathology 
Consortium (mean ±SEM).  
Parameters Control Schizophrenia Major 
Depression 
Bipolar Disorder 
№ 15 15 15 15 
Gender (F/M) 6/9 6/9 5/10 6/9 
Age 48.1 (±10.7) 44.5 (±13.1) 46.5 (±9.3) 42.3 (±11.7) 
Age Onset N/A 23.2 (±8.0) 33.9 (±13.3) 21.5 (±8.4) 
Duration of 
Illness (yrs) 
N/A 21.3 (±11.4) 12.7 (±11.1) 20.1 (±9.7) 
PMI (hrs) 23.7 (±9.9) 33.7 (±14.6) 27.5 (±10.7) 32.5 (±16.1) 
pH 6.3 (±0.2) 6.2 (±0.3) 6.2 (±0.2) 6.2 (±0.2) 
Mth Form 4.4 (±3.9) 11.2 (±8.5)† 8.4 (±6.6)† 9.7 (±3.6)† 
Side (L/R) 8/7 9/6 9/6 7/8 
Suicide 0 4 7 9 
Antidepresants 0 5 8 7 
Antipsychotics 0 15 0 12 
Lithium 0 2 2 4 
†Different from controls, planned contrast p<0.05. PMI - Postmortem Interval; yrs – years; 
hrs – hours; Mth Form - Months in Formalin; F - Female; M - Male; L - Left; R - Right; Integers 
are numbers of cases. 
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Brain specimens were sent to us with a code (IK + number) varying from researcher to 
researcher to ensure that our studies were blinded. The code was released to us only 
when all the data were collected and submitted to Stanley Medical Research Institute 
(SMRI). The brain samples consisted of 15 frozen blocks of premotor cotex (Brodman 
area 06) from a non-psychiatrically ill comparison group (control), 15 from patients 
with schizophrenia, 15 from patients with major depressive disorder, and 15 from 
patients with bipolar disorder. Two collections of 60 frozen blocks of premotor cortex 
were provided and used to carry out protein extraction, glutamate post-synaptic 
density enrichment, protein assay, Western blotting and co-immunoprecipitation 
experiments. 
2.2 Enrichment of the glutamate post-synaptic density 
The technique that was used for post-synaptic density (PSD) extraction consisted of a 
succession of centrifugation steps and the use of gradients of different sucrose 
concentrations to extract PSDs from the synaptosome. The technique used a bench 
centrifuge with two concentrations of sucrose (see Figure 2-1). 
 
2.2.1 Stock solutions preparation and storage 
Prior to PSD extraction, stock solutions were prepared and stored at 4°C (see Table 
2-2).  
 
Table 2-2: Stock solutions for PSD extraction using a bench centrifuge. 
Compound Concentration Volume pH Storage 
MgCl2 0.5 M 5 ml N/A 4°C 
Hepes 0.5 M 20 ml 7 4°C 
KCl 2 M 10 ml N/A 4°C 
MgCl2 – magnesium chloride; Hepes - hydroxyethyl piperazineethanesulfonic acid; KCl - 
potassium chloride; N/A – not appropriate. 
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Stock solutions were used to prepare the extraction buffers utilised for extraction of 12 
samples (see Table 2-3). 
 
Table 2-3: Buffers for PSD extraction using a bench centrifuge. 
Solution Concentration Volume pH Storage 
Sucrose 0.32.M 40 ml N/A 4°C 
Sucrose 0.8 M 10 ml N/A 4°C 
Sucrose, MgCl2 0.32 M, 1 mM 20 ml N/A 4°C 
Hepes 20 mM 20 ml 7 4°C 
KCl, Triton X-100 150 mM, 2% 20 ml N/A 4°C 
KCl, Triton X-100 75 mM, 1% 20 ml N/A 4°C 
MgCl2 – magnesium chloride; Hepes - hydroxyethyl piperazineethanesulfonic acid; Triton X-
100 - nonionic surfactant; KCl - potassium chloride; N/A – not appropriate. 
 
2.2.2 Preparation of the tubes 
The 1.5 ml microcentrifuge tubes used for the different steps of the extraction were 
coated with Sigmacote (Sigma; SL2) and bovine serum albumin (BSA) to prevent 
proteins and PSD sticking to the surface of the tubes. Microcentrifuge tubes were 
coated with 1 ml Sigmacote for 30 seconds and then upside down for another 30 
seconds. After discarding the Sigmacote, the tubes were left to dry for 30 minutes 
under a hood at 25°C. When dried the tubes were washed twice with 1 ml of sterile 
deionised water. A second coating was carried out with 1 ml of a solution of 10% BSA 
in sterile deionised water during 30 minutes on a plate shaker at 300 rotations per 
minute (rpm) and 30 additional minutes with the tubes upside down. Both steps were 
carried out at 25°C. After removal of the BSA solution the tubes were washed twice 
with 1 ml of sterile deionised water. 
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2.2.3 Homogenisation of the human premotor cortex 
Frozen blocks of premotor cortex were weighed (100 mg), thinly chopped on ice and 
placed into homogeniser precellys tubes (Bertin Technologies; 03961-1-003) 
containing 450 µl of ice-cold 0.32 M sucrose, 1 mM MgCl2 solution containing 2.5 % of 
protease inhibitor cocktail (Sigma; P8340). Samples were homogenised in a Precellys 
24 dual tissue homogenizer (Bertin Technologies; 03119.200.RD010) for 15 seconds at 
5000 rpm. After homogenisation the samples were placed on ice and 50 µl of 
homogenate was pipetted into a labelled tube (Total fraction). Total fractions were 
placed at -80°C for future analysis. 
 
2.2.4 Extraction of the PSD 
For PSD extraction all the centrifugation steps were carried out in a refrigerated 
centrifuge (Eppendorf 5417R centrifuge; fixed-angle rotor F-45-30-11). The 
homogenate was transferred into a microcentrifuge tube (tube 1) and centrifuged at 
470×g for 2 minutes at 4°C. During this first step of centrifugation the homogeniser 
Precellys tubes was rinsed with 450 µl of ice-cold 0.32 M sucrose, 1 mM MgCl2 solution 
containing 2.5% of protease inhibitor cocktail (sigma; P8340). Following the 
centrifugation the content of the rinsed homogeniser Precellys tube was added into 
tube 1, the lysate was resuspended by pipetting, then centrifuged at 470×g for 2 
minutes at 4°C.  
The supernatant was placed into another microcentrifuge tube (tube 2) and the pellet 
stored at -80°C for future analysis. The supernatant was centrifuged at 10,000×g for 10 
minutes at 4°C to collect a synaptosome-enriched pellet. The supernatant collected 
after this step of centrifugation was pipetted into a labelled microcentrifuge tube (tube 
3: cytosolic fraction) and stored at -80°C for future analysis. 
The pellet was resuspended with 500 µl of 0.32 M sucrose solution and the suspension 
was layered onto 750 µl of 0.8 M sucrose solution in a labelled microcentrifuge tube 
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(tube 4). The samples were centrifuged at 9,100×g for 15 minutes at 4°C. Following 
centrifugation, the 0.32 M sucrose layer and the myelin/light membrane layer at the 
0.32/0.8 M sucrose interface were pipetted into two microcentrifuge tubes, 
respectively labelled tube 5 and tube 6. Both tubes were stored at -80°C for future 
analysis.  
The collected synaptosomal fraction in 0.8 M sucrose solution (~450 µl into tube 4) was 
diluted with an equal volume of 20 mM Hepes (pH 7) solution and half of the resultant 
synaptosomal fraction was poured in a labelled microcentrifuge tube (tube 7). In both, 
tube 4 and tube 7, an equal volume of 2% Triton X-100, 150 mM KCl solution 
supplemented with 2.5% protease inhibitor cocktail (sigma; P8340) was added and 
samples were agitated on a plate shaker for 15 minutes at 4°C and then centrifuged at 
20,800×g for 45 minutes at 4°C. The supernatants were collected into two labelled 
tubes (tube 8 and tube 9) and stored at -80°C for future analysis. 
The pellets obtained in tube 4 and tube 7 were resuspended in 500 µl of 1% Triton X-
100, 75 mM KCl solution supplemented with 2.5% protease inhibitor cocktail (sigma; 
P8340) and centrifuged at 20,800×g for 30 minutes at 4°C. The supernatants were 
collected into two labelled tubes (tube 10 and tube 11) and stored at -80°C for future 
analysis. The pellets obtained in tube 4 and tube 7 were washed once by resuspending 
them in 500 µl of 20 mM Hepes (pH 7) and centrifuged as above. The supernatants 
were collected into two labelled tubes (tube 12 and tube 13) and stored at -80°C for 
future analysis. 
The pellets collected in tubes 4 and 7 were resuspended in 40 µl TBS-T 0.1% 
supplemented with 2.5% protease inhibitor cocktail (sigma; P8340). Tubes 4 and 7 
were defined as the PSD fractions and stored at -80°C until future analysis (see Figure 
2-1). 
The glutamate post-synaptic density in schizophrenia 
44 
 
 
Figure 2-1: Diagram illustrating the different steps of PSD extraction using a bench 
centrifuge. 
 
2.3 Electron microscopy 
PSD fractions were extracted from two samples using a bench centrifuge (see section 
2.2) to perform transmission electron microscopy (TEM). 
All experiments, described below, were performed at the University of Cambridge 
(Department of Physiology, Development and Neuroscience) by Dr. Jeremy Skepper. 
The samples were fixed, washed, osmicated, dehydrated and embedded in epoxy 
resin. After embedding, ultrathin sections (50 nm) were prepared with a 
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at 4oC
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ultramicrotome (Leica; Ultracut UCT) using a 45° wedge angle diamond knife (Diatome) 
and were mounted on metal grids to be viewed in the TEM (FEI Tecnai G2). 
 
2.3.1 Fixation of the PSD fractions 
The initial fixation step was carried out in a buffered 0.1 M HEPES solution of 4% 
glutaraldehyde for 24 hours at 4°C. Samples were centrifuged at 20,800×g for 30 
minutes at 4°C and washed in 0.1 M HEPES, 2 mM CaCl2 buffer under agitation for 5 
minutes at 4°C. This washing step was repeated three times. Samples were then 
centrifuged at 20,800×g for 5 minutes at 4°C. 
The second fixation step (also called osmication step) was carried out in an HEPES 
buffered 1% osmium solution supplemented with 1.5% potassium ferricyanide (W/V) 
and 2 mM CaCl2 during 2 hours under agitation at 4°C. Samples were centrifuged at 
20,800×g for 5 minutes at 4°C and were washed in 0.1 M HEPES buffer for 5 minutes 
under agitation at 4°C. This washing step was repeated three times. 
The final fixation (also called "bulk stain") was carried out in 2% uranyl acetate in 
0.05M maleate buffer at pH 5.5. Samples were centrifuged at 20,800×g for 5 minutes 
at 4°C and the pellet was resuspended in deionised water. The samples were then 
embedded in epoxy resin prior to ultrathin sectioning. As epoxy resin used for our 
experiment was polymerised in hydrophobic media, the water present in the samples 
was replaced by ethanol. 
 
2.3.2 Dehydration of the PSD fractions 
Dehydration was undertaken in ethanol following the dehydration steps: 50% ethanol 
for 5 minutes (2 times), 70% ethanol 5 minutes (3 times), 95% ethanol 5 minutes (3 
times) and 100% ethanol 10 minutes (3 times). Between each change of solution the 
samples were centrifuged at 20,800×g for 5 minutes at 4°C and resuspended in the 
The glutamate post-synaptic density in schizophrenia 
46 
 
next dehydration solution. After dehydration of the samples was completed, two 
additional changes in dry acetonitrile, for 10 minutes each, were performed. Between 
each change of solution the samples were centrifuged at 20,800×g for 5 minutes at 
25°C. The samples were then ready for embedding. 
 
2.3.3 Embedding of the PSD fractions 
The samples were infiltrated with solutions of resin in solvent (acetonitrile), with 
increasing concentrations of resin and finally with the pure epoxy resin mixture. The 
resin was cured by incubation at 60°C for 48 hours. 
Araldite, a high viscosity epoxy resin was used for the embedding of our samples. The 
hardener (16 mg of dodecenylsuccinic anhydride (DDSA)) and the resin monomer (14 
mg of CY 212: mixture of a resin monomer and the plasticiser (dibutyl pthalate)) were 
pooled into a measuring container, placed in an oven at 60°C and left for 10 minutes 
before mixing to reduce the viscosity of the components. The mixture was then poured 
into a warm conical flask and mixed by swirling until the mixture became transparent. 
After mixing, 600 µl of benzyldimethylamine (BDMA) was added to the mixture and 
mixed again for 1 minute at which point the colour of the resin turned deep amber and 
the resin was ready for use. 
The pellet obtained after dehydration was resupended in 1-1 acetonitrile and resin 
mixture (V/V) 18 hours under rotation at 25°C. The samples were then infiltrated with 
1-2 acetonitrile and resin mixture (V/V) 6 hours with rotation at 25°C and finally with 
100% resin mixture for 24 hours with rotation at 25°C and several changes. Between 
each change of solution the samples were centrifuged at 20,800×g for 5 minutes at 
25°C and resuspended in the next infiltration solution. 
After infiltration, the samples were placed in a resin filled embedding capsules and the 
resin was cured by incubation at 60°C for 48 hours. 
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2.3.4 Staining of the thin sections of PSDs 
The method for staining was based on the use of the heavy metal stains uranyl acetate 
(U) and lead citrate (Pb). Both U and Pb are cations which bind to anionic sites in the 
thin sections conferring the ability to scatter electrons thus generating positive 
contrast. 
After sectioning the embedded PSD fractions, ultrathin sections of the samples were 
dried down onto a support grid and were floated on a drop of 50% methanol 
containing 2% uranyl acetate solution during 4 minutes. The grid and the sample were 
then jet washed with 50% methanol solution followed by deionised water. This was 
followed by staining for 4 minutes with Reynolds lead citrate and further rinsing with 
DIW. The samples were then ready for TEM imaging. 
 
2.3.5 Imaging of the PSDs 
The ultrathin section of the samples sitting on a grid was clamped into a single tilt, 
specimen rod which was inserted, via an airlock, into the microscope (FEI Tecnai G2). 
Inside the column of the TEM, which was maintained at high vacuum, the ultrathin 
section was imaged at 120kv and a magnified image of the interior of the ultrathin 
section of the samples was projected onto a viewing screen. A CCD camera was used 
to record the images which were digitised and archived by a computer. 
2.4 Protein assay 
After extraction of the different fractions from premotor cortex (see section 2.2.4), 
proteins concentrations were assessed using the bicinchoninic acid (BCA) assay (Pierce; 
23235). This protein assay is a detergent-compatible BCA formulation for the 
colorimetric detection and quantification of the total amount of proteins in a sample. 
The technique is based on the detection Cu+1, which is formed when Cu+2 is reduced by 
protein in an alkaline environment. A purple-colored reaction product is formed by the 
chelation of two molecules of BCA with one cuprous ion (Cu+1). This water-soluble 
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complex exhibits a strong absorbance at 562 nm that is linear with increasing protein 
concentrations. 
 
2.4.1 Standard curve and sampling 
Initially, a range of different known concentrations of bovine serum albumin (BSA) 
were prepared to establish a standard curve of protein concentration which was used 
to determine the concentration of protein in our samples. A solution of BSA at 2 mg/ml 
(Pierce; 23209) was used to prepare the seven different concentrations (2.5, 5, 10, 20, 
40, 80 and 100 µg/ml) of the standard curve (see Table 2-4).  
Table 2-4: BSA solutions for the standard curve. 
Final concentration of BSA BSA Added water 
100 µg/ml 50 µl of BSA at 2mg/ml 950 µl 
80 µg/ml 120 µl of BSA at 2mg/ml 2.880 ml 
40 µg/ml 1 ml of BSA at 80 µg/ml 1 ml 
20 µg/ml 1 ml of BSA at 40 µg/ml 1 ml 
10 µg/ml 1 ml of BSA at 20 µg/ml 1 ml 
5 µg/ml 1 ml of BSA at 10 µg/ml 1 ml 
2.5 µg/ml 1 ml of BSA at 5 µg/ml 1 ml 
BSA – bovine serum albumin. 
All protein assay experiments were carried out in 96 well plates (Fishers Scientific; DIS-
971-030J). The solutions of BSA at known concentrations were pipetted in duplicate 
into the first two columns of the 96 well plates. The first two wells of the first row of 
the 96 well plates were loaded with 150 µl of solution of BSA at 100 µg/ml and 150 µl 
of solution of BSA at 80, 40, 20, 10, 5 and 2.5 µg/ml was loaded in a same manner in 
the first two wells of the six following rows. The two first wells of the last row of the 96 
well plates were loaded with 2 µl of lysis buffer used for the extraction of the PSD and 
148 µl of water was added (Blank). The samples were then pipetted in duplicate, 2 µl 
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of sample was loaded in a well for each replicate and 148 µl of water was added in 
each well. 
 
2.4.2 Measurement of the protein concentration 
The BCA solution was prepared by mixing the 3 following reagents (80 wells): 
 Reagent A (Pierce; 23231): 6.25 ml of 0.2 M NaOH containing sodium 
carbonate, sodium bicarbonate and sodium tartrate. 
 Reagent B (Pierce; 23231): 6 ml of 4% BCA in water. 
 Reagent C (Pierce; 23231): 250 µl of 4% cupric sulfate, pentahydrate in water. 
In each well (standards and samples), 150 µl of the BCA solution was added within 5 
minutes. The plates were agitated at 300 rpm on a plate shaker for 30 seconds at 25°C. 
The plates were covered with foil and incubated during 1 hour at 37°C. After 
incubation the plates were left at 25°C for 10 minutes and the absorbance measured 
with a plate reader (Thermo Fisher Scientific; Varioskan Flash Multimode Reader) at 
562 nm. 
The software of the plate reader was set to calculate the average of each duplicate, to 
subtract the blank from the standards, to calculate the coefficient of correlation of the 
standard curve and the protein concentration of our samples in µg/µl. 
 
2.5 Western Blotting 
 
2.5.1 Sample denaturing 
The proteins were denatured by adding 4 µl of 500 mM dithiothreitol reducing agent 
(Invitrogen; NP0004) and 12.5 µl of loading sample buffer (Invitrogen; NP0007) in 25 µl 
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of sample containing 60 µg of protein, followed by 10 minutes incubation in a air dry 
heater at 70°C. 
 
2.5.2 Proteins separation 
To separate the denatured proteins a sodium dodecyl sulfate (SDS) polyacrylamid gel 
1.5 mm in thickness was prepared. The gel was composed of two gels, the main and 
the stacking gel respectively with 8% and 5% acrylamid-bisacrylamid (29:1) (See Table 
2-5). The main gel (8%) at the bottom was first poured between the glass plates with 
permanent bonded gel spacers sealed on a casting stand and left 20 minutes for 
polymerisation at 25°C. The stacking gel (5%) at the top in which the denatured 
proteins were concentrated was then poured on top of the main gel. A polycarbonate 
comb was added between the glass plates in order to mould the 10 wells of the gel 
and left 20 minutes for polymerisation at 25°C. After polymerisation, the glass plates 
containing the polyacrylamid gel were placed in an electrophoresis apparatus for 
protein separation.  
The running buffer composed of 25 mM Tris, 192 mM glycine, 0.1% SDS (W/V) in water 
(see Table 2-6) was poured in the electrophoresis apparatus to cover the wells of the 
gel. The first well was loaded with 4 µl of the ladder of molecular weight (LI-COR; 928-
40000) and 40 µl of denatured proteins were loaded in the subsequent wells of the 
polyacrylamid gel. Migration of the proteins through the polyacrylamid gel occured 
during 2 and 10 minutes respectively at 200 and 75 volts to concentrate proteins into 
the stacking gel, and then for 1 hour at 170 volts to separate proteins according to 
their molecular weight. 
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Table 2-5: Buffers for main and stacking polyacrylamid gels. 
2 gels Main gel 8%  Stacking gel 5%  
Acrylamid-Bisacrylamid 40% 4 ml 625 µl 
Tris-HCl 1 M pH 6.8 - 1.250 ml  
Tris-HCl 1.5 M pH 8.8 7,5 ml - 
SDS 10%  200 µl 50 µl 
APS 10% 200 µl 50 µl 
Temed 8 µl 4 µl 
H2O 8.100 ml 3 ml 
Tris HCl - Tris-buffered saline (TBS) with hydrochloric acid; SDS - sodium dodecyl sulfate; APS 
– ammonium persulfate; Temed - ; H2O - water. 
 
2.5.3 Proteins transfer and unspecific sites blocking 
At the end of the separation, proteins in the gel were transferred onto a polyvinylidene 
difluoride (PVDF) membrane using an electro-blotter for 90 minutes at 350 mA. All 
non-specific binding sites of the membrane were saturated by incubation 1 hour under 
agitation in Tris Buffer Saline (TBS) supplemented with 10% low fat milk (W/V) and 
0.1% Tween (V/V) blocking buffer at 25°C (see Table 2-6). A solution of TBS 5X 
composed of 20 mM Tris and 150 mM NaCl was prepared prior to transfer and stored 
at 4°C (see Table 2-6). The PVDF membranes were soaked in 100% methanol for 2 
minutes and rinsed in 25 mM Tris, 192 mM glycine, 20% methanol transfer buffer (see 
Table 2-6). After migration and separation of the proteins the polyacrylamid gels were 
placed on top of two sponges and a sheet of Whatman filter paper before being 
soaked in transfer buffer. In the gel holder cassettes the PVDF membranes were placed 
on top of the gels and any bubbles that appeared between the gels and the 
membranes were removed. One additional sheet of Whatman filter paper and a 
sponge soaked in transfer buffer were added on top of the membranes. The gel holder 
cassettes were closed and placed into an electro-blotter and a container with iced 
water was added to cool down the system. The transfer buffer was then poured into 
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the buffer chamber to completely cover the gel holder cassettes. The electro-blotter 
was then plugged to the generator and transfer was carried out at 350 mA for 90 
minutes at 25°C. After transfer the membranes were removed from the gel holder 
cassettes and rinsed in TBS-0.1% Tween. The membranes were then blocked with the 
blocking buffer 1 (Table 2-6) for 1 hour at 25°C and washed 3 times with TBS-Tween for 
10 minutes at 20°C. The membranes were then ready for immunodetection.  
 
Table 2-6: Buffers for Western blotting.  
Compounds Running Transfer TBS 5X TBS-tween Blocking 1 Blocking 2 
Tris 3.02 g 3.02 g 24.2 g - - - 
Glycine 14.4 g 14.4 g - - - - 
NaCl - - 87.6 g  - - 
Methanol - 200 ml - - - - 
SDS 1 g - - - - - 
Tween 20 - - - 1 ml - - 
TBS 5X - - - 200 ml - - 
TBS-Tween - - - - up to 10 ml up to 10 ml 
Low fat milk - - - - 1 g - 
BSA - - - -  1 g 
H2O up to 1 l up to 1 l up to 2 l up to 1 l - - 
Tris - Tris-buffered saline (TBS); NaCl – sodium chloride; SDS - sodium dodecyl sulfate; Tween 
20 - polysorbate surfactant; TBS 5X - Tris-buffered saline 5X; TBS-Tween - Tris-buffered saline 
-polysorbate surfactant; BSA - bovine serum albumin; H2O - water. 
 
2.5.4 Immunodetection 
Immunodetection was performed with primary antibodies directed against proteins of 
interest. The primary antibodies were diluted in blocking buffer 2 (Table 2-6), and 
incubated for 16 hours at 4°C (Table 2-7). At the end of the incubation with the 
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primary antibodies, the membranes were washed 3 times in TBS 0.1% Tween to 
eliminate unlinked primary antibodies. Then membranes were incubated in the dark 
with secondary antibodies, diluted in blocking buffer 1 (Table 2-6), directed against the 
species in which were produced the primary antibodies (Table 2-7). Membranes were 
again washed three times in TBS 0.1% Tween. 
 
Table 2-7: Antibodies for Western blotting. 
Antibodies Dilution 
Time of 
incubation 
Type of secondary 
antibody 
Anti PSD-95 (Cell Signaling; #3450) 1/4,000 16 hours at 4°C Anti rabbit 
Anti Trk B (Cell Signaling; #4607S) 1/4,000 16 hours at 4°C Anti rabbit 
Anti-CaMKII (Cell Signaling; #3362 ) 1/4,000 16 hours at 4°C Anti rabbit 
Anti-p75 (R&D system; MAB 367) 1/4,000 16 hours at 4°C Anti mouse 
Anti-NSF (Cell Signaling; #2145) 1/4,000 16 hours at 4°C Anti rabbit 
Anti-NR2A (Cell Signaling; #4205 ) 1/4,000 16 hours at 4°C Anti rabbit 
Anti-AMPAR (Cell Signaling; # 2460) 1/4,000 16 hours at 4°C Anti rabbit 
Anti-Synaptophysin (Cell Signaling; 
#4329) 
1/4,000 16 hours at 4°C Anti rabbit 
Anti-GFAP (Cell Signaling; #3670) 1/4,000 16 hours at 4°C Anti mouse 
Anti β-actin (Sigma, A3516) 1/10,000 16 hours at 4°C Anti mouse 
Anti β-III-tubulin (Sigma, T8578) 1/5,000 16 hours at 4°C Anti mouse 
Anti-rabbit (LI-COR; 926-32210) 1/10,000 1 hour at 25°C - 
Anti-mouse (LI-COR; 926-32220) 1/10,000 1 hour at 25°C - 
 
2.5.5 Detection by immunofluorescence « Western Odyssey » 
This technique is based on the detection of the emission of fluorescence after 
excitation by near-infrared of a fluorophore linked to the secondary antibodies. It 
provides the following benefits: the ability to quantify several proteins on a single 
membrane and the conservation of stable and consistent signal during a long time. To 
read the emission of fluorescence a scanner (Odyssey Infrared Imaging System; LI-COR) 
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was used, which retransmits digital image of the emitted fluorescence and allows 
detection either one or the other of the proteins, or both simultaneously. 
After washes, the membranes were placed on the glass of the scanner proteins facing 
the glass and scanned at 6 and 7.5 intensity respectively for 700 nm (red) and 800 nm 
(green) emissions. 
 
2.6 Co-immunoprecipitation 
Magnetic beads (Invitrogen; 100-02D) were used to co-immunoprcipitate PSDs. 
Magnetic beads are covalently linked to proteins A which are proteins that have the 
capacity to bind constant fragment Fc of the antibody directed against one of the 
protein of the PSD complex. For our experiments we used an antibody against PSD-95 
(Table 2-7).  
 
2.6.1 Tubes coating 
The microcentrifuge tubes used for the co-immunoprecipitation were coated with 
sigmacote (Sigma; SL2) and bovine serum albumin (BSA) in order to avoid the PSDs to 
stick to the hedge of the microcentrifuge tubes. Prior to co-immunoprecipitate the 
PSDs, 1.5 ml microcentrifuge tubes were coated with 1 ml sigmacote during 30 
seconds and the tube upside down for another 30 seconds. After discard of the 
sigmacote, the tubes were left to dry 30 minutes under hood at 25°C. When dried the 
tubes were washed twice with 1 ml of sterile deionised water. A second coating was 
carried out with 1 ml of a solution of 10% BSA in sterile deionised water during 30 
minutes on a plate shaker at 300 rpm and 30 additional minutes with the tubes upside 
down. Both steps were carried out at 25°C. After removal of the BSA solution the tubes 
were washed twice with 1 ml of sterile deionised water and ready for co-
immunoprecipitation of the PSDs. 
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2.6.2 Cross linking of the magnetic beads with antibodies directed to PSD-95 
After coating of the tubes, 50 µl of magnetic beads were resuspended in 700 µl of TBS 
0.1% Tween and 10 µl of antibody directed against PSD-95 were incubated for 20 
minutes on a tilting rotator at 25°C. After incubation with the antibody the tubes were 
placed on a magnet and the supernatant was discarded. The beads were then washed 
3 times with 200 µl of TBS 0.1% Tween to eliminate unlinked antibodies. 
 
2.6.3 Immuno-purification of the PSD fraction 
After washes, the beads-PSD-95 antibodies complexes were resuspended 700 µl of TBS 
0.1% Tween and 60 µg of protein from the PSD fraction was added. The tubes were 
then placed on a tilting rotator and incubated 20 minutes at 25°C. After incubation, 
tubes were placed on a magnet and the supernatant was removed. 
 
2.6.4 Wash of the beads-antibodies-PSDs complexes and elution by 
denaturation 
The beads-antibodies-PSDs complexes were resuspended in 500 µl of TBS 1% tween, 
placed on a tilting rotator and incubated for 15 minutes at 25°C. This step was 
repeated four times in order to remove any proteins that would not have bound the 
beads or the antibody directed to PSD-95 specifically. After removal of the unspecific 
binding, the tubes were placed on a magnet and rinsed three times with 200 µl of TBS 
0.1% Tween to eliminate the excess of Tween. The beads-antibodies-PSDs complexes 
were resuspended in 40 µl of TBS 0.1% Tween and 4 µl of 500 mM dithiothreitol (DTT) 
reducing agent and 12.5 µl of loading sample buffer followed by 10 minutes incubation 
in a air dry bath at 70°C. After denaturing elution 40 µl of elute was loaded in 
polyacrylamid gel for Western blot (see section 2.5). 
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2.7 Data and statistical analysis 
The fluorescence emitted by the secondary antibodies on the membranes was 
recorded with the software of the scanner (Odyssey Infrared Imaging System; LI-COR) 
and was used for data analysis. Data were transferred and analysed on excel tables. 
Statistic analyses were performed using SPSS statistical analysis software. 
 
2.7.1 Data analysis 
For each band detected corresponding to the targeted protein on a membrane the 
signal was quantified using a squared area having the same surface for each sample. 
This squared area was replicated 5 times and the squared areas were disposed on 
different part of the membrane where no protein was detected to define the value of 
the background. The average of the background for the defined squared area was 
subtracted from each value obtained for all the samples on the same membrane. To 
normalise our results, a ratio between the protein of interest and β-actin and β-III-
tubulin was carried out. 
 
2.7.2 Removal of outliers 
After data analysis, the data were pasted in SPSS for statistical analysis. For each 
protein and for each group tested the intensity of fluorescence was represented on a 
boxplot chart in order to remove the outlier values. Outliers were removed for each 
protein concerned and in each ratio where the outlier was involved. In a same way, 
outliers of the ratios were removed. 
 
2.7.3 Statistical test  
After analysis of the normal distribution of our samples and study of the homogeneity 
of variance an ANOVA test was chosen to compare the four different groups for each 
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protein studied. ANOVA and Spearman's correlation coefficient were used for the 
analysis of covariables and when these tests were significant an ANCOVA was 
performed to compare the four different groups for each protein studied. 
  
 
3 Enrichment and characterisation of the glutamate post-
synaptic density  
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3.1 Aims and objectives 
The aims of the present study are to characterise the integrity and the purity of the 
PSD fraction following fractionation of homogenates of frozen human frontal cortex. A 
comparison between the different steps of fractionation will also be done. The 
integrity and morphology of the PSDs will also be determined using osmication staining 
and TEM imaging. Western blotting analysis will be used to determine the presence of 
expected constituents of the PSD such as the scaffolding protein PSD-95, the NR2A 
subunit of the NMDAR and subunits 2, 3 and 4 of AMPARs. Western blotting analysis 
will also be utilised to evaluate the purity of the obtained PSD fractions by assessing 
known contaminants such as the pre-synaptic vesicles marker, synaptophysin, the 
cytoskeletal protein β-III-tubulin and the marker of glial cells, glial fibrillary acidic 
protein (GFAP). 
 
3.2 Introduction 
Glutamate neurons are polarised cells with defined regions consisting of a cell body, an 
axon ending with a synaptic terminal, and the post-synaptic dendrites that receive 
impulses from other neurons. Glutamate neurons receive, conduct, and transmit 
electrochemical impulses in the nervous system via highly differentiated structures 
called excitatory synapses (see Figure 3-1). These excitatory synapses are characterised 
by an electron-dense structure forming a thickening of the postsynaptic membrane of 
dendritic spines, called the PSD (Kennedy, 2000; Sheng and Sala, 2001). 
The PSD is a highly organized multi-protein complex with disk-like structure, 30-40 nm 
thick and 250-500 nm wide, which contains receptors, receptor-associated scaffold 
proteins, cytoskeleton elements, and regulatory enzymes. The PSD plays a crucial role 
in the re-organisation of the receptors at the postsynaptic dendrites and the induction 
of signal transduction molecules in response to presynaptic terminal glutamate release 
(Dosemeci et al., 2006). These changes in the molecular organisation of the post-
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synaptic dendrites modulate the excitability of the neurones and their ability to make 
new synaptic connections by rearrangement of their cytoskeleton (Ho et al., 2011). 
This mechanism is called synaptic plasticity and maybe disturbed in psychiatric 
disorders (Eastwood, 2003; Lewis and Moghaddam, 2006). 
 
 
Figure 3-1: Electron micrograph of glutamate synapses.  
(a)Region of the hippocampus highlighted with illustrative colours (scale bar: 1 μm). (b) High 
magnification of an excitatory synapse. (Taken from (Sheng and Hoogenraad, 2007)). 
 
During the 20th and beginning of the 21th century several methods were developed to 
isolate the PSD and combined with proteomic methods to analyse protein content of 
the PSD. Most of these studies were carried out using non-human mammalian brains 
(Dosemeci et al., 2007; Cohen et al., 1977; Cotman et al., 1974) . 
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3.2.1 Enrichment of the glutamate post-synaptic density 
Isolation of the PSD is based on a technique, developed at the beginning of the fifties, 
which uses sucrose density gradient followed by centrifugation. This method consists 
of centrifugation of a mixed population of particles with different densities in a 
discontinuous sucrose gradient containing two or more layers of sucrose, the top layer 
having the lowest concentrated solution of sucrose. A mixture of particles with 
different densities are layered onto the sucrose density gradient and centrifuged. The 
particles are separated at the interfaces of the sucrose density gradient depending on 
their density, the particles with high density passing further through the sucrose 
density gradient while particles with low density are retained at the interfaces of the 
sucrose density gradient (Brakke, 1951).  
In the mid seventies, a first attempt to use this technique to isolate the PSD was 
developed. Rat brains were homogenised in an isotonic 0.32 M sucrose solution and 
the resulting mixture submitted to several steps of centrifugation for separation and 
isolation of the PSD. The method that was developed to isolate a PSD fraction involved 
the preparation of a synaptosomal fraction containing synaptic junctions using a 
sucrose density gradient (0.8, 1, 1.2 M sucrose). The synaptosomal fraction was 
collected at the interface between 1 and 1.2 M sucrose layers and incubated with N-
lauroyl sarcosinate to detach the PSD from the synaptosomal membranes which 
remained insoluble in this detergent. The dissolved synaptosomal fraction was then 
layered on a second sucrose density gradient (1, 1.4, 2.2 M sucrose) to separate the 
PSD from other residual contaminants (see Figure 3-2). The purity and the integrity of 
the isolated PSDs were assessed respectively by electron microscopy and enzymatic 
assays. They showed that the isolated PSDs were structurally intact and exhibited 
properties which characterise them in situ. They also showed that the size, shape, and 
electron opacity of the isolated PSDs were those seen in tissue; and that the purity of 
the PSD fraction was better than 85% (Cotman et al., 1974). 
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Figure 3-2: Diagram illustrating the steps of fractionation to enrich and purify the post-
synaptic density (Adapted from (Cotman et al., 1974)). 
3
2
5
6
1
Fractions 
specific to the 
protocol
Common 
fraction with 
other protocols
Steps of extraction: 
Differences and 
similarities with 
other protocols (see 
Table 3.1)
Rat Brain tissue
20g
Homogenisation in 0.32 M 
Sucrose, 1 mM MgCl2
Total fraction
1,000xg  for 5 minutes
Pellet
Supernatant
Pellet
Supernatant
Mitochondrial 
fraction
(Re-suspended in 0.32 M Sucrose)
Sucrose gradient
(0.8 M – 1 M – 1.2 M)
Synaptosomal
fraction
14,500xg  for 10 minutes
Diluted 1:2 with 0.05 mM CaCI2
PSD fraction
Supernatant
Pooled
25,000 rpm  for 105 minutes
Interface 
(1 M – 1.2 M)
Supernatant
Incubated with sodium N-lauroyl
Sarcosinate 3% for 10 minutes at 4oC 
Pellet Resuspended in 2 mM Bicine (pH 7.5)
Diluted 1:3 with 0.1 mM EDTA 
63,600xg  for 75 minutes
78,500xg  for 20 minutes
1,000xg  for 5 minutes
Mitochondrial 
precipitation
Incubated 25 minutes at 30oC in 5 mM 
p-iodonitrotetrazolium violet (INT), 
400n mM succinate,  0.05 mM CaCl2 in 
0.2 M Na2PO4 , pH 7.5
Pellet
8,720xg  for 7 minutes
(Re-suspended in 0.05 mM CaCI2, pH 7.0 
and incubated  20 minutes at 0oC)
Pellet
Supernatant
(Re-suspended in 0.16 M sucrose, 
0.05 mM CaCI2)
Pellet
34,880xg  for 15 minutes
Supernatant
(Re-suspended in 0.16 M sucrose, 
0.05 mM CaCI2)
Pellet
34,880xg  for 15 minutes
Supernatant
(Re-suspended in 0.32 M sucrose, 
0.05 mM CaCI2)
Sucrose gradient
(1 M – 1.4 M – 2.2 M)
78,500xg  for 20  minutes
Interface 
(1.4 M – 2.2 M)
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Another study showed that the detergent Triton X-100 could be used as an alternative 
to N-lauroyl sarcosinate detergent and introduced ultracentrifugation (100,000g) to 
extract the PSD fraction from dog cerebral cortex. In this study they compared two 
methods of isolation of the PSDs, one with a short procedure of isolation (see Figure 
3-3) and one with a long procedure of isolation (see Figure 3-4), both based on Cotman 
et al., 1974 method with slight modifications. For the long procedure of isolation of the 
PSDs one sucrose density gradient separation was added after collection of the 
synaptosomal fraction as described by Cotman et al., 1974 method. They obtained 
similar results with both short and long procedure for the isolation of the PSDs 
regarding the purity and integrity of the PSDs determined by electron microscopy, 
enzymatic assays, and gel electrophoresis of the proteins (Cohen et al., 1977). 
A study demonstrated that the previous short procedure of extraction developed by 
Cohen et al., 1977 could be used for the isolation of the PSDs in different regions of the 
dog brain. In this study they extracted PSDs from cerebral cortex, midbrain, 
cerebellum, and brain stem using the Triton X-100 method (see Figure 3-5). They 
compared the protein composition, the protein phosphorylation, and the morphology 
of the PSDs in the different regions of the brain. They showed using electron 
microscopy and gel electrophoresis of the proteins that PSDs had different molecular 
phenotype depending on their localisation into the brain. The shape and the protein 
content of the PSDs were similar in cerebral cortex and midbrain whereas the shape 
and protein content were different in cerebellum of dog brain than the two regions 
previously mentioned (Carlin et al., 1980). 
Previous techniques to isolate the PSDs mentioned above were utilised either for 
whole brain or brain regions of relatively large mammals such as dogs and rats. In 
those studies they were using between 20 and 80 grams of brain tissue. For the 
isolation of the PSDs from human post-mortem brain tissue a reduction in the amount 
of tissue used for extraction of the PSD is desirable as human brain tissue samples are 
precious. 
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Figure 3-3: Diagram illustrating the steps of fractionation (short procedure) to enrich and 
purify the post-synaptic density (Adapted from (Cohen et al., 1977)). 
3
5
6
1
Rat-dog Brain 
tissue
20-80g
Homogenisation in 0.32 M Sucrose, 1 mM NaHCO3, 
1 mM MgCI2, 0.5 mM CaCI2
Total fraction
1,475xg  for 10 minutes
Pellet
Supernatant
Pellet
Supernatant
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3, 1 mM MgCI2, 0.5 mM CaCI2)
17,300xg  for 10 minutes
Supernatant
Pooled
755xg  for 5 minutes
Pellet
755xg  for 5 minutes
Pellet
Supernatant
Pellet
Supernatant
17,300xg  for 10 minutes
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3, 1 mM MgCI2, 0.5 mM CaCI2)
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
Sucrose gradient
(0.85 M – 1 M – 1.2 M)
Synaptosomal
fraction
PSD fraction
100,000xg  for 2 hours at 4oC
Interface 
(1 M – 1.2 M)
Supernatant
Pellet
Re-suspended in 0.16 M sucrose, 0.5% triton X-100, 
6 mM Tris-HCl pH 8.1  and stirred 15 minutes at 4oC
Supernatant
Pellet
48,200xg for 20 minutes at 4oC
48,200xg  for 20 minutes at 4oC
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
Sucrose gradient
(1 M – 1.5 M – 2 M)
Synaptosomal
Plasma membranes 
(SPM) fraction
275,000xg  for 2 hours at 4oC
Interface 
(1.5 M – 2 M)
Interface 
(0.32 M – 1 M)
Fractions 
specific to the 
protocol
Common 
fraction with 
other protocols
Steps of extraction: 
Differences and 
similarities with 
other protocols (see 
Table 3.1)
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Figure 3-4: Diagram illustrating the steps of fractionation (long procedure) to enrich and 
purify the post-synaptic density (Adapted from (Cohen et al., 1977)). 
3
4
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1
5
Rat-dog Brain 
tissue
20-80g
Homogenisation in 0.32 M Sucrose, 1 mM NaHCO3, 
1 mM MgCI2, 0.5 mM CaCI2
Total fraction
1,475xg  for 10 minutes
Pellet
Supernatant
Pellet
Supernatant
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3, 1 mM MgCI2, 0.5 mM CaCI2)
17,300xg  for 10 minutes
Supernatant
Pooled
755xg  for 5 minutes
Pellet
755xg  for 5 minutes
Pellet
Supernatant
Pellet
Supernatant
17,300xg  for 10 minutes
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3, 1 mM MgCI2, 0.5 mM CaCI2)
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
Sucrose gradient
(0.85 M – 1 M – 1.2 M)
Synaptosomal
fraction
100,000xg  for 2 hours at 4oC
Interface 
(1 M – 1.2 M)
Supernatant
Pellet (Re-suspended in 6 mM Tris-HCl pH 8.1  and stirred 45 minutes at 4oC)
Supernatant
Pellet
48,200xg for 20 minutes at 4oC
48,200xg  for 20 minutes at 4oC
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
Sucrose gradient
(0.85 M – 1 M – 1.2 M)
100,000xg  for 2 hours at 4oC
PSD fraction
Sucrose gradient
(1 M – 1.5 M – 2 M)
Synaptosomal
Plasma membranes 
(SPM) fraction
275,000xg  for 2 hours at 4oC
Interface 
(1.5 M – 2 M)
Interface 
(0.32 M – 1 M)
Synaptosomal
Membrane 
fraction (SM)
Interface 
(1 M – 1.2 M)
Supernatant
48,200xg  for 20 minutes at 4oC
(Re-suspended in 0.32 M sucrose, 0.5% triton X-100, 
6 mM Tris-HCl pH 8.1  and stirred 15 minutes at 4oC)Pellet
Supernatant
48,200xg  for 20 minutes at 4oC
Pellet
Fractions 
specific to the 
protocol
Common 
fraction with 
other protocols
Steps of extraction: 
Differences and 
similarities with 
other protocols (see 
Table 3.1)
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Figure 3-5: Diagram illustrating the steps of fractionation to enrich and purify the post-
synaptic density (Adapted from (Carlin et al., 1980)). 
3
5
6
1
Canine Brain 
region
40-60g
Homogenisation in 0.32 M Sucrose, 1 mM NaHCO3, 
1 mM MgCI2, 0.5 mM CaCI2
Total fraction
1,400xg  for 10 minutes
Pellet
Supernatant
Pellet
Supernatant
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3, 1 mM MgCI2, 0.5 mM CaCI2)
13,800xg  for 10 minutes
Supernatant
Pooled
710xg  for 10 minutes
Pellet
710xg  for 10 minutes
Supernatant
Pellet (Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
Sucrose gradient
(0.85 M – 1 M – 1.2 M)
Synaptosomal
fraction
PSD fraction
82,500xg  for 2 hours at 4oC
Interface 
(1 M – 1.2 M)
Re-suspended in 0.16 M sucrose, 0.5% triton X-100, 
6 mM Tris-HCl pH 8.1  and stirred 15 minutes at 4oC
Supernatant
Pellet
32,800xg for 20 minutes at 4oC
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
(Re-suspended in 0.32 M Sucrose, 1 mM NaHCO3)
Sucrose gradient
(1 M – 1.5 M – 2 M)
201,800xg  for 2 hours at 4oC
Interface 
(1.5 M – 2 M)
(Re-suspended in 0.16 M Sucrose, 0.5 mM
NaHCO3,  0.5% triton X-100,  75 mM KCl)
201,800xg  for 20 minutes at 4oC
Fractions 
specific to the 
protocol
Common 
fraction with 
other protocols
Steps of extraction: 
Differences and 
similarities with 
other protocols (see 
Table 3.1)
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Two recent studies present new approaches to reduce the amount of starting tissue 
and the time needed for the isolation of the PSDs. The first study reported a simple 
and highly effective procedure for the rapid isolation of PSDs from 200 mg of adult 
mouse hippocampus (see Figure 3-6). In this study the authors replaced the first 
sucrose density gradient (0.8, 1, 1.2 M sucrose) previously described to isolate the 
synaptosomal fraction by two successive filtrations using 100 and 5 μm filters. After 
filtration of the hippocampus homogenate they used the same second sucrose density 
gradient (1, 1.4, 2 M sucrose) previously utilised to isolate the PSDs. They 
characterised the obtained PSD fractions using electron micrographs and Western blot 
analysis and showed that this technique yields purified PSD fraction sample. Moreover, 
they compared two different protocols using swing and fixed bucket rotors for PSD 
isolation and both resulted in very pure PSD fractions (Villasana et al., 2006). Although 
the amount of starting tissue required for the isolation of the PSDs using the technique 
presented above was substantially reduced, the amount of tissue remained too 
important for human post-mortem brain studies. A second technique was recently 
developed to isolate the PSDs from 5-6 slices (400 μm thick) of rat hippocampus (see 
Figure 3-7). 
In this study the authors described a simple and convenient method based on the 
fractionation of the tissue homogenate by sucrose density gradient (0.32, 0.8 M 
sucrose), followed by two consecutive extractions of a synaptosomal fraction with 
Triton X-100 for the preparation of PSD fractions. They showed that PSD fractions 
obtained were signiﬁcantly enriched in the protein PSD-95, one of the most abundant 
protein of the PSD, using Western blotting and that the shape of the PSDs after 
isolation was similar to those observed in situ using electron microscopy. They studied 
the composition of the PSD fraction by 2D LC-MS/MS and they identified PSD-
scaﬀolding proteins, signaling molecules, cytoskeletal elements known to be present in 
the PSD. In addition, they showed that further puriﬁcation of PSDs was possible using 
magnetic beads coated with a PSD-95 antibody (Dosemeci et al., 2006). 
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Figure 3-6: Diagram illustrating the steps of fractionation to enrich and purify the post-
synaptic density (Adapted from (Villasana et al., 2006)). 
All the previous methods described above were used for the extraction of non human 
brain samples and the PSD fractions were prepared from tissue freshly removed from 
the host. Biochemical fractionation of postmortem brain tissues faces special 
challenges due to the impact of the agonal state, complicating medical conditions, the 
post-mortem interval (PMI), inconsistent pH, and duration of storage. These conditions 
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may affect the integrity of the PSDs by modifying the structure of the proteins inside 
the complex (Hunsucker et al., 2008).  
 
 
Figure 3-7: Diagram illustrating the steps of fractionation to enrich and purify the post-
synaptic density (Adapted from (Dosemeci et al., 2006)). 
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A study recently assessed the feasibility of the isolation of PSDs from human post-
mortem tissue and the integrity of the PSDs after extraction. In their study they 
examined three different methods: 1) Method 1, using the a slightly modified version 
of the short procedure previously developed by Cohen et al. 1977 (see Figure 3-8); 2) 
Method 2, a sucrose density gradient based purification of synaptosomes, followed by 
detergent extraction and pH based differential extraction of synaptic membranes (see 
Figure 3-9); and 3) Method 3, a mixture of the two precedent methods (see Figure 
3-10). 
 
Figure 3-8: Diagram illustrating the steps of fractionation (method 1) to enrich and purify the 
post-synaptic density (Adapted from (Hahn et al., 2009)). 
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Figure 3-9: Diagram illustrating the steps of fractionation (method 2) to enrich and purify the 
post-synaptic density (Adapted from (Hahn et al., 2009)). 
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Figure 3-10: Diagram illustrating the steps of fractionation (method 3) to enrich and purify 
the post-synaptic density (Adapted from (Hahn et al., 2009). 
 
For all three methods electron microscopy experiments showed that the integrity of 
the PSDs was conserved after their extraction and that the typical PSD proteins were 
present and enriched after isolation of the PSDs using western blotting and 2D LC-
MS/MS (Hahn et al., 2009). 
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Table 3-1: Summary of main differences (orange) and similarities (blue) between protocols 
developed to extract the PSD. 
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All techniques presented above have been intensively used during the last two 
decades to isolate the PSDs and have been combined with proteomic methods to 
analyse and characterise the content of the PSDs.  
 
3.2.2 Characterisation of the glutamate post-synaptic density 
Several methods such as electron microscopy, gel electrophoresis, Western blotting 
and liquid chromatography coupled with mass spectrometry can be used to 
characterise the morphology and the composition of the isolated PSDs. 
The morphology of the PSDs can be assessed using negative staining and TEM and was 
widely described by many studies (Dosemeci et al., 2006; Cohen et al., 1977; Cotman 
et al., 1974; Hahn et al., 2009). All these studies referenced an electron dense disk-
shaped structure with 200-500 nm diameter and 20-40 nm in thickness. A recent study 
demonstrated that the PSDs can be extracted from human brain samples (see Figure 
3-11) and could be used for further proteomic analyses (Hahn et al., 2009).  
Electron micrographs of the synaptosomal fraction are often presented to characterise 
the different steps of purification of the isolation of the PSD (see Figure 3-11). It 
consists of a fraction rich in membrane vesicles and organelles with electron dense 
opacity (see Figure 3-11 A). Within this synaptosomal fraction pre- and post-synaptic 
structures such as neurotransmitter vesicles and PSD can be observed. The PSD is 
often associated with presynaptic dense zone rich in proteins with high electron 
opacity (see Figure 3-11 B). In the PSD fraction this symetric structure can be observed 
after PSD isolation at pH 8 (see Figure 3-11 C). Depending on the method of extraction 
(pH 6) the pre-synaptic structure can be removed and the symmetric structures do not 
appear anymore in the electron micrograph images of the PSD fraction (see Figure 
3-11 D). 
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Figure 3-11: Electron micrographs of the synaptosomal and PSD fractions obtain after 
fraction of human brain samples. 
(A) Thin section of synaptosomal fraction. (B) High magnification of the synaptosomal 
fraction. (C) PSD fraction extracted with Triton X-100 at pH 6 from synaptic membranes. (D) 
PSD fraction extracted with Triton X-100 at pH 6 from synaptic membranes. Arrows show the 
PSDs (Taken from (Hahn et al., 2009)). 
 
Other studies used gold immunolabelling and TEM, rotary shadow electron microscopy 
or rotary shadow electron microscopy coupled with gold immunolabelling to describe 
the three dimensional morphology of the PSDs (see Figure 3-12) and to determine the 
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arrangement of receptors, scaffold proteins and kinases such as NMDAR, PSD-95 and 
CaMKII within the PSD (Carlin et al., 1980; Dosemeci et al., 2000; Chen et al., 2005). 
 
Figure 3-12: Micrographs of the PSD obtained by rotary shadow electron microscopy. 
(a) Granular surface of the PSD facing the synaptic cleft. (b) Intra-cytoplasm surface of the 
PSD. (Taken from (Sheng and Hoogenraad, 2007)). 
 
Although electron microscopy gives information on the morphology of the PSD and the 
localisation of specific proteins at the PSD, this technique is not appropriated to 
identify and to quantify the proteins in the PSD. Isolation of the PSDs coupled with 
proteomic techniques such as gel electrophoresis, Western blotting and LC-MS/MS 
give more qualitative and quantitative information regarding the protein composition 
of the PSD. 
Studies using LC-MS/MS have been critical to identify specific markers of the PSD such 
as receptors and scaffolding proteins (Yoshimura et al., 2004b; Collins et al., 2006b), 
such as NMDAR subunits, AMPAR subunits and PSD-95. Moreover LC-MS/MS and 
Western blotting were used to assess the purity of the PSD fraction by the 
Enrichment and characterisation of the glutamate post-synaptic density 
79 
 
identification of contaminants coming from the presynaptic terminal and mitochondria 
such as synaptophysin, SNAP-25 and proteins involved in metabolic processes. 
 
3.3 Materials and methods 
3.3.1 Enrichment of the glutamate post-synaptic density 
Six frozen blocks of human brain were weighed (100 mg), thinly chopped on ice and 
placed into homogeniser tubes (Precellys Bertin Technologies) containing 450 µl of ice-
cold 0.32 M sucrose, 1 mM MgCl2 solution containing 2.5 % of protease inhibitor 
cocktail (Sigma). Samples were homogenised in a Precellys 24 dual tissue homogenizer 
(Bertin Technologies) for 15 seconds at 5000 rpm. After homogenisation the samples 
were placed on ice and 50 µl of homogenate was pipetted into a labelled tube (Total 
fraction). The homogenates were fractionated using the extraction protocol described 
in section 2.2. 
At the end the procedure 12 PSD fractions were obtained. Two PSD fractions were 
used for electron microscopy analysis and all fractions collected during the 
fractionation of the 6 samples were used for Western blotting analysis. 
 
3.3.2 Electron microscopy 
Two PSD fractions extracted from two different frozen premotor cortex samples were 
used to perform transmission electron microscopy (TEM). 
All experiments were performed at the University of Cambridge (Department of 
Physiology, Development and Neuroscience) by Dr. Jeremy Skepper. 
The samples were fixed, washed, osmicated, dehydrated and embedded in epoxy 
resin. After embedding, ultrathin sections (50 nm) were prepared and were mounted 
on metal grids to be viewed in the TEM as described in section 2.3. 
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3.3.3 Protein concentration and protein assay 
Before assaying the protein concentration for each fraction collected after PSDs 
isolation, the collected washing steps were concentrated in a vacuum drier for 1 hour 
at 60°C. The dried pellet obtained was then re-suspended in 50 μl of sterile deionised 
water. 
A protein assay was then carried out on each fraction (Total fraction, cytosolic fraction, 
0.32 M sucrose fraction, light membrane/myelin fraction, washing 1, 2 and 3 fractions, 
and PSD fractions) during the PSD extraction of the six samples as described in section 
2.4. 
 
3.3.4 Western blotting 
For each fraction collected, 60 μg of protein was denatured and loaded onto 5-8% 
polyacrylamid gel. Proteins were separated and transferred on PVDF membranes for 
immunodectection of PSD-95, NR2A, AMPAR, synaptopysin, GFAP, β-III-tubulin and β-
actin. Western blotting was performed as described in section 2.5. 
Synaptophysin, Beta-III-tubulin and beta-actin were first detected and the membranes 
were then probed with PSD-95 and NR2A. The membranes were stripped 1 hour at 
25°C on a plate agitator, and probed with AMPAR and GFAP antibodies. 
 
3.3.5 Data analysis 
For each protein detected the background signed was substracted and a ratio of each 
protein with β-actin was calculated. An average of the ratio for the 6 experiments was 
calculated and total, cytosolic, myelin/light membranes and PSD fraction were 
compared. Statistical analysis was performed using SPSS-ANOVA test to assess the 
significant differences between each fraction compared.  
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3.4 Results 
3.4.1 Electron microscopy 
Electron microscopy was carried out on the pelleted PSD fraction and thin section were 
stained and visualised by TEM. Amongst all pictures recorded, two of them were 
selected to show the content of the PSD fraction.  
 
 
Figure 3-13: Electron micrograph of the PSD fraction. 
(magnification x 3,500). 
Electron micrographs showed a heterogenic composition of the PSD fraction with 
circular structures with low density (light grey) surrounded by particulate structures 
with higher density (dark grey). Amongst the particles with higher density, some have a 
symmetrical structure separated by a white gap (200-500 µm wide). These structures 
are the PSDs in transversal view (light blue arrows). Near circular shaped structures 
with high electron density indicated by the dark blue arrows show the PSDs via a top 
view. Additional circular shaped structures with smaller diameter and higher electron 
PSDs transversal view
PSDs top view
CaMKII clusters
Membrane vesicles
Mitochondria
Myelin
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density than the PSDs shown by the yellow arrows are the CaMKII clusters. Also, 
contaminants such as membrane vesicles (red arrows), mitochondrion (green arrow) 
and myelin (light grey arrows) were present in the PSD fractions (see Figure 3-13). The 
mitochondrion was differentiated from PSDs top view because of its regular ovoidal 
shape compared to the PSDs top view and the presence of internal membranes (visible 
on the digital picture). 
 
 
Figure 3-14: Electron micrograph of the PSD fraction with higher magnification. 
(magnification x 7,800). 
Observation of the PSD fraction with higher magnification (see Figure 3-14) showed 
the presence of the isolated PSDs. Three symmetrical PSDs separated by the synaptic 
cleft were observed and at least five PSDs without pre-synaptic dense electron opacity 
were also visible (light blue arrows). Disk-shaped structures were distinguishable and 
were designed either as transversal view of the PSD (dark blue arrow) or as CaMKII 
clusters (yellow arrows) depending on their electron opacity and diameter. 
PSDs transversal view
PSDs top view
CaMKII clusters
Membrane vesicles
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Contaminants such as membrane vesicles were also observed as indicated by red 
arrows (see Figure 3-14). 
 
3.4.2 Expression of PSD-95 
Each fraction separated and collected after PSD isolation was blotted on a PVDF 
membrane and PSD-95 was immunodetected (see Figure 3-15). The experiment was 
repeated 6 times (see Figure A-1) and the average of the ratio PSD-95/β-actin (β-actin 
being the protein used to normalise our results) for each fraction was compared to the 
ratio PSD-95/β-actin of the total fraction (see Figure 3-16). 
 
 
Figure 3-15: Digital image of a representative membrane after detection of PSD-95, tubulin, 
and actin.  
(L) ladder; (T) Total fraction; (C) Cytosolic fraction; (S) Sucrose 0.32 M fraction; (M) 
Myelin/light membranes fractions; (W1) wash 1 fraction; (W2) wash 2 fraction; (W3) wash 3 
fraction; (P) PSD fraction. 
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Immunodetection of PSD-95 showed visible green bands at 95 KDa which is the 
expected size of the target protein (see Figure 3-15). These bands were observed in 
the total, myelin/light membranes and PSD fractions. The signal observed in the PSD 
fraction was much stronger than in any other fraction. The signal for PSD-95 in the 
total and myelin/light membranes fractions was similar in both.  
 
 
Figure 3-16: Mean (± SEM) of the ratio PSD-95/β-actin in percentage of the total fraction. 
Statistical test ANOVA with Bonfferoni correction. Comparison with the total fraction (** 
p<0.01; *** p<0.001) 
The analysis of the results obtained from 6 experiments showed a significant increase 
in the ratio PSD-95/β-actin (up to 200 %; p<0.001) in the PSD fractions compared to 
***
**
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the total fractions. Moreover, the ratio PSD-95/β-actin was significantly decreased in 
the cytosolic fraction compared to the total fraction (p<0.01). No significant change 
was observed for the myelin/light membranes fractions compared to the total 
fractions (see Figure 3-16).  
 
3.4.3 Expression of NR2A 
The NR2A subunit of the NMDAR receptor was immunodetected at the same time as 
PSD-95 (see Figure 3-17). The experiment was repeated 6 times (see Figure A-3) and 
the average NR2A/β-actin ratio for each fraction was compared to the NR2A/β-actin 
ratio of the total fraction (see Figure 3-18). 
 
 
Figure 3-17: Digital picture of the membrane after detection of NR2A.  
(L) ladder; (T) Total fraction; (C) Cytosolic fraction; (S) Sucrose 0.32 M fraction; (M) 
Myelin/light membranes fractions; (W1) wash 1 fraction; (W2) wash 2 fraction; (W3) wash 3 
fraction; (P) PSD fraction. NR2A specificity (See Figure A-2). 
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As PSD-95 and NR2A were detected at the same time and the NR2A signal was much 
lower than PSD-95, the image showed very high unspecific binding (extra bands) due 
to the immunodetection of PSD-95. However, visible green bands were detected at the 
expected size (180 KDa) of NR2A (see Figure 3-17). These bands were observed with 
very weak intensity in the total, myelin/light membranes fractions and with much 
higher intensity in the PSD fractions. NR2A could not be visually detected in any other 
fraction. 
 
 
Figure 3-18: Mean (± SEM) of the ratio NR2A/β-actin in percentage of the total fraction. 
Statistical test ANOVA with Bonfferoni correction. Comparison with the total fraction 
(***p<0.001) 
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Comparison between fractions showed a significant increase of the amount of NR2A in 
the PSD fractions. No significant change was observed for the cytosolic and 
myelin/light membranes fractions compared to the total fraction (see Figure 3-16).  
3.4.4 Expression of AMPAR 
After detection of PSD-95 and NR2A the membranes were stripped and re-probed with 
an antibody directed to AMPAR subunits 2, 3 and 4 (see Figure 3-19). 
 
 
Figure 3-19: Digital picture of the membrane after detection of AMPAR.  
(L) ladder; (T) Total fraction; (C) Cytosolic fraction; (S) Sucrose 0.32 M fraction; (M) 
Myelin/light membranes fractions; (W1) wash 1 fraction; (W2) wash 2 fraction; (W3) wash 3 
fraction; (P) PSD fraction. 
 
Subunits 2,3,4 of the AMPAR have an expected size of 90 KDa. Immunodetection of 
AMPAR subunits showed visible green bands at 90 KDa in the total, myelin/light 
membranes and PSD fractions (see Figure 3-19). A much higher intensity of the signal 
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was observed for the PSD fraction than in any other fraction. The signal detected for 
AMPAR subunits in the total and myelin/light membranes fractions was similar in both 
fractions. No signal was detected in the other fractions. 
 
Figure 3-20: Mean (± SEM) of the ratio AMPAR/β-actin in percentage of the total fraction. 
Statistical test ANOVA with Bonfferoni correction. Comparisons with the total fraction 
(***p<0.001) 
 
Repeated measurements of the 6 experiments showed a significant increase of the 
AMPAR subunits (p<0.001) in the PSD fractions compared to the total fractions. No 
significant change was observed for the cytosolic and myelin/light membranes 
***
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fractions. However a decreasing trend could be observed for the cytosolic fraction 
compared to the other fractions (see Figure 3-20). 
 
3.4.5 Expression of synaptophysin, beta-III-tubulin and GFAP 
In order to determine the purity of the PSD fraction, synaptophysin, β-III-tubulin, and 
GFAP were detected on the membranes (see Figure 3-21). β-actin was detected at the 
same time as used for normalisation of the expression of each protein. GFAP was 
detected at the same time as AMPAR subunits after the membranes were stripped. 
 
 
Figure 3-21: Digital picture of the membranes after detection of synaptophysin, GFAP, β-III-
tubulin and β-actin. 
(A) Detection of synaptophysin and β-III-tubulin. (B) Detection of GFAP. (L) ladder; (T) Total 
fraction; (C) Cytosolic fraction; (S) Sucrose 0.32 M fraction; (M) Myelin/light membranes 
fractions; (W1) wash 1 fraction; (W2) wash 2 fraction; (W3) wash 3 fraction; (P) PSD fraction. 
 
Immunodetection of synaptophysin (green), β-III-tubulin and β-actin showed specific 
bands for all three proteins at their expected size, respectively 37, 52 and 42 KDa. β-
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actin was detectable in each fraction, whilst synaptophysin and β-III-tubulin did not 
appear in all fractions. β-III-tubulin was detected in almost all fractions but with very 
weak intensity in washes fractions. Synaptophysin, a maker of the pre-synaptic 
terminal was not detected in the last washes fractions nor the PSD fractions (see 
Figure 3-21 A). Astroglial cell marker GFAP, showed between 3 and 5 main bands 
indicating the one at expected size of GFAP (50 KDa). GFAP was detected in the total 
and myelin/light membranes fractions with similar intensities and with higher intensity 
in the PSD fractions. 
 
 
Figure 3-22: Mean of the ratio synaptophysin/β-actin in percentage of the total fraction. 
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Statistical test ANOVA with Bonfferoni correction. Comparison with the total fraction (*** 
p<0.001) 
Comparison of synaptophysin expression in total, cytosolic, myelin/light membranes 
and PSD fractions showed a significant decrease of synaptophysin expression in the 
PSD fractions (p<0.001). No further differences in expression of synaptophysin were 
found between the total, cytosolic and myelin/light membrane fractions. However a 
trend decrease of expression of synaptophysin was observed in the cytosolic fractions 
compared to the total and myelin/light membranes fractions (see Figure 3-22). 
 
 
Figure 3-23: Mean of the ratio β-III-tubulin/β-actin in percentage of the total fraction. 
#
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Statistical test ANOVA with Bonfferoni correction (# p<0.05;Comparison with cytosolic 
fraction). 
 
No significant difference was found for the expression of β-III-tubulin between the 
different fractions compared to the total fraction. However a significant increase of the 
expression of β-III-tubulin (# p<0.05) was found in the PSD fraction compared to the 
cytosolic fraction (see Figure 3-23).  
 
 
Figure 3-24: Mean (± SEM) of the ratio GFAP/β-actin in percentage of the total fraction. 
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Statistical test: ANOVA with Bonfferoni correction. Comparison with the total fraction 
(*p<0.05) 
 
The expression of the marker of glial cells GFAP showed a significant increase in the 
PSD fraction compared to the total fraction (p<0.05). A trend decrease of the 
expression of GFAP can also be observed in the cytosolic fraction compared to the 
other fractions. 
3.5 Discussion and conclusion 
 
This part of the study has verified: 
1. That it is possibility to extract PSDs from frozen human premotor cortex using 
sucrose gradient separation and bench centrifugation. 
2.  That the developped method leads to PSD fraction with an acceptable yield 
and PSD integrity. 
3. That proteins expressed mainly at the post-synaptic terminals are enriched in 
the PSD fraction compared to the whole homogenate.  
 
The characterisation of the PSD fraction using electron microscopy showed a 
heterogenic composition of the PSD. Indeed PSDs were detected in the PSD fractions 
with contaminants that resembled CaMKII clusters, mitochondria, myelin and 
membrane vesicles. These results were previously reported in a study using the same 
technique of PSD isolation (Dosemeci et al., 2006). The presence of PSDs in transverse 
view with or without symmetrical structures and disk-like shaped structures with high 
electron density indicated that integrity of the PSDs seems to be conserved after 
isolation from frozen blocks human brain (see Figure 3-14) as reported previously in a 
study using a different PSD isolation method on human PFC (Hahn et al., 2009). These 
results suggest the presence of both asymmetrical and symmetrical synapses in the 
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cerebral cortex as reported in other studies in the cerebral cortex of non-human 
mammalians (Carlin et al., 1980; Peters et al., 2008). 
Proteins of the PSD such as NMDAR, AMPAR and the scaffolding protein PSD-95 play a 
crucial role into the complex machinery of the PSD and their function maybe disturbed 
in psychiatric diseases such schizophrenia, major depressive and bipolar disorders 
(Petrie et al., 2000; Stahl, 2007). Detection of these proteins in the PSDs isolated from 
post-mortem frozen blocks of human brain was crucial for our study. The protein PSD-
95, the subunit NR2A of the NMDAR, the subunits 2, 3, 4 of the AMPAR were all 
detected in the PSD fractions (see Figure 3-15; Figure 3-17 and Figure 3-19). Moreover 
all of these proteins were enriched in the PSD fraction compared to the total fractions 
as previously mentioned in other studies (Dosemeci et al., 2006; Villasana et al., 2006; 
Hahn et al., 2009).  
Semi-quantitative analysis of the amount of PSD-95, NR2A and AMPAR subunits was 
carried out on six independent experiments of the isolation of the PSDs. The results 
showed a significant increase of the ratio PSD-95/β-actin (p<0.001) (see Figure 3-16), 
NR2A/β-actin (p<0.001) (see Figure 3-18) and AMPAR/ β-actin (p<0.001) (see Figure 
3-20) in the PSD fractions compared to the total fractions. These results concord with 
previous studies (Villasana et al., 2006; Hahn et al., 2009). 
As mentioned above electron micrographs showed that the PSD fractions contained 
contaminants. The pre-synaptic vesicles marker synaptophysin, the cytoskeletal 
protein β-III-tubulin and the marker of glial cells GFAP were immunodetected to 
determine the nature of the contaminants in the PSD fractions (see Figure 3-21). β-
actin was also detected and the intensity detected was used as a denominator to 
normalise our results. 
Comparison of synaptophysin expression in total, cytosolic, myelin/light membranes 
and PSD fractions showed a significant decrease of synaptophysin expression in the 
PSD fractions (p<0.001) (see Figure 3-22). No significant difference was found for the 
expression of β-III-tubulin between the different fractions compared to the total 
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fraction. However a significant increase of the expression of β-III-tubulin (# p<0.05) 
(see Figure 3-23) was found in the PSD fraction compared to the cytosolic fraction. The 
expression of the marker of glial cells GFAP showed a significant increase in the PSD 
fraction compared to the total fraction (p<0.05) (see Figure 3-24). These results were 
similar to results obtained in previous studies (Dosemeci et al., 2006; Hahn et al., 
2009), and also contradictory with a study using another type of isolation (Villasana et 
al., 2006). 
Our results establish that PSDs can be isolated from frozen blocks of human brain in 
reasonable purity using the protocol developed by Dosemeci et al,. 2006. Electron 
micrographs showed the presence of the PSDs in the PSD fractions and Western 
blotting analysis of the PSD fraction demonstrated an enrichment of the most common 
scaffolding protein of the PSD, PSD-95, and the subunits of the two more important 
receptors implicated in synaptic plasticity, NR2A and AMPAR subunits. Contaminants 
such as mitochondria and myelin were also detected in the PSD fraction. The marker of 
the pre-synaptic vesicles, the protein synaptophysin was absent in our PSD fractions. 
The method used in our study allowed us to use a minimum amount of human brain 
sample and to get reasonable purity of the PSD fraction. Moreover this technique of 
isolation maybe followed with PSD-95 immunoprecipitation in order to increase the 
purity of the PSD and study protein-protein interactions within the PSD with better 
efficacy (Dosemeci et al., 2006).  
 
  
 
4 Expression of proteins involved in neuronal plasticity in the 
premotor cortex in schizophrenia 
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4.1 Aims and objectives 
The aims of the present study are to quantify the level of protein expression of the 
NR2A subunit of the NMDAR, the scaffolding protein PSD-95, the protein kinases 
CaMKIIα and CaMKIIβ and the vesicle transporter NSF in the BA 6 in schizophrenia and 
to compare the findings with patients with major depressive disorder, bipolar disorder 
and healthy controls. Expression of the proteins mentioned above shall be quantified 
using Western blotting on BA 6 homogenate PSD fractions. Protein expression shall 
also be assessed after co-immunoprecipited PSD and the findings compared to direct 
Western blotting of the BA 6 homogenate PSD fractions. 
4.2 Introduction 
The human neocortex is a thick 6-layered structure containing neuronal cell bodies 
that cover the cerebrum and form sulci, gyry and lobuli that define the four cerebral 
lobes: the frontal lobe, the parietal lobe, the temporal lobe and the occipital lobe (see 
Figure 4-1). The frontal lobe is phylogenetically and ontogenically the latest developed 
part of the cortex and it occupies nearly a third of the neocortex (Fuster, 2002). 
 
 
Figure 4-1: Diagram illustrating the localisation of the cerebral lobes. 
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Figure 4-2: Diagram illustrating the position of the Brodmann's areas of the frontal cortex. 
(A) Lateral part of the left hemisphere of the brain. (B) Medial part of the right 
hemisphere of the brain. (4) BA 4 (Primary motor cortex), (6) BA 6 (Premotor cortex 
and supplementary motor cortex), (8) BA 8 (Dorsomedial frontal cortex), (9) BA 9 
(Dorsolateral prefrontal cortex), (10) BA 10 (Anterior prefrontal cortex), (11) BA 11 
(Orbitofrontal cortex), (12) BA 12 (Orbitofrontal cortex), (25) BA 25 (Ventromedial 
prefrontal cortex), (44) BA 44 (Broca's area), (45) BA 45 (Broca's area), (46) BA 46 
(Dorsolateral prefrontal cortex), (47) BA 47 (Ventrolateral prefrontal cortex).  
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The frontal lobe is composed of areas anatomically and functionally heterogeneous 
that play key roles in motor, emotional and cognitive functions. In the early 20th 
century several regions (Brodmann's area; BA) of the cortex were described depending 
on their cytoarchitectonic structure by Brodmann (see Figure 4-2). The frontal lobe 
consists of two sub-regions called the motor cortex (BA 4 and BA 6) and the PFC (BA 8 
to 12, BA 25 and BA 44 to 47) (Brodmann, 1909). 
 
4.2.1 Structure of the premotor cortex 
In humans, Brodmann's area 6 (BA 6) is located in the precentral region of cerebral 
cortex at the caudal part of the superior, the middle and the inferior frontal gyri and 
the rostral part of the precentral gyrus that is not occupied by the BA 4. It also covers 
the medial side of the hemisphere down to the cingulate sulcus. Cytoarchitecturally, 
BA 6 is bounded rostrally by the PFC and caudally by BA 4. The main cytoarchitectural 
feature of the BA 6 is its characteristic agranular structure (Friederici, 2006). BA 6, also 
called premotor cortex, is composed of several functionally heterogeneous regions 
(see Figure 4-3). The premotor cortex which lies to the lateral aspect of the frontal lobe 
is divided into four sections, the premotor cortex dorsal (PMd) rostral, the PMd caudal, 
the premotor ventral (PMv) rostral (BA 44 in human) and the PMv caudal. In addition 
the supplemental motor area (SMA) is located on the medial aspect of the brain in the 
dorsomedial frontal cortex (Picard and Strick, 2001) and is divided into three sections, 
the pre-supplemental motor area (Pre-SMA), the supplemental motor area proper 
(SMA proper) and the supplemental eye field (SEF) which lies at the border of the SMA 
and the pre-SMA, close to the paracentral sulcus (Grosbras et al., 1999). 
The premotor cortex constitutes a separate fronto-parietal cortical network and is also 
directly or indirectly connected to the subcortical nuclei, cerebellum and spinal cord. 
These projections, interconnections and loops which have been mostly studied in non-
human primates are discribed below. 
The glutamate post-synaptic density in schizophrenia 
102 
 
The PMd receives a combination of somatosensory and visual information from the 
medial intraparietal area in the superior parietal lobule (Colby and Duhamel, 1991; 
Galletti, 1996). The rostral portion of PMd is strongly interconnected with the 
prefrontal cortex (BA 46) (Lu et al., 1994; Barbas, 2000) whereas the caudal portion of 
PMd has strong interconnections with the primary motor cortex (M1) (Dum and Strick, 
2005). 
 
Figure 4-3: Diagram illustrating the parcellation of the Brodmann area 6.  
(A) Lateral part of the left hemisphere of the brain. (B) Medial part of the right hemisphere 
of the brain. Pre-supplementary motor area (Pre-SMA); Supplementary motor area (SMA); 
Supplementary eye field (SEF); Premotor cortex dorsal (PMd); Premotor cortex ventral 
(PMv). 
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The caudal portion of the PMd projects outputs to M1 and directly to the spinal cord 
(Muakkassa and Strick, 1979; Dum and Strick, 1991) and does not have connections 
with the prefrontal cortex (Lu et al., 1994). In contrast, the rostral portion of the PMd 
does not project to M1 or to the spinal cord (Muakkassa and Strick, 1979; Dum and 
Strick, 1991). The rostral portion of the PMd is interconnected with areas of prefrontal 
cortex (BA 46) and with the reticular formation of the cerebellum (Lu et al., 1994). In 
addition, the rostral portion of the PMd does not appear to have any substantial 
interconnections with the caudal portion of the PMd (Kurata, 1991). 
The caudal and rostral portions of the PMv receive input from the ventral and anterior 
intraparietal cortex respectively (Rizzolatti et al., 1988; Murata et al., 1997; Luppino et 
al., 1999). Both portions of the PMv receive inputs from the secondary somatosensory 
cortex (SII). The caudal portion of the PMv is connected more strongly with the SMA 
proper than with the pre-SMA. In contrast, the rostral portion of the PMv is connected 
more strongly with the pre-SMA than the SMA (Geyer et al., 2000). M1 receives dense 
input from the caudal portion of the PMv (Dum and Strick, 2005; Godschalk et al., 
1984). The rostral portion of the PMv receives inputs from the lateral prefrontal 
cortex, especially from the opercular and the ventral prefrontal cortex (Dum and 
Strick, 2005). In addition, the caudal portion of the PMv sends outputs to the reticular 
formation of the cerebellum, spinal cord and facial nucleus of the brainstem (Geyer et 
al., 2000). 
Input sources from the dorsolateral prefrontal cortex are different depending on the 
region of the PM cortex implicated. The PMd receives main inputs from the dorsal area 
of the PFC, whereas the PMv receives inputs from the ventral area of the PFC (Barbas 
and Pandya, 1987; Wang et al., 2002; Hoshi, 2006). The same differences are observed 
for the inputs from the parietal cortex. The PMd receives main inputs from the 
superior parietal lobule (Johnson et al., 1996; Matelli et al., 1998) whereas the PMv 
receives inputs from the inferior parietal lobule (Rozzi et al., 2006). Thus, 
neuroanatomical considerations suggest that the PMd and PMv are involved in 
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networks that are distinct (Tanné-Gariépy et al., 2002; Rizzolatti and Matelli, 2003; 
Stepniewska et al., 2006). 
The SMA send outputs that makes a direct and substantial contribution to the 
corticospinal tract as it comprises approximately 10 % of all corticospinal cells (Dum 
and Strick, 1991; He et al., 1995; Wise, 1996). By comparison, the pre-SMA has a 
sparse projection in the corticospinal system (Dum and Strick, 1991; Luppino et al., 
1994). The SMA has reciprocal connections with M1, whereas the pre-SMA does not 
(Luppino et al., 1993). Also, as the rostral portions of the PMd and PMv, the pre-SMA 
and the SEF project to the dorsolateral prefrontal cortex (BA 46 mainly) (Lu et al., 
1994; Luppino et al., 1993; Wang et al., 2005). 
The premotor cortex has also connections to sub-cortical nuclei giving rise to direct or 
indirect loops connecting the premotor cortex to the basal ganglia. These inter-
connections are defined as the basal ganglia-thalamo-cortical loops. The premotor and 
the supplementary motor loops are similar. The premotor, the SMA, the pre-SMA and 
the SEF all send outputs to the caudate nucleus/putamen which send outputs onto the 
the internal segment of the globus pallidus both directly and indirectly (through the 
external segment of the globus pallidus). In turn, the internal segment of the globus 
pallidus send outputs to the motor areas of the thalamus which return the information 
received back to the premotor areas (Nakano et al., 2000; Nachev et al., 2008). In 
addition, both the SMA and the pre-SMA have a "hyperdirect" connection to the 
subthalamic nucleus which interacts with internal and external segment of the globus 
pallidus (Nambu et al., 1996). 
 
4.2.2 Functions of the premotor cortex 
The basic function of the premotor cortex is clearly the motor sequencing and the 
planning of movements. For instance, damage in the human lateral premotor area by 
stroke results in kinetic apraxia and other motor impairments, which include defects in 
planning, initiating, and sequencing (Miyai et al., 1999). A study using whole-brain 
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fMRI showed that in the absence of any movement, attending to and predicting 
increasingly complex target motion rely on premotor cortices. Serial prediction caused 
activations in premotor and parietal cortices (Schubotz and Von Cramon, 2002). The 
Tower of London task is a test of motor planning in which subjects must move 
coloured balls on a computer screen to match a specified arrangement in a minimum 
of number of moves. This test was used in a study using to map the network of brain 
structures involved in planning movement. In this study they demonstrated that BA 6, 
particularly the lateral premotor cortex, with other areas of the cortex forms a 
network implicated in motor planning (Dagher et al., 1999). In addition to motor 
sequencing and planning movement the BA 6 is also involved in processes such as 
movement initiation (Jenkins et al., 2000), movement preparation and imagined 
movement (Stephan et al., 1995), motor learning (Halsband and Lange, 2006), 
horizontal saccadic eye movements (Tanaka and Kunimatsu, 2011) and interlimb 
coordination (Henrik Ehrsson et al., 2000).  
The left premotor cortex, particularly the left SMA, participates in language initiation 
and maintenance of voluntary speech production. A study utilising fMRI blood-oxygen-
level-dependent (BOLD) response showed that left premotor cortex was involved with 
other areas of the cortex in speech production (Shuster and Lemieux, 2005). Another 
study using scan PET demonstrated the involvement of the SMA in speech desorder 
such as stuttering (Fox et al., 2000). Imaging studies also revealed the activation of the 
SMA during language processing such as verbal fluency, phonological and semantic 
language tasks (Basho et al., 2007; De Carli et al., 2007). Furthermore the premotor 
cortex is involved in diverse language processes such as language switching (Price et 
al., 1999), reading novel words (Dietz et al., 2005), updating verbal information 
(Tanaka et al., 2005), phonological processing (McDermott et al., 2003), object naming 
(Baciu et al., 1999), lipreading (Paulesu et al., 2003), word retrieval (Warburton et al., 
1996) and lexical decision on words and pseudowords (Price et al., 1994). 
The BA6 also participate in memory, attention, and executive functions due to the 
activation of an extended brain network, that sometimes involves BA6. Many 
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neuroimaging studies have highlighted the role of prefrontal regions in the sustained 
maintenance and manipulation of information over short delays, or working memory. 
In addition, neuroimaging findings have highlighted the role of prefrontal regions in 
the formation and retrieval of memories for events, or episodic long-term memory. 
Studies also showed co-activation of the BA 6 during both long term and short term 
memory (Tulving et al., 1994; Rämä et al., 2001; Ranganath et al., 2003). The BA 6 has 
also been reported to be involved in mnemonic rehearsal (Goldberg et al., 1996; Kapur 
et al., 1996) and topographic memory (Berthoz, 1997). 
Functional neuroimaging studies also revealed the neural system underlying 
visuospatial attention and dynamic visuospatial imagery. These studies provide strong 
and consistent evidence that the human premotor mesial and lateral premotor 
cortices are involved in visuospatial attention and dynamic visuospatial imagery (Nobre 
et al., 1997; Lamm et al., 2001). In human, the left ventral premotor cortex was also 
reported to be activated when alphabetical characters were passively observed and 
that the same region was also involved in handwriting. Visual presentation of letters 
and pseudoletters activated a part of the left premotor cortex, more ventrally and 
medially, compared to the area activated when the letters were being written by the 
subjects (Longcamp et al., 2003; Longcamp et al., 2005). In addition to visuospatial 
attention functional neuroimaging studies also reported the involvement of the 
premotor cortex in selective attention to rhythm and processing sequential sounds as 
well as attention to human voices (Platel et al., 1997; Nakai et al., 2005). 
Executive functions define the cognitive processes that regulate, control, and manage 
cognitive processes, such as planning, working memory, attention, problem solving, 
verbal reasoning, inhibition, mental flexibility, multi-tasking, and initiation and 
monitoring of actions (Chan et al., 2008). Neuropsychological studies have shown that 
the PFC plays a crucial role in executive functions; however functional neuroimaging 
studies seem to reveal the activation of a more extended brain network during 
executive functions which sometimes involves the BA 6. For instance, imaging studies 
showed a bilateral activation of the premotor cortex as well as the left supplementary 
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motor area in planning and solving novel problems (Crozier et al., 1999; Fincham et al., 
2002). The BA 6 was also reported to be activated in processes such as executive 
control of the behavior (Burton et al., 2001) and deductive reasonning (Knauff et al., 
2002; Reverberi et al., 2007). 
 
4.2.3 The premotor cortex and the pathophysiology of schizophrenia 
Research exploring the cognitive impairments in schizophrenia generally focuses on 
dysfunction of association cortices such as the PFC, the temporal cortex and the 
parietal cortex. However several lines of evidence suggest that these impairments are 
reflective of a dysfunction of a more extended neural network which may imply the 
premotor cortex.  
Motor sequencing and motor planning seems to be disturbed in schizophrenia. For 
instance, when patients with schizophrenia are required to reproduce relatively simple 
drawings of geometric shapes, their performance is significantly worse than controls 
when visual feedback of their movements is removed (Mlakar et al., 1994). 
Furthermore, minor abnormalities in motor coordination and motor sequencing are 
readily identified for tasks such as finger tapping and finger–thumb alternation. 
Increased incidence of minor abnormalities in motor coordination and motor 
sequencing have been observed in first-episode psychosis patients and in people 
identified as having a high risk for developing psychosis (Dazzan and Murray, 2002). In 
addition studies demonstrated deficits in motor control and motor imagery in patients 
with schizophrenia (Danckert et al., 2002; Franck et al., 2001; Maruff et al., 2003). 
Neuroimaging studies also revealed reduced activation of the SMA in simple motor 
tasks in catatonic or akinetic patients with schizophrenia (Payoux et al., 2004; 
Scheuerecker et al., 2009). Reduced volumes of the left SMA was reported in patients 
with schizophrenia presenting persistent negative symptoms compared to non-deficit 
patients (Galderisi et al., 2008; Cascella et al., 2010). Furthermore, alterations in the 
premotor areas such as reduced pre-SMA (Exner et al., 2006) and premotor cortex 
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(Baudendistel et al., 1997; Kodama et al., 2001; Rowland et al., 2008) gray matter 
volume were linked to disturbances in motor skill learning in schizophrenia. In addition 
to alteration of higher motor functions such as coordination, planning, fine-tuning, and 
learning of motion sequences, disturbances in intention or volition might originate 
from both cognitive and premotor deficits. For instance, voliton has been connected 
with the function of the pre-SMA (Haggard, 2008). In summary, neuroimaging studies 
of different modalities support the view of an altered structure and function of the 
premotor system in schizophrenia. These studies suggest that disturbed volition, 
learning, initiation and execution of movements in schizophrenia may result from 
dysfunctions of the premotor cortex and of impaired structural connectivity with 
association cortices such as PFC and parietal cortex. 
 
4.2.4 Summary 
The human premotor system in the brain includes the dorsal and ventral premotor 
areas, the supplemental motor area, the pre-supplemental motor area and the 
supplemental eye field. The system is organised in different parallel loops 
interconnected the basal ganglia, the M1, the PFC, the parietal cortex, the cerebellum 
and the spinal cord. The lateral premotor cotex (PMd and PMv) is involved in goal-
directed movements, whilst the medial premotor cortex (SMA proper, pre-SMA) is 
engaged in motor planning and execution. Furthermore, the pre-SMA has been 
implicated in volitional aspects of behavior and drive. 
A recent study using repetitive transcranial magnetic stimulation in the premotor 
cortex which suppresses cortical excitability in M1 in healthy subjects showed reduced 
motor cortical inhibition in patients with schizophrenia (Oxley et al., 2004). This study 
suggests that abnormal neural plasticity in the premotor cortex may be involved in the 
pathophysiology of schizophrenia. Furthermore, altered NRG1-ErbB4 signalling was 
associated with NMDAR hypofunction in the prefrontal cortex in schizophrenia (Hahn 
et al., 2006). In the BA 6 of schizophrenic patients reduced NRG1 C-terminal fragments 
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has been reported, indicating altered NRG1 signalling in this premotor cortex (Barakat 
et al., 2010). These findings suggest that the glutamate system, particularly 
disturbances in molecular processes involved in synaptic plasticity, may be involved in 
the dysfunction of the premotor cortex in schizophrenia. 
 
4.3 Materials and methods 
4.3.1 Enrichment of the glutamate post-synaptic density 
Sixty frozen blocks of human brain were weighed, thinly chopped on ice and 
homogenised (see section 2.2.3). The homogenates were fractionated as described in 
section 2.2.4. The extraction was carried out three times. PSD fractions were collected 
and used for both direct Western blotting analyses and co-immunoprecipitations. 
 
4.3.2 Protein concentration and protein assay 
A protein assay was carried out on the PSD fractions as described in section 2.4. Sixty 
micrograms of protein of each fraction were used either for direct Western blotting or 
co-IP experiments. 
 
4.3.3 Co-immunoprecipitation 
The tubes used for co-IP were coated, then the magnetic beads were cross linked with 
antibodies directed to PSD-95 and the PSDs were immuno-purified, washed and eluted 
by denaturation as described in section 2.6. 
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4.3.4 Western blotting 
For direct WB of the PSD fractions, 60 μg of protein was denatured and loaded onto 5-
8% polyacrylamid gel. Proteins were separated and transferred on PVDF membranes 
for immunodectection of PSD-95, NR2A, CaMKIIα and CaMKIIβ, NSF, β-III-tubulin and 
β-actin. Western blotting was performed as described in section 2.5. For the co-
immunoprecipited PSDs WB was carried out after denaturing elution of the complex 
beads-antibodies-PSDs and PSD-95, NR2A, CaMKIIβ, NSF, β-III-tubulin and β-actin were 
detected as described above. 
 
4.3.5 Data analysis 
For each membrane an average of the background was substracted from the signal 
quantified for each protein detected. A ratio between the protein of interest and 
either β-actin or β-III-tubulin was calculated. An average of the ratio of three 
experiments was calculated for WB experiments on the PSD fraction. Co-IP experiment 
was carried out once. Expression of NR2A, PSD-95, CaMKIIα, CaMKIIβ and NSF in PSD 
fractions and co-immunoprecipited PSDs were compared. 
Effects of demographic and peri-mortem factors were assessed using ANOVA, 
Student's t-test and Spearman's correlation statistical analysis. When no significant 
effect of the demographic and peri-mortem factors was found ANOVA statistical 
analysis was performed to assess the effect of diagnosis, and Bonferroni post-hoc tests 
were used to assess interactions between teh diagnostic groups. When significant 
effect of demographic or peri-mortem variables were found, ANCOVA statistical 
analysis was performed with the associated co-variable. 
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4.4 Results 
Western blotting using IR-dye secondary antibodies and primary antibodies directed to 
NMDAR NR2A subunit, PSD-95, CamKIIα and β, NSF, β-actin and β-III-tubulin revealed 
the presence of all six proteins in the PSD fraction and five of them co-
immunoprecipited with PSD-95. For the co-immunoprecipited PSDs the signal from 
CamKIIα protein was indistinguishable from the primary antibody heavy chain. 
Consequently, CamKIIαwas excluded from the co-IP study.  
The first part of the analysis consisted of identifying the most appropriate protein (β-
actin or β-III-tubulin) for normalisation of the WB and co-IP data. Expression of the 
NMDAR subunits NR2A, PSD-95, CamKIIα and β and NSF was then presented as a ratio 
of these proteins with β-actin or β-III-tubulin respectively for WB and co-IP 
experiments (see section 4.4.1). 
 
4.4.1 Expression of β-actin and β-III-tubulin in the PSD fraction and within the 
PSD 
The mean of the fluorescence intensity of β-actin and β-III-tubulin was compared 
between the four diagnostic groups for both WB and co-IP experiments using one-way 
ANOVA (see Figure 4-4). For both β-actin and β-III-tubulin, no significant main effects 
of diagnosis were found for WB (β-actin F(3, 54) = 0.847, p = 0.474; β-III-tubulin F(3, 
56) = 1.034, p = 0.385) or co-IP experiments (β-actin F(3, 54) = 1.604, p = 0.199; β-III-
tubulin F(3, 54) = 0.545, p = 0.654)  
By observing the bar charts (Figure 4.4) the variance from the mean for β-actin was 
more homogeneous in the WB experiments (see Figure 4-4 A and C), while for the co-
IP PSD, the variance from the mean for β-III-tubulin was more homogeneous between 
diagnostic groups. Therefore, β-actin was chosen as the denominator to normalise 
data from WB experiments and β-III-tubulin was used as the denominator to normalise 
data from co-IP experiments. 
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Figure 4-4: Mean (± SEM) fluorescence intensity for β-actin and β-III-tubulin in the PSD 
fraction and co-IP PSD depending on diagnosis. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction. (B) Mean 
fluorescence intensity for β-actin after co-IP of the PSD fraction. (C) Mean fluorescence 
intensity for β-III-tubulin after WB of the PSD fraction. (D) Mean fluorescence intensity for β-
III-tubulin after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive 
disorder ; (con) control ; (scz) schizophrenia 
 
The effects of gender (see Figure 4-5 A and B) and cerebral hemisphere (see Figure 4-5 
C and D) on dependent variables β-actin and β-III-tubulin for WB and co-IP 
experiments respectively, were examined using Student's T-test. No significant effect 
of gender was found for β-actin (t(56) = 0.011, p = 0.991) or β-III-tubulin (t(56) = 0.786, 
A B
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p = 0.435). Similarly, no effect of brain hemisphere was foundfor both WB (β-actin; 
t(56) = 0.135, p = 0.893) and co-IP (β-III-tubulin; t(56) = 0.110, p = 0.913) experiments. 
 
 
Figure 4-5: Mean (± SEM) fluorescence intensity for β-actin and β-III-tubulin in the PSD 
fraction and co-IP PSD depending on gender and side of the cerebral hemisphere. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction. (B) Mean 
fluorescence intensity for β-III-tubulin after co-IP of the PSD fraction. (C) Mean fluorescence 
intensity for β-actin after WB of the PSD fraction. (D) Mean fluorescence intensity for β-III-
tubulin after co-IP of the PSD fraction. 
 
The effect of psychotic symptoms on tdependent variables β-actin and β-III-tubulin for 
WB (see Figure 4-6 A) and co-IP experiments respectively (see Figure 4-6 B) were also 
A B
C D
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examined using Student's T-test. However, in this case the group control was removed 
from the analysis. No significant effect of psychosis was found for both β-actin (t(42) = 
0.232, p = 0.818) and β-III-tubulin (t(41) = 0.188, p = 0.852). 
 
 
Figure 4-6: Mean (± SEM) fluorescence intensity for β-actin and β-III-tubulin in the PSD 
fraction and co-IP PSD depending on psychotic symptoms. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction. (B) Mean of the 
fluorescence intensity for β-III-tubulin after co-IP of the PSD fraction. 
 
To assess potentially confounding effects of death by suicide on the β-actin and β-III-
tubulin for WB (see Figure 4-7 A and C) and co-IP experiments respectively (see Figure 
4-7 B and D), a Student's t-test analysis was carried out with and without the group 
control. No significant effect of death by suicide was found for both β-actin (t(56) = 
1.121, p = 0.267) and β-actin (t(42) = 0.839, p = 0.406) respectively with or without the 
control group. Student's t-test for both with (t(48.34) = 1.972, p = 0.054) or without 
(t(40.16) = 1.819, p = 0.076) the control group revealed a trend towards a significant 
decrease in the group with death by suicide for β-III-tubulin. 
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Expression of proteins involved in neuronal plasticity in the premotor cortex in schizophrenia 
 
115 
 
 
Figure 4-7: Mean (± SEM) fluorescence intensity for β-actin and β-III- in the PSD fraction and 
co-IP PSD depending on death by suicide. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction. (B) Mean 
fluorescence intensity for β-III-tubulin after co-IP of the PSD fraction. (C) Mean fluorescence 
intensity for β-actin after WB of the PSD fraction (without controls). (D) Mean fluorescence 
intensity of β-III-tubulin after co-IP for the PSD fraction (without controls). 
 
One-way ANOVA was used to compare the mean fluorescence intensity for β-actin and 
β-III-tubulin between substance and alcohol abuse groups for both WB (see Figure 4-8 
A and C) and co-IP (see Figure 4-8 B and D) experiments. A significant increase of 
expression of β-actin (F(4, 52) = 3.921, p = 0.017) for WB experiments (see Figure 4-8 
A) was found for the group that was taking drug of abuse at present and moderately 
compared to the group with none or little consummation of drug abuse. For the co-IP 
A B
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experiments no significant difference (F(4, 52) = 0.702, p = 0.594) between the severity 
of substance abuse was found for β-III-tubulin (see Figure 4-8 B). For both β-actin (F(5, 
52) = 1.148, p = 0.347) and β-III-tubulin (F(5, 52) = 0.783, p = 0.567) respectively for WB 
and co-IP experiments, no significant effect of the severity of alcohol abuse was 
observed (see Figure 4-8 C and D). 
 
 
Figure 4-8: Mean (± SEM) fluorescence intensity for β-actin and β-III- in the PSD fraction and 
co-IP PSD depending on severity of substance and alcohol abuse. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction. (B) Mean 
fluorescence intensity for β-III-tubulin after co-IP of the PSD fraction. (C) Mean fluorescence 
intensity for β-actin after WB of the PSD fraction. (D) Mean fluorescence intensity for β-III-
tubulin after co-IP of the PSD fraction. Statistical test ANOVA with Bonferroni correction. 
Comparison with little/none (* p<0.05). 
*
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In order to identify an eventual correlation between the expression of β-actin and β-III-
tubulin with the effect of the severity of substance and alcohol abuse a non-parametric 
Spearman’s correlation analysis was performed. An increase of β-actin was 
significantly correlated with an increase of the severity of substance (ρ(57) = 0.385; p = 
0.002) whereas no correlation was observed for β-III-tubulin (ρ(57) = -0.011; p = 
0.933). Neither the expression of β-actin (ρ(58) = -0.012; p = 0.927) or β-III-tubulin 
(ρ(58) = 0.168; p = 0.208) were significantly correlated with an increase of the severity 
of alcohol abuse. 
 
Table 4-1: Correlational effects of demographic and peri-mortem factors on the expression 
of β-actin and β-III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
β-actin (n=58) -0.374** -0.237 0.258 0.131 0.190 
β-III-tubulin (n=58) 0.089 -0.173 0.063 0.124 0.087 
**p<0.01 
 
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain for both β-actin and β-III-tubulin were examined with non-
parametric Spearman’s correlation analysis. A significant negative correlation was 
found between age at death and expression of β-actin (ρ(58) = -0.374; p = 0.004) 
whereas pH of the brain, mass of the brain, PMI and duration of storage of the brain 
were found to have no effect. Age at death, pH of the brain, mass of the brain, PMI 
and duration of storage of the brain were found to have no effect on expression of β-
III-tubulin (see Table 4-1). 
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Table 4-2: Correlational effects of demographic and peri-mortem factors on the expression 
of β-actin and β-III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
β-actin (n=44) -0.389** -0.131 -0.267 -0.059 
β-III-tubulin (n=43) 0.467 0.335 0.443 0.352 
**p<0.01 
 
The effects of age at death, age of onset of disease, duration of diseases and life time 
quantity of fluphenazine or equivalent for both β-actin and β-III-tubulin were also 
examined with non-parametric correlation analysis. However in this case the group 
control was removed. As previously observed a significant negative correlation was 
found between age at death and expression of β-actin (ρ(44) = -0.389; p = 0.009). Age 
of onset of disease, duration of diseases and life time quantity of fluphenazine or 
equivalent were found to have no effect on the expression of β-actin. Age at death, 
age of onset of disease, duration of diseases and life time quantity of fluphenazine or 
equivalent were found to have no effect on the expression of β-III-tubulin (see Table 
4-2). 
To summarise the expression of β-III-tubulin was not significantly affected by 
demographic and peri-mortem factors for the co-IP experiments whereas the 
expression of β-actin was affected by severity of substance abuse and age at death. 
Consequently an ANCOVA statistical analysis was performed to assess whether any 
significant difference of the mean of β-actin for each diagnosis group would appear 
with the effect of severity of substance abuse and the age at death as co-variables. No 
significant difference between diagnosis was found for β-actin (F(3, 51) = 0.283, p = 
0.837) with the effect of severity of substance abuse and the age at death as co-
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variables. Subsequently β-actin was then chosen as denominator to normalise data 
from WB experiments and β-III-tubulin to normalise data from co-IP experiments. 
 
4.4.2 Expression of NR2A in the PSD fraction and within the PSD 
The ratios NR2A/β-actin and NR2A/β-III-tubulin were compared between each 
diagnostic group for both WB and co-IP experiments using one-way ANOVA. A 
significant difference in the mean ratios NR2A/β-actin and NR2A/β-III-tubulin between 
diagnosis was found for both WB and co-IP experiments (see Figure 4-9).  
 
 
Figure 4-9: Mean (± SEM) ratios NR2A/β-actin and NR2A/β-III-tubulin in the PSD fraction and 
co-IP PSD depending on diagnosis. 
(A) Mean ratio NR2A/β-actin after WB of the PSD fraction. (B) Mean ratio NR2A/β-III-tubulin 
after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive disorder ; 
(con) control ; (scz) schizophrenia. Statistical test ANOVA with Bonferroni correction. 
Comparison with control (* p<0.05; ** p<0.01) or schizophrenia (#p<0.05). Statistical 
ANCOVA was also perfomed with co-variable (see Figure 4-20). 
 
* * *
** **
#
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Bonferroni post-hoc analysis of the WB data revealed a significant decrease in the 
mean ratio NR2A/β-actin in bipolar disorder disorder (F(3, 53) = 4.817, p = 0.047), 
major depressive disorder disorder (F(3, 53) = 4.817, p = 0.011) and schizophrenia (F(3, 
53) = 4.817, p = 0.014) compared to the group control (see Figure 4-9 A).  
 
 
Figure 4-10: Mean (± SEM) ratios NR2A/β-actin and NR2A/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on gender and side of the cerebral hemisphere. 
(A) Mean ratio NR2A/β-actin after WB of the PSD fraction. (B) Mean ratio NR2A/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio NR2A/β-actin after WB of the PSD fraction. (D) 
Mean of the ratio NR2A/β-III-tubulin after co-IP of the PSD fraction. 
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In addition, a significant decrease in the mean ratio NR2A/β-III-tubulin in major 
depressive disorder (F(3, 46) = 7.927, p = 0.003) and schizophrenia (F(3, 46) = 7.927, p 
= 0.001) but not in bipolar disorder (F(3, 46) = 7.927, p = 1.000) compared to controls 
was found in the co-IP experiment (see Figure 4-9 B). Also the mean ratio NR2A/β-III-
tubulin was lower in schizophrenia (F(3, 46) = 7.927, p = 0.039) and major depressive 
disorder (trend: F(3, 46) = 7.927, p = 0.080) relative to bipolar disorder in the co-IP 
experiment. 
The effects of gender (see Figure 4-10 A and B) and cerebral hemisphere (see Figure 
4-10 C and D) on dependent variables NR2A/β-actin and NR2A/β-III-tubulin for WB and 
co-IP experiments respectively were examined using Student's T-test analysis. No 
significant effects of gender were found for NR2A/β-actin (t(55) = 0.140, p = 0.889) and 
NR2A/β-III-tubulin (t(48) = 1.007, p = 0.319) or cerebral lateralisation for WB (NR2A/β-
actin; t(55) = 0.136, p = 0.892) and co-IP (NR2A/β-III-tubulin; t(48) = 1.029, p = 0.308) 
experiments. 
 
 
Figure 4-11: Mean (± SEM) ratios NR2A/β-actin and NR2A/β-III- in the PSD fraction and co-IP 
PSD depending on psychotic symptoms. 
(A) Mean ratio NR2A/β-actin after WB of the PSD fraction. (B) Mean NR2A/β-III-tubulin after 
co-IP of the PSD fraction. 
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The effect of psychotic symptoms on NR2A/β-actin and NR2A/β-III-tubulin for WB (see 
Figure 4-11 A) and co-IP experiments respectively (see Figure 4-11 B) were also 
examined using Student's T-test analysis and omission of the control group from the 
analysis. No significant effect of psychosis was found for both NR2A/β-actin (t(41) = 
0.061, p = 0.952) or NR2A/β-III-tubulin (t(33) = 0.045, p = 0.964). 
 
 
Figure 4-12: Mean (± SEM) ratios NR2A/β-actin and NR2A/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on death by suicide. 
(A) Mean ratio NR2A/β-actin after WB of the PSD fraction. (B) Mean ratio NR2A/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio NR2A/β-actin after WB of the PSD fraction 
(without controls). (D) Mean ratio NR2A/β-III-tubulin after co-IP of the PSD fraction (without 
controls). Statistical Student's t test (** p<0.01). 
**
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For the effect of death by suicide on NR2A/β-actin and NR2A/β-III-tubulin rfor WB (see 
Figure 4-12 A and C) and co-IP experiments respectively (see Figure 4-12 B and D), a 
Student's t-test analysis was carried out with and without the control group. A trend 
towards a significant decrease in the suicide group for NR2A/β-actin (t(55) = 1.800, p = 
0.077) was found when controls were included, however this was no longer significant 
when the controls were excluded (t(41) = 0.495, p = 0.624). 
 
 
Figure 4-13: Mean (± SEM) ratios NR2A/β-actin and NR2A/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on severity of substance and alcohol abuse. 
(A) Mean ratio NR2A/β-actin after WB of the PSD fraction. (B) Mean ratio NR2A/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio NR2A/β-actin after WB of the PSD fraction. (D) 
Mean ratio NR2A/β-III-tubulin after co-IP of the PSD fraction. 
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A significant increase in NR2A/β-III-tubulin (t(33) = 3.082, p = 0.004) was found in the 
suicide group when controls were excluded, but not when they were included (t(45.78) 
= 0.480, p = 0.634). One-way ANOVA was used to assess the effects of severity of 
substance and alcohol abuse on NR2A/β-actin and NR2A/β-III-tubulin respectively for 
WB (see Figure 4-13 A and C) and co-IP (see Figure 4-13 B and D) experiments. 
A significant difference of the mean of NR2A/β-actin (F(4, 52) = 2.992, p = 0.027) was 
found using ANOVA on the effect of substance abuse, however there was no 
significant change after Bonferroni correction (see Figure 4-13 A). For the co-IP 
experiments no significant difference (F(4, 45) = 0.672, p = 0.615) between the severity 
of substance abuse was found for NR2A/β-III-tubulin (see Figure 4-13 B). For both 
ratios NR2A/β-actin (F(5, 51) = 1.037, p = 0.406) and NR2A/β-III-tubulin (F(5, 44) = 
0.933, p = 0.469) respectively for WB and co-IP experiments, no significant effect of the 
severity of alcohol abuse was observed (see Figure 4-13 C and D). 
 
Table 4-3: Correlational effects of demographic and peri-mortem factors on the ratios 
NR2A/β-actin and NR2A/β-III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
NR2A/β-actin (n=57) 0.307* -0.028 -0.191 -0.122 -0.189 
NR2A/β-III-tubulin 
(n=50) 
-0.083 -0.082 -0.106 -0.051 -0.062 
*p<0.05 
The correlation of both ratios NR2A/β-actin and NR2A/β-III-tubulin with the effect of 
the severity of substance and alcohol abuse was assessed with a non-parametric 
correlation analysis of Spearman. A negative correlation of the ratio NR2A/β-actin was 
found significant with the severity of substance (ρ(57) = -0.425; p = 0.001) whereas no 
correlation was observed for NR2A/β-III-tubulin (ρ(50) = -0.144; p = 0.320). Neither the 
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ratio NR2A/β-actin (ρ(57) = -0.057; p = 0.676) or the ratio NR2A/β-III-tubulin (ρ(50) = -
0.142; p = 0.326) were significantly correlated with an increase of the severity of 
alcohol abuse. 
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain for both ratios NR2A/β-actin and NR2A/β-III-tubulin were 
examined with non-parametric correlation analysis. A significant positive correlation 
was found between age at death and the ratio NR2A/β-actin (ρ(57) = 0.307; p = 0.020) 
whereas pH of the brain, mass of the brain, PMI and duration of storage of the brain 
were found to have no effect. Age at death, pH of the brain, mass of the brain, PMI 
and duration of storage of the brain were not found to have any effect on the ratio 
NR2A/β-III-tubulin (see Table 4-3). 
 
Table 4-4: Correlational effects of demographic and peri-mortem factors on the ratios 
NR2A/β-actin and NR2A/β-III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
NR2A/β-actin (n=43) 0.232 0.015 0.300 0.287 
NR2A/β-III-tubulin 
(n=35) 
-0.244 -0.375* 0.153 0.024 
*p<0.05 
 
The effects of age at death, age of onset of disease, duration of diseases and life time 
quantity of fluphenazine or equivalent for both ratios NR2A/β-actin and NR2A/β-III-
tubulin were also examined with non-parametric correlation analysis. In this study the 
group control was removed. Age at death, age of onset of disease, duration of diseases 
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and life time quantity of fluphenazine or equivalent were found to have no effect on 
the expression of NR2A/β-actin. A significant negative correlation was observed 
between age of onset of the disease and the mean of the ratio NR2A/β-III-tubulin 
(ρ(35) = -0.375; p = 0.026). Age at death, duration of the disease and life time quantity 
of fluphenazine or equivalent were not found to have any effect on the mean of the 
ratio NR2A/β-III-tubulin (see Table 4-4). 
The mean of the ratio NR2A/β-III-tubulin was found to not be significantly affected by 
any of the demographic and peri-mortem factors for the co-IP experiments whereas 
the ratio NR2A/β-actin was affected by the age at death. Subsequently an ANCOVA 
was performed to assess whether the ratio NR2A/β-actin was affected for each 
diagnosis group with the effect of the age at death as co-variable.  
 
 
Figure 4-14: Mean (± SEM) ratios NR2A/β-actin (ANCOVA) and NR2A/β-III-tubulin (ANOVA) 
in the PSD fraction and co-IP PSD depending on diagnosis. 
(A) Mean ratio NR2A/β-actin after WB of the PSD fraction. (B) Mean ratio NR2A/β-III-tubulin 
after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive disorder ; 
(con) control ; (scz) schizophrenia. Statistical test ANCOVA with age at death as co-variable 
for NR2A/β-actin was performed with Bonferroni correction. Comparison with control 
(*p<0.05; **p<0.01) or schizophrenia (#p<0.05). 
 
*
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A significant difference between the different diagnosis group was found for NR2A/β-
actin (F(3, 52) = 4.597, p = 0.006) with the effect of the age at death as co-variables. In 
order to determine which diagnosis groups were different from the others a 
Bonferroni correction was carried out. A significant decrease of the mean of the ratio 
NR2A/β-actin (F(3, 52) = 4.597, p = 0.010) for the diagnosis group with major 
depressive disorder compared to the group control. A significant decrease in the group 
with schizophrenia (NR2A/β-actin: F(3, 52) = 4.597, p = 0.021) was found with the 
group control but not for the diagnosis group with bipolar disorder (NR2A/β-actin: F(3, 
52) = 4.597, p = 0.088) (see Figure 4-14 A). 
 
4.4.3 Expression of PSD-95 in the PSD fraction and within the PSD 
The mean of the ratios of PSD-95/β-actin and PSD-95/β-III-tubulin was compared 
between each diagnosis groups for both WB and co-IP (see Figure 4-15). For both PSD-
95/β-actin (F(3, 51) = 0.704, p = 0.554) and PSD-95/β-III-tubulin (F(3, 51) = 2.358, p = 
0.080) no significant difference between diagnosis was found for both respectively WB 
and co-IP experiments using ANOVA (see Figure 4-15 A and B). However the chart 
representing the difference of the means of the ratio PSD-95/ β-III-tubulin for each 
group of diagnosis showed a decrease of the ratio PSD-95/β-III-tubulin between the 
group of diagnosis with schizophrenia and the group (see Figure 4-15 B).  
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Figure 4-15: Mean (± SEM) ratios PSD-95/β-actin and PSD-95/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on diagnosis. 
(A) Mean ratio PSD-95/β-actin after WB of the PSD fraction. (B) Mean ratio PSD-95/β-III-
tubulin after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive 
disorder ; (con) control ; (scz) schizophrenia. Statistical test ANOVA with Bonferroni 
correction. Statistical test ANCOVA was also perfomed with co-variables (see Figure 4-20). 
 
This difference of the mean of the ratio PSD-95/β-III-tubulin between these two groups 
was also assessed with Student's t-test and revealed a significant decrease of the ratio 
PSD-95/β-III-tubulin (t(26) = 4.214, p = 0.0003) for the group of diagnosis with 
schizophrenia compared to the group control. 
The difference of the mean of the two dependent variables PSD-95/β-actin and PSD-
95/β-III-tubulin respectively for WB experiments and co-IP experiments depending on 
gender (see Figure 4-16 A and B) and the side of the cerebral hemisphere (see Figure 
4-16 C and D) was assessed with Student's T-test analysis. Neither significant 
difference of the mean of the ratio PSD-95/β-actin was revealed for gender (t(53) = 
0.404, p = 0.688) or the side of the cerebral hemisphere (t(53) = 0.018, p = 0.985). A 
significant decrease of the mean of the ratio PSD-95/β-III-tubulin was found in female 
(t(53) = 2.077, p = 0.043) and a trend towards a significant decrease in the left 
hemisphere of the cerebrum (t(53) = 1.828, p = 0.073). 
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Figure 4-16: Mean (± SEM) ratios PSD-95/β-actin and PSD-95/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on gender and side of the cerebral hemisphere. 
(A) Mean ratio PSD-95/β-actin after WB of the PSD fraction. (B) Mean ratio PSD-95/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio PSD-95/β-actin after WB of the PSD 
fraction. (D) Mean ratio PSD-95/β-III-tubulin after co-IP of the PSD fraction. 
 
The effect of psychotic symptoms on the dependent variables PSD-95/β-actin and PSD-
95/β-III-tubulin respectively for WB experiments (see Figure 4-17 A) and co-IP 
experiments (see Figure 4-17 B) were also examined with Student's T-test analysis. The 
group control was removed from the analysis and no significant difference was found 
for both ratios PSD-95/β-actin (t(24.63) = 0.328, p = 0.745) and PSD-95/β-III-tubulin 
(t(38) = 0.234, p = 0.816). 
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Figure 4-17: Mean (± SEM) ratios PSD-95/β-actin and PSD-95/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on psychotic symptoms. 
(A) Mean ratio PSD-95/β-actin after WB of the PSD fraction. (B) Mean ratio PSD-95/β-III-
tubulin after co-IP of the PSD fraction. 
 
Study of the incidence of death by suicide on the dependent variables PSD-95/β-actin 
and PSD-95/β-III-tubulin respectively for WB experiments (see Figure 4-18 A and C) and 
co-IP experiments (see Figure 4-18 B and D) was also assessed using Student's t-test 
analysis for both with and without the group control. No significant difference was 
found for both the ratio PSD-95/β-actin with (t(53) = 0.122, p = 0.903) or without (t(40) 
= 0.479, p = 0.635) the control group. Student's t-test for both with (t(53) = 2.696, p = 
0.009) or without (t(38) = 3.530, p = 0.001) the control group revealed a significant 
increase in the group with death by suicide for PSD-95/β-III-tubulin. The means of the 
ratios PSD-95/β-actin and PSD-95/β-III-tubulin obtained for each degree of severity of 
substance and alcohol abuse for both WB (see Figure 4-19 A and C) and co-IP (see 
Figure 4-19 B and D) experiments were compared with one-way ANOVA. No significant 
difference of the mean of the ratios PSD-95/β-actin and PSD-95/β-III-tubulin for both 
WB and co-IP experiments, neither for the degree of severity of drug abuse (PSD-95/β-
actin: F(4, 49) = 1.489, p = 0.220; PSD-95/β-III-tubulin: F(4, 50) = 1.078, p = 0.377) nor 
A B
Expression of proteins involved in neuronal plasticity in the premotor cortex in schizophrenia 
 
131 
 
alcohol abuse (PSD-95/β-actin: F(5, 49) = 0.641, p = 0.670; PSD-95/β-III-tubulin: F(5, 49) 
= 0.737, p = 0.599), was observed. 
 
 
Figure 4-18: Mean (± SEM) ratios PSD-95/β-actin and PSD-95/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on death by suicide. 
(A) Mean ratio PSD-95/β-actin after WB of the PSD fraction. (B) Mean ratio PSD-95/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio PSD-95/β-actin after WB of the PSD 
fraction (without controls). (D) Mean ratio PSD-95/β-III-tubulin after co-IP of the PSD 
fraction (without controls). Statistical Student's t-test (** p<0.01). 
 
 
 
**
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Figure 4-19: Mean (± SEM) ratios PSD-95/β-actin and PSD-95/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on severity of substance and alcohol abuse. 
(A) Mean ratio PSD-95/β-actin after WB of the PSD fraction. (B) Mean ratio PSD-95/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio PSD-95/β-actin after WB of the PSD 
fraction. (D) Mean ratio PSD-95/β-III-tubulin after co-IP of the PSD fraction. 
 
Correlation between the mean of the ratios PSD-95/β-actin and PSD-95/β-III-tubulin 
and the level of the severity of substance and alcohol abuse were assessed with a non-
parametric correlation analysis of Spearman. A trend towards a decrease of the ratio 
PSD-95/β-actin was correlated with an increase of the severity of substance abuse 
(ρ(54) = -0.239; p = 0.082) whereas no correlation was found for the ratio PSD-95/β-III-
tubulin (ρ(55) = -0.137; p = 0.319). Neither the mean of the ratio of PSD-95/β-actin 
(ρ(55) = 0.026; p = 0.851) nor the mean of the ratio PSD-95/β-III-tubulin (ρ(55) = -
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0.132; p = 0.336) were significantly correlated with an increase of the severity of 
alcohol abuse. 
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain for both ratios PSD-95/β-actin and PSD-95/β-III-tubulin were 
examined with non-parametric correlation analysis of Spearman. Age at death, pH of 
the brain, mass of the brain, PMI and duration of storage of the brain were found to 
have no effect on the ratio PSD-95/β-actin. A significant decrease of the mean of the 
ratio PSD-95/β-III-tubulin (ρ(55) = -0.343; p = 0.010) was correlated with an increase of 
the post-mortem interval. Age at death, pH of the brain, mass of the brain and 
duration of storage of the brain were found to have no effect the ratio PSD-95/β-III-
tubulin (see Table 4-5). 
 
Table 4-5: Correlational effects of demographic and peri-mortem factors on the ratios PSD-
95/β-actin and PSD-95/β-III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
PSD-95/β-actin (n=55) 0.206 0.075 -0.138 -0.112 -0.045 
PSD-95/β-III-tubulin 
(n=55) 
-0.125 0.189 0.209 -0.343* -0.168 
*p<0.05 
 
The group control was removed to study the effect of age at death, age of onset of 
disease, duration of diseases and life time quantity of fluphenazine or equivalent on 
both ratios PSD-95/β-actin and PSD-95/β-III-tubulin using non-parametric correlation 
analysis. No effect of the age at death, the age of onset of the disease, the duration of 
The glutamate post-synaptic density in schizophrenia 
134 
 
the disease and the life time quantity of fluphenazine or equivalent were revealed 
neither for the ratio PSD-95/β-actin nor the ratio PSD-95/β-III-tubulin (see Table 4-6). 
 
Table 4-6: Correlational effects of demographic and peri-mortem factors on the ratios PSD-
95/β-actin and PSD-95/β-III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
PSD-95/β-actin (n=42) 0.186 0.279 -0.052 -0.045 
PSD-95/β-III-tubulin 
(n=40) 
-0.159 -0.231 0.006 -0.154 
 
To summarise there was no effect of the demographic and peri-mortem factors on the 
ratio PSD-95/β-actin whereas gender, death by suicide and post-mortem interval were 
found to have an effect on the mean of the ratio PSD-95/β-III-tubulin for the co-IP 
experiments. ANCOVA statistical analysis showed a significant difference of the mean 
of the ratio PSD-95/β-III-tubulin between diagnosis groups (F(3, 48) = 2.995, p = 0.040). 
The post-hoc test with Bonferroni's correction revealed that the mean of the ratio PSD-
95/β-III-tubulin was significantly reduced in schizophrenia compared to control (F(3, 
48) = 2.995, p = 0.049) (see Figure 4-20 B). 
In contrast no significant difference was found either for the group with bipolar 
disorder (F(3, 48) = 2.995, p = 0.824) or the group with major depressive disorder (F(3, 
48) = 2.995, p = 0.155) for the mean of the ratio PSD-95/β-III-tubulin compared to the 
group control (Figure 4-20 A). 
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Figure 4-20: Mean (± SEM) ratios PSD-95/β-actin and PSD-95/β-III-tubulin in the PSD fraction 
and co-IP PSD depending on diagnosis (ANCOVA). 
(A) Mean ratio PSD-95/β-actin after WB of the PSD fraction. (B) Mean ratio PSD-95/β-III-
tubulin after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive 
disorder ; (con) control ; (scz) schizophrenia. Statistical test ANCOVA with gender, death by 
suicide and post-mortem interval as co-variables for PSD-95/β-III-tubulin was performed 
with Bonferroni correction. Comparison with control (* p<0.05). 
 
4.4.4 Expression of CaMKIIα in the PSD fraction 
The signal for the detection of CaMKIIα was undistinguishable from the signal emitted 
from the detection of the heavy chain of the primary antibody used to carry out the 
co-IP experiments.  
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Figure 4-21: Mean (± SEM) ratio CaMKIIα/β-actin in the PSD fraction (WB) depending on 
diagnosis.  
(bpd) bipolar disorder ; (mdd) major depressive disorder ; (con) control ; (scz) schizophrenia. 
 
Consequently in this study the expression of CaMKIIα was only assessed in the PSD 
fraction by WB. The mean of the ratio CaMKIIα/β-actin was compared for each 
diagnosis groups with one-way ANOVA statistical test (see Figure 4-21). No significant 
difference between diagnosis was found for the ratio CaMKIIα/β-actin (F(3, 50) = 
1.557, p = 0.211) by WB experiments in the PSD fraction. However the chart 
representing the difference of the means of the ratio CaMKIIα/β-actin for each group 
of diagnosis showed a decrease of the ratio CaMKIIα/β-actin between the group of 
diagnosis with major depressive disorder and the group with bipolar disorder. This 
difference of the mean of the ratio CaMKIIα/β-actin between these two groups was 
assessed with Student's t-test and revealed a trend towards a decrease of the ratio 
CaMKIIα/β-actin (t(25) = 1.914, p = 0.067) for the group with major depressive disorder 
and the group with bipolar disorder. 
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Figure 4-22: Mean (± SEM) ratio CaMKIIα/β-actin in the PSD fraction depending on gender, 
side of the cerebral hemisphere and psychotic symptoms. 
(A) Mean ratio CaMKIIα/β-actin after WB of the PSD fraction (gender). (B) Mean ratio 
CaMKIIα/β-actin after WB of the PSD fraction (cerebral hemisphere) (C) Mean ratio 
CaMKIIα/β-actin after WB of the PSD fraction (psychosis). 
 
Student's T-test analysis was performed to assess the level of expression of CaMKIIα 
depending on gender (see Figure 4-22 A) and the side of the cerebral hemisphere (see 
Figure 4-22 B). No significant effect of gender was found for the ratio CaMKIIα/β-actin 
(t(52) = 0.241, p = 0.811) or cerebral lateralisation by WB (t(523) = 0.773, p = 0.443) 
experiments. The group control was removed from the analysis and the effect of 
psychotic symptoms on the dependent variable CaMKIIα/β-actin was also examined 
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with Student's t-test analysis (see Figure 4-22 C). No significant effect of psychosis was 
found for the ratio CaMKIIα/β-actin (t(40) = 0.648, p = 0.520). 
For the effect of death by suicide on the dependent variable CaMKIIα/β-actin for WB 
experiments (see Figure 4-23 A and C) a Student's t-test analysis was carried out with 
and without the group control. No significant effect of death by suicide was found for 
the mean of the ratio CaMKIIα/β-actin  with (t(52) = 1.112, p = 0.271) or without (t(40) 
= 0.648, p = 0.520) the control group. 
 
 
Figure 4-23: Mean (± SEM) ratio CaMKIIα/β-actin in the PSD fraction depending on death by 
suicide (WB). 
(A) Mean ratio CaMKIIα/β-actin after WB of the PSD fraction. (B) Mean ratio CaMKIIα/β-
actin after WB of the PSD fraction (without controls). 
 
The effects of the severity of substance and alcohol abuse on the mean of the ratio 
CaMKIIα/β-actin were tested using one-way ANOVA statistical test (see Figure 4-24 A 
and B). No significant difference of the mean of the ratio CaMKIIα/β-actin was found 
either for the effect of the severity of substance abuse (F(4, 48) = 2.552, p = 0.051) or 
alcohol abuse (F(5, 48) = 0.456, p = 0.807). Because of the trend observed for the 
effect of the severity of substance abuse on the mean of the ratio CaMKIIα/β-actin a 
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post-hoc with Bonferroni's correction was performed. A trend towards a decrease of 
CaMKIIα/β-actin (F(4, 48) = 2.552, p = 0.078) between moderate present and heavy 
present consummation of drug abuse (see Figure 4-24 A). 
 
 
Figure 4-24: Mean (± SEM) ratio CaMKIIα/β-actin in the PSD fraction depending on severity 
of substance and alcohol abuse. 
(A) Mean ratio CaMKIIα/β-actin after WB of the PSD fraction (substance abuse). (B) Mean 
ratio CaMKIIα/β-actin after WB of the PSD fraction (alcohol abuse). 
 
Non-parametric correlation analysis of Spearman was carried out to identify an 
eventual correlation between the difference of the mean of the ratio CaMKIIα/β-actin 
and the severity of substance and alcohol abuse. No correlation was observed for the 
ratio CaMKIIα/β-actin either for the severity of substance abuse (ρ(53) = -0.015; p = 
0.917) or the severity of alcohol abuse (ρ(54) = -0.045; p = 0.745). 
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Table 4-7: Correlational effects of demographic and peri-mortem factors on the ratio 
CaMKIIα/β-actin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
CaMKIIα/β-actin (n=54) -0.172 -0.008 -0.057 0.215 0.107 
 
Table 4-8: Correlational effects of demographic and peri-mortem factors on the ratio 
CaMKIIα/β-actin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
CaMKIIα/β-actin (n=42) -0.184 -0.105 -0.073 0.106 
 
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain for CaMKIIα/β-actin were examined with non-parametric 
correlation analysis (see Table 4-7). The effects of age at death, age of onset of 
disease, duration of diseases and life time quantity of fluphenazine or equivalent for 
CaMKIIα/β-actin were also examined with non-parametric correlation analysis with the 
group control removed (see Table 4-8). None of these demographic and peri-mortem 
factors had any correlation with the expression of CaMKIIα by WB. 
To summarise the expression of CaMKIIα was not significantly affected by any of the 
demographic and peri-mortem factors and subsequently no ANCOVA statistical 
analysis was performed. 
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4.4.5 Expression of CaMKIIβ in the PSD fraction and within the PSD 
The expression of CaMKIIβ in each diagnosis groups was compared by measuring the 
difference of the mean of the ratios CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin 
respectively for both WB and co-IP experiments using one-way ANOVA statistical test 
(see Figure 4-25). The ratio CaMKIIβ/β-actin (F(3, 50) = 2.025, p = 0.122) was found to 
have no significant difference between diagnosis with WB experiments (see Figure 
4-25 A).  
 
 
Figure 4-25: Mean (± SEM) ratios CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on diagnosis. 
(A) Mean ratio CaMKIIβ/β-actin after WB of the PSD fraction. (B) Mean ratio CaMKIIβ/β-III-
tubulin after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive 
disorder ; (con) control ; (scz) schizophrenia. Statistical test ANOVA with Bonfferoni 
correction. Comparison with control (* p<0.05). ANCOVA statistical analysis was also 
performed CaMKIIβ/β-actin including post mortem interval as co-variable (see Table 4-9), No 
significant difference was found between diagnosis. 
 
In contrast, a significant one-way ANOVA was found for the mean of the ratio 
CaMKIIβ/β-III-tubulin (F(3, 48) = 3.876, p = 0.015) and a post hoc test with Bonferroni's 
*
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correction was carried out in order to distinguish which groups of diagnosis were 
significantly different. Post-hoc analysis showed a significant decrease of the mean of 
the ratio CaMKIIβ/β-III-tubulin in the group with schizophrenia compared to the group 
control (F(3, 48) = 3.876, p = 0.013). The groups with bipolar disorder (F(3, 48) = 3.876, 
p = 1.000) and major depressive disorder (F(3, 48) = 3.876, p = 0.273) were not found 
to have any significant difference with the group control (see Figure 4-25 B). 
 
 
Figure 4-26: Mean (± SEM) ratios CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on gender and side of the cerebral hemisphere. 
(A) Mean ratio CaMKIIβ/β-actin after WB of the PSD fraction. (B) Mean ratio CaMKIIβ/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio CaMKIIβ/β-actin after WB of the PSD 
fraction. (D) Mean of the ratio CaMKIIβ/β-III-tubulin after co-IP of the PSD fraction. 
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The expression of CaMKIIβ depending on gender (see Figure 4-26 A and B) and the side 
of the cerebral hemisphere (see Figure 4-26 C and D) was assessed for CaMKIIβ/β-actin 
and CaMKIIβ/β-III-tubulin respectively for WB experiments and co-IP experiments with 
Student's t-test analysis. There was no significant different level of expression of 
CaMKIIβ between male and female (t(52) = 0.329, p = 0.744) or right and left 
hemisphere of the cerebrum (t(52) = 1.102, p = 0.275) using WB analysis. Same results 
were found for the expression of CaMKIIβ measured by co-IP for both gender (t(50) = 
0.968, p = 0.338) and cerebral hemisphere (t(50) = 0.159, p = 0.874). 
The effect of psychotic symptoms on the dependent variables CaMKIIβ/β-actin and 
CaMKIIβ/β-III-tubulin respectively for WB experiments (see Figure 4-27 A) and co-IP 
experiments (see Figure 4-27 B). The group control was removed and the difference 
between the means of the ratios CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin was also 
examined with Student's T-test analysis. No significant effect of psychosis was found 
for both CaMKIIβ/β-actin (t(38) = 0.897, p = 0.375) and CaMKIIβ/β-III-tubulin (t(36) = 
0.302, p = 0.765). 
 
 
Figure 4-27: Mean (± SEM) ratios CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on psychotic symptoms. 
(A) Mean ratio CaMKIIβ/β-actin after WB PSD fraction. (B) Mean of the ratio CaMKIIβ/β-III-
tubulin after co-IP of the PSD fraction. 
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Student's t-test analysis was also carried out with and without the group control to 
determine the effect of death by suicide on the dependent variables CaMKIIβ/β-actin 
and CaMKIIβ/β-III-tubulin respectively for WB experiments (see Figure 4-28 A and C) 
and co-IP experiments (see Figure 4-28 B and D).  
 
Figure 4-28: Mean (± SEM) ratios CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on death by suicide. 
(A) Mean ratio CaMKIIβ/β-actin after WB of the PSD fraction. (B) Mean ratio CaMKIIβ/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio CaMKIIβ/β-actin after WB of the PSD 
fraction (without controls). (D) Mean ratio CaMKIIβ/β-III-tubulin after co-IP of the PSD 
fraction (without controls). Statistical Student's t test (* p<0.05). 
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No significant effect of death by suicide was found for both CaMKIIβ/β-actin (t(52) = 
0.166, p = 0.869) and CaMKIIβ/β-actin (t(38) = 0.100, p = 0.921) respectively with or 
without the control group (see Figure 4-28 A and C). There was also no significant 
difference of the mean of the ratio CaMKIIβ/β-III-tubulin between the groups with or 
without psychosis when the group control was included in the statistical analysis (t(50) 
= 0.700, p = 0.487). In contrast Student's t-test revealed a significant increase in the 
group with death by suicide for CaMKIIβ/β-III-tubulin (t(24.03) = 2.119, p = 0.045) 
when the group control was removed (see Figure 4-28 B and D). 
One-way ANOVA statistical test was performed to compare the mean of the ratios 
CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin between each degree of severity of 
substance abuse and alcohol abuse for both WB (see Figure 4-29 A and C) and co-IP 
(see Figure 4-29 B and D) experiments. One-way ANOVA statistical test for WB 
experiments revealed a trend of difference between groups with different degrees of 
substance abuse (F(4, 49) = 2.119, p = 0.093) whereas no significant difference was 
found for the expression of CaMKIIβ (F(5, 48) = 0.366, p = 0.869) looking at the severity 
of alcohol abuse (see Figure 4-29 A and C).  
Because of the trend observed for the effect of the severity of substance abuse on the 
mean of the ratio CaMKIIβ/β-actin a post-hoc with Bonferroni's correction was 
performed. A trend towards a decrease of CaMKIIα/β-actin (F(4, 49) = 2.119, p = 0.082) 
between moderate present and heavy present consummation of drug abuse (see 
Figure 4-29 A). For the co-IP experiments there was no significant difference between 
the expression of CaMKIIβ either when considering the severity of substance abuse 
(F(4, 46) = 0.493, p = 0.741) or the severity of alcohol abuse (F(5, 46) = 0.875, p = 
0.505) (see Figure 4-29 B and D). 
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Figure 4-29: Mean (± SEM) ratios CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on severity of substance and alcohol abuse. 
(A) Mean ratio CaMKIIβ/β-actin after WB of the PSD fraction. (B) Mean ratio CaMKIIβ/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio CaMKIIβ/β-actin after WB of the PSD 
fraction. (D) Mean ratio CaMKIIβ/β-III-tubulin after co-IP of the PSD fraction. 
 
Correlation between the expression of CaMKIIβ with the the severity of substance 
abuse and alcohol abuse was also assessed by non-parametric correlation analysis of 
Spearman. Neither the difference of the means of the ratio CaMKIIβ/β-actin (ρ(54) = -
0.060; p = 0.664) nor the ratio CaMKIIβ/β-III-tubulin (ρ(52) = -0.075; p = 0.602) were 
significantly correlated with an increase of the severity of substance abuse. In addition 
neither the difference of expression of CaMKIIβ was significantly correlated with an 
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increase of the severity of alcohol abuse with WB analysis (ρ(54) = 0.058; p = 0.676) 
nor with co-IP analysis (ρ(52) = -0.100; p = 0.481). 
 
Table 4-9: Correlational effects of demographic and peri-mortem factors on the ratios 
CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
CaMKIIβ/β-actin (n=54) 0.030 -0.070 -0.090 0.268* 0.229 
CaMKIIβ/β-III-tubulin 
(n=52) 
-0.097 0.255 0.003 -0.115 -0.058 
*p<0.05 
 
Correlational effects of demographic and peri-mortem factors were assessed for the 
age at death, the pH of the brain, the mass of the brain, the PMI and the duration of 
storage of the brain for both CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin with non-
parametric correlation analysis. A significant increase of the mean of the ratio 
CaMKIIβ/β-actin was significantly correlated with an increase of the post-mortem 
interval (ρ(44) = -0.389; p = 0.009). No significant correlation was found between the 
ratio CaMKIIβ/β-actin and the demographic and peri-mortem factors such as pH of the 
brain, mass of the brain, PMI and duration of storage of the brain. Age at death, pH of 
the brain, mass of the brain, PMI and duration of storage of the brain were found to 
have no effect on the ratio CaMKIIβ/β-III-tubulin (see Table 4-9). 
For both WB and co-IP experiments the effects of age at death, age of onset of disease, 
duration of diseases and life time quantity of fluphenazine or equivalent on the 
expression of CaMKIIβ were also examined with non-parametric correlation analysis. 
For this study the group control was removed. None of the demographic and peri-
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mortem factors mentioned above were found to be significantly correlated with the 
level of expression of CaMKIIβ either for WB or co-IP experiments (see Table 4-10). 
 
Table 4-10: Correlational effects of demographic and peri-mortem factors on the ratios 
CaMKIIβ/β-actin and CaMKIIβ/β-III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
CaMKIIβ/β-actin (n=40) -0.044 -0.124 0.147 0.216 
CaMKIIβ/β-III-tubulin 
(n=38) 
-0.210 -0.127 0.017 -0.071 
 
None of the demographic and peri-mortem factors that were tested were found to 
affect the ratio CaMKIIβ/β-III-tubulin whereas the ratio CaMKIIβ/β-actin was affected 
by an increase of the post-mortem interval. Consequently an ANCOVA statistical 
analysis was performed including post mortem interval as co-variable. No significant 
difference between each group of diagnosis for the mean of the ratio CaMKIIβ/β-actin 
(F(3, 49) = 2.027, p = 0.122) was found with the effect of the post-mortem interval as 
co-variable. 
 
4.4.6 Expression of NSF in the PSD fraction and within the PSD 
The means of the ratios NSF/β-actin and NSF/β-III-tubulin were compared between 
each diagnosis groups for both WB and co-IP experiments using one-way ANOVA 
statistical test (see Figure 4-30). For both NSF/β-actin (F(3, 53) = 0.586, p = 0.627) and 
NSF/β-III-tubulin (F(3, 50) = 1.109, p = 0.354) no significant difference between 
diagnosis was found (see Figure 4-30 A and B). 
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Figure 4-30: Mean (± SEM) ratios NSF/β-actin and NSF/β-III-tubulin in the PSD fraction and 
co-IP PSD depending on diagnosis. 
(A) Mean ratio NSF/β-actin after WB of the PSD fraction. (B) Mean ratio NSF/β-III-tubulin 
after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive disorder ; 
(con) control ; (scz) schizophrenia. ANCOVA statistical analysis with death by suicide as co-
variable was performed for the mean ratio NSF/β-III-tubulin (see Figure 4-33 B), no 
significant difference was found between diagnosis. 
 
Using Student's T-test analysis the effects of gender (see Figure 4-31 A and B) and of 
the side of the cerebral hemisphere (see Figure 4-31 C and D) were determined on the 
dependent variables NSF/β-actin and NSF/β-III-tubulin respectively for WB 
experiments and co-IP experiments.  
 
A B
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Figure 4-31: Mean (± SEM) ratios NSF/β-actin and NSF/β-III-tubulin in the PSD fraction and 
co-IP PSD depending on gender and side of the cerebral hemisphere. 
(A) Mean ratio NSF/β-actin after WB of the PSD fraction. (B) Mean ratio NSF/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio NSF/β-actin after WB of the PSD fraction. (D) 
Mean ratio NSF/β-III-tubulin after co-IP of the PSD fraction. 
 
Neither significant effect of gender was found for both NSF/β-actin (t(55) = 0.363, p = 
0.718) and NSF/β-III-tubulin (t(52) = 1.310, p = 0.196) or cerebral lateralisation for WB 
(NSF/β-actin; t(55) = 1.070, p = 0.289). For the co-IP experiment a trend towards a 
decrease of the mean of the ratio NSF/β-III-tubulin (t(52) = 1.828, p = 0.073) was found 
in the left hemisphere of the cerebrum (see Figure 4-31 D). 
A B
C D
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To determine the effect of psychotic symptoms on the dependent variables NSF/β-
actin and NSF/β-III-tubulin respectively for WB experiments (see Figure 4-32 A) and co-
IP experiments (see Figure 4-32 B) the group control was removed and Student's t-test 
analysis was performed. There was no significant difference between the expression of 
NSF with or without psychosis for both WB (NSF/β-actin: t(42) = 0.683, p = 0.498) and 
co-IP (NSF/β-III-tubulin: t(38) = 0.402, p = 0.690). 
 
 
Figure 4-32: Mean (± SEM) ratios NSF/β-actin and NSF/β-III-tubulin in the PSD fraction and 
co-IP PSD depending on psychotic symptoms. 
(A) Mean ratio NSF/β-actin after WB of the PSD fraction. (B) Mean ratio NSF/β-III-tubulin 
after co-IP of the PSD fraction. 
 
For the effect of death by suicide on the dependent variables NSF/β-actin and NSF/β-
III-tubulin respectively for WB (see Figure 4-33 A and C) and co-IP experiments (see 
Figure 4-33 B and D), a Student's t-test analysis was carried out with (see Figure 4-33 A 
and B) and without (see Figure 4-33 C and D) the group control. No significant effect of 
death by suicide was found for both NSF/β-actin (t(55) = 1.006, p = 0.319) and NSF/β-
actin (t(42) = 0.779, p = 0.440) respectively with or without the control group. 
Student's t-test for both with (t(52) = 4.149, p = 0.0001) or without (t(38) = 3.634, p = 
A B
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0.001) the control group revealed a significant increase in the group with death by 
suicide for NSF/β-III-tubulin. 
 
 
Figure 4-33: Mean (± SEM) ratios NSF/β-actin and NSF/β-III-tubulin in the PSD fraction and 
co-IP PSD depending on death by suicide. 
(A) Mean ratio NSF/β-actin after WB of the PSD fraction. (B) Mean ratio NSF/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio NSF/β-actin after WB of the PSD fraction 
(without controls). (D) Mean ratio NSF/β-III-tubulin after co-IP of the PSD fraction (without 
controls). Statistical Student's t test (** p<0.01; *** p<0.001). 
 
The effects of the severity of substance abuse (see Figure 4-34 A and B) and the 
severity of alcohol abuse (see Figure 4-34 C and D) were examined with one-way 
***
**
A B
C D
Expression of proteins involved in neuronal plasticity in the premotor cortex in schizophrenia 
 
153 
 
ANOVA statistical for both ratios NSF/β-actin (see Figure 4-34 A and C) and NSF/β-III-
tubulin (see Figure 4-34 B and D). 
 
 
Figure 4-34: Mean (± SEM) ratios NSF/β-actin and NSF/β-III- in the PSD fraction and co-IP PSD 
depending on severity of substance and alcohol abuse. 
(A) Mean ratio NSF/β-actin after WB of the PSD fraction. (B) Mean ratio NSF/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio NSF/β-actin after WB of the PSD fraction. (D) 
Mean ratio NSF/β-III-tubulin after co-IP of the PSD fraction. 
 
No significant difference of the level of expression of NSF was revealed for both WB 
(F(4, 51) = 1.319, p = 0.275) and co-IP (F(4, 48) = 0.235, p = 0.917) experiments 
considering the degree of severity of substance abuse (see Figure 4-34 A and B). For 
A B
C D
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both NSF/β-actin (F(5, 51) = 0.385, p = 0.857) and NSF/β-III-tubulin (F(5, 48) = 1.029, p 
= 0.412) respectively for WB and co-IP experiments, no significant effect of the severity 
of alcohol abuse was observed (see Figure 4-34 C and D). 
Non-parametric correlation analysis of Spearman was performed to determine an 
eventual correlation between the expression of NSF with the effect of the severity of 
substance and alcohol abuse. No effect either with the severity of substance abuse 
(NSF/β-actin: ρ(56) = -0.154, p = 0.256; NSF/β-III-tubulin: (ρ(53) = 0.031, p = 0.825) or 
for the severity of alcohol abuse (NSF/β-actin: ρ(57) = 0.136, p = 0.314; NSF/β-III-
tubulin: ρ(54) = -0.160, p = 0.246) on the expression of NSF with both WB and co-IP 
experiments. 
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain for both ratios NSF/β-actin and NSF/β-III-tubulin were examined 
with non-parametric correlation analysis. No significant correlation was found for any 
of the demographic and peri-mortem factors with both ratios NSF/β-actin and NSF/β-
III-tubulin (see Table 4-11). 
 
Table 4-11: Correlational effects of demographic and peri-mortem factors on the ratios 
NSF/β-actin and NSF/β-III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
NSF/β-actin (n=57) 0.259 0.009 -0.058 0.019 -0.107 
NSF/β-III-tubulin (n=54) -0.177 0.158 -0.045 -0.228 -0.054 
 
Non-parametric correlation analysis was also carried out to correlate the effects of age 
at death, age of onset of disease, duration of diseases and life time quantity of 
fluphenazine or equivalent on both NSF/β-actin and NSF/β-III-tubulin. For this study 
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the group control was removed. None of the demographic and peri-mortem factors 
was found to be correlated with with the expression of (see Table 4-12). 
 
Table 4-12: Correlational effects of demographic and peri-mortem factors on the ratios 
NSF/β-actin and NSF/β-III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
NSF/β-actin (n=44) 0.215 0.040 0.235 0.005 
NSF/β-III-tubulin(n=40) -0.129 -0.262 0.067 -0.259 
 
To summarise the expression of NSF was not significantly affected by any demographic 
and peri-mortem factors for the WB experiments whereas the ratio NSF/β-III-tubulin 
by the effect of death by suicide. ANCOVA statistical analysis with death by suicide as 
co-variable was performed and no significant difference of the mean of the ratio 
NSF/β-III-tubulin (F(3, 49) = 0.402, p = 0.752) was revealed between diagnosis. 
 
4.5 Discussion and conclusions 
 
This part of the investigation has demonstrated: 
1. That expression of proteins involved in synaptic plasticity NR2A, PSD-95 and 
CaMKIIβ is decreased in schizophrenia compared to healthy control. 
2. That expression of the protein NSF involved in AMPAR trafficking is not 
affected in any psychiatric disorder tested in this study compared to control. 
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3. That proteins mentioned above are differentialy expressed and disturbed 
depending on their cellular localisation (extra-post-synaptic density (WB) and 
intra-post-synaptic density (co-IP)) in schizophrenia. 
4. That β-actin is more appropriated to normalise direct WB of the PSD 
compared to β-III-tubulin whereas β-III-tubulin is more appropriated to 
normalise WB after co-IP of the PSD compared to β-actin. 
 
Utilising co-IP, the present study revealed a significant decrease of the expression of 
the NMDAR subunit NR2A within the PSD in the premotor cortex of patients with 
schizophrenia (F(3, 46) = 7.927, p = 0.001) and major depressive disorder (F(3, 46) = 
7.927, p = 0.003) compared to healthy control. This study also revealed that the 
expression of NR2A within the PSD is significantly reduced in the premotor cortex of 
patients with schizophrenia compared to patients with bipolar disorder (F(3, 46) = 
7.927, p = 0.039). Using WB of the PSD fraction the results showed a significant 
decrease of the expression of NR2A in the premotor cortex of patients with major 
depressive disorder compared to control (F(3, 51) = 0.601, p = 0.025). In addition a 
trend towards a significant decrease of the expression of NR2A was found in the 
premotor cortex of patients with schizophrenia compared to control (F(3, 51) = 0.601, 
p = 0.058) (see section 4.4.2). 
Previous postmortem studies of NR2A mRNA and protein in schizophrenia have 
yielded variable results depending on the region of the brain studied, the techniques 
used and the variable effects of demographical/clinical factors.  
A study using in situ hybridisation showed a decrease in NR2A mRNA in the DLPFC of 
patients with schizophrenia and major depressive disorder but not in bipolar disorder 
relative to controls. In the same study, using receptor autoradiography, the authors 
revealed no alterations in receptor binding in any of the illnesses (Beneyto and 
Meador-Woodruff, 2008). This suggests that there is no change in the number of 
NMDAR in the DLPFC of patients with schizophrenia, major depressive disorder and 
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bipolar disorder but an abnormal NMDAR stoechiometry in the DLPFC of patients with 
schizophrenia and major depressive disorder. Our findings of decreased NR2A in PSD 
are in accordance with this study. However, other studies report conflicting findings. 
For example, one study found increased mRNA levels for NR2A in the DLPFC and 
occipital cortex of elderly patients with schizophrenia compared to matched healthy 
subjects (Dracheva et al., 2001). Whereas, another study found no significant changes 
of the expression of NR2A proteins in the DLPFC and other regions investigated in 
schizophrenia compared to healthy subjects (Kristiansen et al., 2007b).  
Other studies have focused on the expression of NR2A in interneurons. A recent study 
found that the density of interneurons that expressed NR2A mRNA was significantly 
decreased by 48-50% in layers 3 and 4 in PFC (BA 9) of subjects with schizophrenia, but 
the cellular expression of NR2A mRNA in the neurons that exhibited a detectable level 
of this transcript was unchanged (Bitanihirwe et al., 2009). Another study found similar 
findings, reporting that interneurons that expressed NR2A mRNA were decreased by 
73% and 52%, in layers 2 and 5, respectively, in anterior cingulate cortex (BA 24) of 
subjects with schizophrenia. However the expression level of NR2A mRNA was 
unaltered (Woo et al., 2004). 
Animal studies have been useful to observe potential links between reduced NR2A and 
the pathophysiology of schizophrenia. One study used lentivirus mediated RNA-
interference (RNAi) to knockdown the glial enzyme DAO in the mouse cerebellum and 
showed a 22% decrease in NR2A mRNA relative to controls in cerebellum (Burnet et 
al., 2011). Another study that used NR2A knockout mice to model schizophrenia 
demonstrated that these mice had impaired locomotor activity. Impairment of the 
locomotor activity was attenuated by treatment with antipsychotics such as 
haloperidol and risperidone (Miyamoto et al., 2001). 
The studies mentioned above illustrate the complexities of postmortem studies. 
Consideration needs to be given to the regional, cellular and subcellular origins of the 
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brain samples, the potentially confounding effects of numerous demographical, 
perimortem and clinical factors and also the techniques used.  
In the present study, co-IP and WB of the PSD occasionally showed similar findings, 
however, more often than not, the findings were different. Co-IP (with PSD-95) of the 
PSD fraction, may represent proteins of interest specifically docked at the synapse, 
whereas, WB of the PSD may also include proteins that are present at extra-synaptic 
regions or in the process of intracellular recycling. The differences between WB and 
co-IP data could also be due to the removal of more contaminants in the co-IP 
experiments. Previous studies and our results together, suggest that NR2A may be 
downregulated without changes in NMDAR number in premotor cortex of patients 
with schizophrenia and major depressive disorder. This change in the stoechiometry of 
the NMDAR may lead to a dysfunction of the PSD machinery in these two psychiatric 
illnesses. 
The present study also revealed a significant decrease (F(3, 48) = 2.995, p = 0.049) in 
the expression of scaffolding protein PSD-95 within the PSD in the premotor cortex of 
patients with schizophrenia compared to healthy subjects, utilising co-IP. In contrast to 
the findings for NR2A in major depressive disorder, no significant changes for PSD-95 
within the PSD were found. In addition no changes in the expression of PSD-95 were 
found in the premotor cortex of patients with bipolar disorder. WB analysis of the PSD 
fraction did not reveal any changes in PSD-95 for all three psychiatric illnesses 
compared to the control group (see section 4.4.3). 
Postmortem studies of PSD-95 mRNA and protein in different regions of the brain of 
patients with schizophrenia have reported heterogenous results. Studies using in situ 
hybridisation reported changes in the expression of PSD-95 mRNA in schizophrenia 
dependant on brain region. In the DLPFC, one study reported no changes in PSD-95 
mRNA expression in schizophrenia, major depressive disorder and bipolar disorder 
(Beneyto and Meador-Woodruff, 2008). Another study reported increased PSD-95 
mRNA in thalamus of elderly patients with schizophrenia (Clinton et al., 2003), 
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whereas a decreased PSD-95 mRNA was observed in thalamus of young patients with 
schizophrenia and bipolar disorder but not in patients with major depressive disorder 
(Clinton and Meadow-Woodruff, 2004). In the anterior cingulate cortex, PSD-95 mRNA 
was increased in patients with schizophrenia (Kristiansen et al., 2006). Furthermore, an 
increased expression of PSD-95 mRNA was found in the occipital cortex of patients 
with schizophrenia compared to healthy subjects (Dracheva et al., 2001). 
Studies comparing the expression of the PSD-95 protein between patients with 
schizophrenia and healthy subjects or others psychiatric groups have also reported 
conflicting results. A study using WB showed increased PSD-95 protein expression in 
the dorsomedial thalamus of patients with schizophrenia compared to healthy subjects 
(Clinton et al., 2006). Other studies reported decreased expression of PSD-95 protein 
in the anterior cigulate cortex of patients with schizophrenia compared to healthy 
controls (Kristiansen et al., 2006; Funk et al., 2009). In the hippocampus, a study using 
immunoautoradiographical techniques showed a decrease in PSD-95 protein in the 
dentate molecular layer in both schizophrenia and bipolar disorder relative to major 
depression (Toro and Deakin, 2005). Other studies reported no change in the 
expression PSD-95 proteins in the orbitofrontal cortex, the DLPFC and ventral thalamus 
of patients with schizophrenia compared to healthy subjects (Kristiansen et al., 2007b). 
In the present study, decreased expression of the scaffolding protein PSD-95 was 
reported in schizophrenia. There have been no previous studies that have assessed the 
expression of PSD-95 within the PSD. Both NR2A and PSD-95 that are known to 
interact within the PSD are significantly reduced in schizophrenia whereas no 
significant change in the expression of PSD-95 was found in patients with major 
depressive disorder. These findings suggest that distinct interactions/signalling 
pathways within the PSD may be disturbed in these two different psychiatric illnesses. 
The present study also revealed a significant decrease in the expression of the 
signalling protein CaMKIIβ within the PSD in the premotor cortex of patients with 
schizophrenia compared to the group control utilising co-IP. No significant difference 
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in the expression of CaMKIIβ within the PSD was found in the premotor cortex of 
patients with major depressive disorder or bipolar disorder. Using WB no significant 
differences between diagnosis was found for the expression CaMKIIα in the PSD 
fraction (see sections 4.4.4 and 4.4.5). 
Few postmortem studies have been carried out previously to assess the expression of 
CaMKIIα and CaMKIIβ in schizophrenia. A preliminary study using qPCR showed that 
mRNA for CaMKIIβ was significantly elevated in the DLPFC in the schizophrenia (Novak 
et al., 2000). In frontal cortex the same authors showed that the expression of CaMKIIα 
was significantly elevated in major depressive disorder but not in schizophrenia and 
that the expression of CaMKIIβ was significantly elevated in schizophrenia and in major 
depressive disorder (Novak et al., 2006). Another study using in situ hybridisation in 
the PFC reported no changes in the expression of CaMKIIα mRNA in schizophrenia and 
major depressive disorder whereas a significant decrease was found in bipolar disorder 
compared to healthy subjects (Xing et al., 2002). A behavioural study that assessed 
memory performances showed that phosphorylation of CaMKII proteins was 
significantly reduced in PCP animal model of schizophrenia compared to controls 
(Nabeshima et al., 2006). 
The previous finding of increased CaMKIIβ mRNA in schizophrenia (Novak et al., 2006) 
is in contradiction with our results. However the Novak et al study assessed mRNA 
levels in PFC, whereas protein levels in PSD of BA6 were assessed here. The present 
study highlights a decrease in CaMKIIβ expression specifically in schizophrenia and not 
major depressive disoder or bipolar disorder.  
Previous postmortem studies of NSF in patients with schizophrenia have reported 
conflicting results. A study using in situ hybridisation showed a significant decrease of 
NSF in PFC of subjects with schizophrenia compared to healthy controls (Mirnics et al., 
2000). Others studies reported no change in the expression of NSF in same brain area 
in schizophrenia. For instance, one study used qPCR and WB to measure NSF and 
found that expression was not altered significantly in the prefrontal cortex of 
Expression of proteins involved in neuronal plasticity in the premotor cortex in schizophrenia 
 
161 
 
schizophrenic patients compared to subjects controls (Imai et al., 2001). In addition, 
another study confirmed the results of the latter study using WB in a different BA 
region of the PFC (Gray et al., 2006). 
Our findings for the expression of NSF in the premotor cortex of patients with 
schizophrenia are in concordance with last two studies. The expression of the vesicular 
protein NSF was not affected within the PSD in the premotor cortex in any of the 
psychiatric illnesses compared to the healthy subjects either using co-IP or WB (see 
section 4.4.6). As NSF is known to regulate trafficking of GluR2 at the post synaptic 
membrane it is possible that AMPAR trafficking is not disturbed in the premotor cortex 
of patients with schizophrenia. However, other components of the trafficking 
machinery would need to be studied to make any firm conclusions. 
Overall, the results from the present study suggest that both schizophrenia and major 
depressive disorder share in common, disturbed NMDAR subunit stochiometry with 
less NR2A subunits. In addition, a decrease in NR2A, PSD-95 and CaMKIIβ expression 
within the PSD seems to be a specific feature of schizophrenia. All together, our 
findings confirm that glutamatergic system may be disturbed in schizophrenia and that 
disturbance in the premotor cortex may be due to a disturbed signalling pathway 
implicated in synaptic plasticity. 
 
  
 
5 Expression of neurotrophin receptors in the premotor cortex 
in schizophrenia 
 
Expression of neurotrophin receptors in the premotor cortex in schizophrenia 
165 
 
5.1 Aims and objectives 
The aims of the present study are to semi-quantify protein expression of the 
neurotrophin receptors TrkB, TrkB-T1 and p75 in BA 6 in schizophrenia relative to 
major depressive disorder, bipolar disorder and healthy controls. Protein expression 
will be assessed using WB and co-IP of the PSD fraction. New WB will be carried out for 
the detection of TrkB, TrkB-T1 and p75 on BA 6 homogenate PSD fractions whereas 
detection of TrkB, TrkB-T1 and p75 after co-IP will be performed on the membranes 
used for the previous study (Chapter 4). 
 
5.2 Introduction 
Neurotrophins, namely nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), are neurotrophic 
factors that bind to the high affinity tropomyosin receptor kinase (Trk) receptors, as 
well as to the low affinity p75 receptor. NGF binds to TrkA, BDNF and NT-4/5 to TrkB, 
and NT-3 to TrkC (and weakly to TrkB). Activation of these receptors stimulates various 
intracellular signalling pathways such as mitogen-activated protein kinase/extracellular 
signal-regulated kinases (MAPK/ERK), phospholipase Cγ (PLCγ), and phosphoinositide 
3-kinase (PI3K) pathways, involved in cell survival, proliferation, differentiation and 
apoptosis (Huang and Reichardt, 2003).  
BDNF plays a crucial role in neurodevelopment and function of the mammalian central 
nervous system. BDNF is released from neurons and regulates synaptic plasticity, 
which is thought to underlie learning and memory (Chao, 2003; Lu et al., 2005). BDNF 
is translated as a precursor protein (pro-BDNF) which is subsequently cleaved to 
produce a mature protein (BDNF) (Matsumoto et al., 2008). Pro-BDNF binds the p75 
neurotrophin receptor with high affinity whereas BDNF binds TrkB with high affinity 
(Lee et al., 2001). In addition a recent study reported that neurons release both pro-
BDNF and BDNF (Yang et al., 2009). 
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Several studies have reported that the expression of BDNF is decreased in 
schizophrenia, bipolar disorder and major depressive disorder relative to healthy 
controls (Knable et al., 2004; Gervasoni et al., 2005; Karege et al., 2005; Pillai, 2008). 
 
5.2.1 Function of TrkB receptor within the PSD 
The full-length TrkB isoform (TrkB) is a tyrosine kinase that forms homodimers during 
ligand binding. The homodimerisation triggers tyrosine phosphorylations in the 
intracellular Trk domains thereby activating transduction of the BDNF signal. These 
phosphorylations activate MAPK, PI3K or PLCγ intracellular signaling pathways that 
regulate the assembling of TrkB within the PSD, gene transcription, protein translation 
and trafficking. TrkB activation of the three signalling pathways is described in more 
detail below. 
Phosphorylation of tyrosine residue 785 of TrkB, recruits and activates PLCγ which in 
turn hydrolyses phosphatidylinositol 4,5-bisphosphate, to produce diacylglycerol (DAG) 
and inositol 1,4,5-trisphosphate (IP3) (Huang and Reichardt, 2003; Reichardt, 2006b). 
DAG activates protein kinase C (PKC), and IP3 receptor releases Ca2+ from intracellular 
reticulum endoplasmic stores. A study has shown that BDNF triggers intracellular 
Ca2+.release at postsynaptic sites of cultured hippocampal neurons (Lang et al., 2007). 
Then, both Ca2+ and DAG activate the plasma membrane transient receptor potential 
canonical subfamily channel 3/6 (TRPC3/6) that contribute to BDNF-induced Ca2+ 
elevations at growth cones and synapses (Li et al., 2005; Amaral and Pozzo-Miller, 
2007).  
A study using cultured cortical pyramidal neurons showed that TrkB-BDNF-triggered 
Ca2+ transients translocate GluR1 subunit of AMPAR, but not NMDAR subunits to 
synapses (Nakata and Nakamura, 2007). Another study using (HEK) 293 cells carrying 
TrkB and transfected with GluR2 cDNA or GluR1 cDNA, showed that BDNF triggered 
the translocation of GluR2 but not that of GluR1 via NSF (Narisawa-Saito et al., 2002). 
These finding suggest a direct involvement of triggered-TrkB-BDNF in synaptic 
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plasticity. In addition, the elevated Ca2+ concentration triggered by PLCγ also increases 
Ca2+-sensitive adenyl cylclase (AC) activity which is involved in the formation of PSD-
95-TrkB complexes (Ji et al., 2005). Ca2+-sensitive AC also activates the cyclic AMP 
responsive element binding (CREB) which is involved in nuclear transcription (Nguyen 
et al., 1994; Shaywitz and Greenberg, 1999). 
Phosphorylation of TrkB also occurs at tyrosine residue 515 which recruits and 
phophorylates Shc. Phosphorylated Shc interacts with the adaptor protein Grb2 that 
recruits and activates the guanine nucleotide exchange factor SOS which promotes the 
removal of GDP from Ras that can then bind GTP and become active. Ras activates the 
downstream kinase B-raf, MEK and MAPK/Erk (Huang and Reichardt, 2003; Reichardt, 
2006b). MEK-MAPK/Erk signalling pathway also activates CREB (Shaywitz and 
Greenberg, 1999). Protein-synthesis also occurs via phosphorylation of eukaryotic 
initiation factor 4E (eIF4E), the 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 
triggered by MAPK/Erk (Kelleher III et al., 2004; Klann and Dever, 2004). These findings 
emphasise the crucial role played by MAPK/Erk signalling pathway in synaptic 
plasticity. 
The PI3K pathway is also activated by TrkB via Shc, Grb2 and Ras as previously 
described (Reichardt, 2006b). Activation of PI3K changes the composition of inositol 
phospholipids which leads to the translocation of Akt/protein kinase B to the plasma 
membrane. Akt activates translation within the post-synaptic dendrite via the 
mammalian target of rapamycin (mTOR) which regulates protein synthesis (Sarbassov 
et al., 2005). Then mTOR phosphorylates the protein kinases p70S6K and 4E-BP1 
allowing mRNA translation by ribosomes located in the post-synaptic dendrite. The 
PI3K-Akt pathway also regulates the trafficking of synaptic proteins (Yoshii and 
Constantine-Paton, 2007b). This pathway also plays a pivotal role synaptic plasticity 
through translation and transport of synaptic proteins. 
The TrkB receptor is present within the PSD of rat cerebral cortex and hippocampus 
(Wu et al., 1996). TrkB also co-localises with NMDAR at the PSD of cultured cortical 
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neurons (Gomes et al., 2006). Activation of the TrkB-PLCγ pathway, or direct 
application of BDNF to cultured neurons, increased synaptic co-localisation of TrkB 
with PSD-95 and co-IP of PSD-95 and TrkB is correlated with increased synaptic activity 
(Ji et al., 2005; Yoshii and Constantine-Paton, 2007b). Furthermore BDNF triggered 
TrkB also induces a rapid transport of PSD-95 from the soma to the dendritic regions of 
developing neurons in a PI3K-AKT- and microtubule- dependent, protein synthesis-
independent, process (Yoshii and Constantine-Paton, 2007b). A study demonstrated 
that over-expression of PSD-95 increases spine number, size and synaptic efficacy (El-
Husseini et al., 2000). 
Taken together these studies emphasise the crucial role of TrkB at the post-synaptic 
dendrite and its contribution to synaptic plasticity and the organisation of the 
glutamatergic synapse through stabilisation of PSD-95 within the PSD. 
 
5.2.2 Functions of truncated TrkB receptor 
Truncated TrkB (TrkB-T1) is a splice variant of TrkB in which alternative splicing 
removes the exons that code for the intracellular tyrosine kinase domain. Therefore, 
TrkB-T1 binds to BDNF but it does not undergo autophosphorylation. TrkB-T1 was 
considered as a dominant-negative form of TrkB as several studies showed negative 
functions against TrkB, such as TrkB phosphorylation (Knüsel et al., 1994), calcium 
efflux (Eide et al., 1996), neurite outgrowth (Fryer et al., 1997), cell survival activity 
(Haapasalo et al., 2001), and gene expression by BDNF (Renn et al., 2009).  
TrkB-T1 can form a homodimer or a heterodimer with TrkB, which suppresses TrkB 
signalling pathway or reduces the availability of BDNF to neurons by binding excess of 
BDNF (Biffo et al., 1995). However the suggestion that TrkB-T1 is a dominant-negative 
form of TrkB remains controversial and other functions have also been suggested. For 
instance several studies revealed that the expression of TrkB-T1 increases markedly at 
various important periods of neuronal development such as axonal remodelling and 
synaptogenesis (Ohira et al., 1999; Ohira et al., 2001). In addition several studies 
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reported that BDNF-triggered TrkB-T1 activates its own signalling pathway. TrkB-T1 
binds directly to Rho GDI1, a Rho guanine nucleotide dissociation inhibitor, which in 
turn promotes the removal of GDP from Rho GTPase that can then bind GTP and 
become active (Ohira et al., 2006). The Rho signalling pathway regulates the 
arrangement of microfilaments, intermediate filaments, and microtubules (Etienne-
Manneville and Hall, 2002). A study reported that in the BDNF-triggered TrkB-T1 
signalling pathway, Rho GDI1 is released from TrkB-T1 in a BDNF-dependent manner, 
which causes decreases of the activities of Rho-signalling molecules such as RhoA, Rho-
associated kinase (ROCK), p21-activated kinase (PAK), and ERK 1/2 (Ohira et al., 2006). 
These studies suggest that TrkB-T1 regulates the Rho-signalling pathways and the actin 
cytoskeleton and may be implicated in synaptic plasticity. Other studies showed that 
TrkB-T1 induces neurite outgrowth (Yacoubian and Lo, 2000; Haapasalo et al., 1999), 
regulates cytoskeletal changes in astrocytes and may stimulate PLCγ and MAPK 
signalling (Ohira et al., 2007).  
The ratio of cortical TrkB to TrkB-T1 decreases with age as TrkB-T1 protein levels are 
higher in infants. This increase corresponds with the period of cellular and synaptic 
pruning (Bracken and Tyrrigiano, 2009). Furthermore the level of expression and 
localisation seem to vary in different cortical regions. For instance, TrkB-T1 is 
preferentially localised to pyramidal neurons in the motor cortex layers II–VI (Ohira et 
al., 2005), but evenly distributed between pyramidal and interneurons in the visual 
cortex (Bracken and Tyrrigiano, 2009). The differential distribution of TrkB-T1 between 
brain regions may regulate localised BDNF function. 
The positive or negative effect of BDNF-triggered TrkB-T1 on synaptic plasticity 
remains unclear. However, these studies show its involvement in cytoskeletal 
rearrangement which may be disturbed in psychiatric disorders.  
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5.2.3 Function of the p75 receptor within the PSD 
The p75 receptor was originally described as a low-affinity receptor for neurotrophins. 
Recent studies have demonstrated that p75 can promote cell death or survival and 
modulate neurite outgrowth depending on the operative ligands and co-receptors. 
Increased expression of p75 has been shown to be involved in neuronal cell death in 
cultured cells. In addition, studies showed that p75 is disturbed in major depressive 
disorder and schizophrenia (Fujii and Kunugi, 2009).  
Animal studies using p75 mutant mice show impairments in water maze learning, 
inhibitory avoidance and habituation tasks, which indicates that p75 signalling might 
modulate synaptic plasticity (Peterson et al., 1999; Wright et al., 2004). Studies also 
revealed that p75−/− mice have increased hippocampal neuron spine numbers 
(Koshimizu et al., 2009) and that over-expression of p75 in these neurons reduced the 
number of dendritic spines (Zagrebelsky et al., 2005). Similarly treatment with a 
cleavage-resistant proBDNF in cultured neurons decreased the number of spines 
(Koshimizu et al., 2009). Spine retraction is a mechanism that regulates dendritic 
arborisation.  
Recent studies revealed that activation of p75 receptor is necessary for NMDAR-
dependent LTD in CA1 hippocampal neurons (Rösch et al., 2005; Woo et al., 2005). 
NMDAR-dependent LTD is also absent in the hippocampal CA1 region of p75-knockout 
mice without affecting NMDAR-dependent LTP or NMDAR-independent LTD (Rösch et 
al., 2005; Woo et al., 2005). During synaptic depression p75 seems to involve a specific 
NMDAR subunit NR2B that is implicated in LTD but not in LTP (Massey et al., 2004; Liu 
et al., 2004). A study using immunostaining and Western blot experiments showed 
that there was a significant decrease in expression of NR2B in the hippocampus of 
p75−/− mice. In addition whole-cell recordings revealed that the NR2B-mediated 
synaptic currents were reduced in CA1 neurons of p75−/− mice. Finally, application of 
proBDNF to wild-type slices increased the NR2B-mediated synaptic currents and the 
proBDNF-induced enhancement of LTD was reversed by an NR2B-specific antagonist. 
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This study demonstrates that proBDNF activates p75 to promote NMDAR-dependent 
hippocampal LTD, and that this is achieved primarily by enhancing the expression of 
the NR2B subunit (Woo et al., 2005). 
 
5.3 Materials and methods 
5.3.1 Enrichment of the glutamate post-synaptic density 
The extraction and purification of PSDs was performed as described in Chapter 4 (see 
section 4.3.1, page 109). 
 
5.3.2 Protein concentration and protein assay 
A protein assay was carried out on the PSD fractions as described in in Chapter 4 (see 
section 4.3.2, page 109). 
 
5.3.3 Co-immunoprecipitation 
The co-immunoprecipitation of PSDs was performed as described in Chapter 4 (see 
section 4.3.3, page 109). 
 
5.3.4 Western blotting 
The WB of PSDs was performed as described in Chapter 4 (see section 4.3.4, page 110), 
exept that TrkB, TrkB-T1, p75 were immunodetected instead of NR2A, PSD-95, 
CaMKIIα, CaMKIIβ and NSF. New membranes were immunoblotted for WB 
experiments. Consequently novel statistical analysis for β-actin was performed (see 
section 5.4.1, page 172). 
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5.3.5 Data analysis 
Data analysis was performed as described in Chapter 4 (see section 4.3.5, page 110). 
 
5.4 Results 
Co-immunprecipitation experiments revealed the presence TrkB, T-TrkB, p75, β-actin 
and β-III-tubulin. The receptor p75 was indistinguishable from the background of the 
membranes for the western blotting experiments. Therefore this receptor was 
excluded from the WB study. The first result analysis consisted on confirming that β-
actin was appropriate for the normalisation of the results for WB experiments. 
Expression of TrkB, T-TrkB and were then measured as a ratio of these proteins with β-
actin or β-III-tubulin respectively for WB and co-IP experiments. For the co-IP 
experiment β-III-tubulin used to normalise our results was the same used in co-IP 
experiments presented above (see section 4.4.1) 
 
5.4.1 Expression of β-actin in the PSD fraction 
The mean of the fluorescence intensity of β-actin was compared between each 
diagnosis groups using one-way ANOVA statistical test. No significant difference 
between diagnosis was found for the mean of the fluorescence of β-actin (F(3, 55) = 
1.907, p = 0.139) by WB. The chart representing the difference of the means of the 
flurescence of β-actin between each group of diagnosis showed an appropriate 
homogeneity of variance of the mean (see Figure 5-1). However the expression of β-
actin was assessed for each demographic and peri-mortem factors in order to 
determine wether β-actin could be used as denominator to normalise data from WB 
experiments. 
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Figure 5-1: Mean (± SEM) fluorescence intensity for β-actin in the PSD fraction. 
(bpd) bipolar disorder ; (mdd) major depressive disorder ; (con) control ; (scz) schizophrenia 
 
Student's T-test analysis was performed in order to determine an eventual difference 
of expression of β-actin between male and female (see Figure 5-2 A) and between the 
right and the left side of the cerebral hemisphere (see Figure 5-2 B). No significant 
difference in the expression of β-actin was found either for gender (t(57) = 0.167, p = 
0.868) or for the right and left hemisphere of the cerebrum (t(57) = 1.122, p = 0.267). 
The group control was removed and the effect of psychotic symptoms on the 
dependent variable β-actin was also examined with Student's T-test analysis. No 
significant difference of the expression of β-actin (t(43) = 0.636, p = 0.528) was found 
between both groups with and without psychosis (see Figure 5-2 C). 
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Figure 5-2: Mean (± SEM) fluorescence intensity for β-actin in the PSD depending on gender, 
side of the cerebral hemisphere and psychosis. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction (Gender). (B) Mean 
fluorescence intensity for β-actin after WB of the PSD fraction (Cerebral hemisphere). (C) 
Mean fluorescence intensity for β-actin after WB of the PSD fraction (Psychosis). 
 
The expression of β-actin was compared between groups of individu that died by 
suicide or not with Student's t-test analysis. In this study both expression of β-actin 
with (see Figure 5-3 A) and without (see Figure 5-3 B) the group control were 
compared. No significant effect of death by suicide was found for β-actin either with 
(t(29.18) = 1.135, p = 0.266) or without the group control (t(43) = 0.908, p = 0.369). 
A B
C
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Figure 5-3: Mean (± SEM) fluorescence intensity for β-actin in the PSD fraction depending on 
death by suicide. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction. (B) Mean 
fluorescence intensity for β-actin after WB of the PSD fraction (without controls). 
 
One-way ANOVA statistical test was performed to compare the mean of the 
fluorescence intensity of β-actin between each of the degrees of severity of substance 
and alcohol abuse (see Figure 5-4 A). A trend towards a significant increase of the 
expression of β-actin (F(4, 53) = 3.524, p = 0.064) was found in the group 
moderate/present compared to the group none/little consummation of drug abuse. 
No significant effect of the severity of alcohol abuse (F(5, 53) = 0.623, p = 0.683) was 
observed on the expression of β-actin (see Figure 5-4 B). 
Non-parametric correlation analysis of Spearman was performed to identify an 
eventual correlation between the expression of β-actin with the effect of the severity 
of substance and alcohol abuse. An increase of β-actin was significantly correlated with 
an increase of the severity of substance (ρ(58) = 0.413; p = 0.001) whereas no 
correlation was observed for the severity of alcohol abuse (ρ(59) = 0.074; p = 0.579).  
 
 
A B
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Figure 5-4: Mean (± SEM) fluorescence intensity for β-actin and β-III-tubulin in the PSD 
fraction depending on severity of substance and alcohol abuse. 
(A) Mean fluorescence intensity for β-actin after WB of the PSD fraction. (B) Mean 
fluorescence intensity for β-III-tubulin after co-IP of the PSD fraction. (C) Mean fluorescence 
intensity for β-actin after WB of the PSD fraction. (D) Mean fluorescence intensity for β-III-
tubulin after co-IP of the PSD fraction. 
 
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain on the expression of β-actin were examined with non-parametric 
correlation analysis. A significant negative correlation was found between age at death 
and expression of β-actin (ρ(59) = -0.319; p = 0.014) whereas pH of the brain, mass of 
the brain, PMI and duration of storage of the brain were found to have no effect (see 
Table 5-1). 
The group control was removed and the effects of age at death, age of onset of 
disease, duration of diseases and life time quantity of fluphenazine or equivalent for 
the expression of β-actin were also examined with non-parametric correlation analysis. 
As previously observed in the study with the group control a significant negative 
correlation was found between age at death and the expression of β-actin (ρ(45) = -
0.375; p = 0.011). Age of onset of disease, duration of diseases and life time quantity of 
A B
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fluphenazine or equivalent were found to have no effect on the expression of β-actin 
(see Table 5-2). 
 
Table 5-1: Correlational effects of demographic and peri-mortem factors on the expression 
of β-actin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
β-actin (n=59) -0.319* -0.174 0.151 0.213 0.177 
*p<0.05 
 
Table 5-2: Correlational effects of demographic and peri-mortem factors on the expression 
of β-actin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
β-actin (n=45) -0.375* -0.186 -0.161 0.027 
*p<0.05 
The expression of β-actin was affected by the effect of severity of substance abuse and 
the age at death. Consequently an ANCOVA statistical analysis was performed in order 
to reveal any significant difference of the mean of β-actin between diagnosis. No 
significant difference between diagnosis was found for β-actin (F(3, 52) = 0.713, p = 
0.549) with the effect of severity of substance abuse and the age at death as co-
variables. Subsequently β-actin was then used as denominator to normalise data from 
WB experiments. 
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5.4.2 Expression of TrkB in the PSD fraction and within the PSD 
Means of the ratios TrkB/β-actin and TrkB/β-III-tubulin were compared between each 
diagnosis groups for both WB and co-IP experiments using one-way ANOVA statistical 
test (see Figure 5-5 A and B).  
 
 
Figure 5-5: Mean (± SEM) ratios TrkB/β-actin and TrkB/β-III-tubulin in the PSD fraction and 
co-IP PSD epending on diagnosis. 
(A) Mean ratio TrkB/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB/β-III-tubulin 
after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive disorder ; 
(con) control ; (scz) schizophrenia. ANCOVA statistical analysis was performed with the pH of 
the brain and severity of substance abuse, the age at death as co-variables respectively for 
TrkB/β-actin (see Table 5-3) and TrkB/β-III-tubulin (see Figure 5-9 B and Table 5-4), no 
significant differences were found between diagnosis. 
 
ANOVA revealed a trend towards an increase of the mean of the ratio TrkB/β-actin for 
the group with schizophrenia compared to the group control (F(3, 50) = 3.675, p = 
0.066) and the group with bipolar disorder(F(3, 50) = 3.675, p = 0.057). In contrast no 
significant difference of the means between diagnosis was observed for for the ratio 
TrkB/β-III-tubulin (F(3, 52) = 0.330, p = 0.804). 
A B
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Figure 5-6: Mean (± SEM) ratios TrkB/β-actin and TrkB/β-III-tubulin in the PSD fraction and 
co-IP PSD depending on gender and side of the cerebral hemisphere. 
(A) Mean ratio TrkB/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio TrkB/β-actin after WB of the PSD fraction. (D) 
Mean ratio TrkB/β-III-tubulin after co-IP of the PSD fraction. 
 
The expression of TrkB was compared in both genders (see Figure 5-6 A and B) and in 
both cerebral hemispheres (see Figure 5-6 C and D) for WB experiments and co-IP 
experiments with Student's t-test analysis. No significant difference was found 
between gender for both TrkB/β-actin (t(52) = 0.659, p = 0.513) and TrkB/β-III-tubulin 
(t(54) = 0.937, p = 0.435). No cerebral lateralisation was observed for both WB (TrkB/β-
A B
C D
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actin: t(52) = 1.533, p = 0.131) and co-IP (TrkB/β-III-tubulin: t(54) = 0.822, p = 0.415) 
experiments. 
The expression of TrkB was also compared in group of patients presenting or not 
psychotic symptoms for both WB experiments (see Figure 5-7 A) and co-IP experiments 
(see Figure 5-7 B) with Student's T-test analysis. As psychotic symptoms occur only in 
groups with psychiatric disorders the group control was removed from the analysis. No 
significant difference was found between groups with or without psychosis for both 
TrkB/β-actin (t(40.10) = 0.481, p = 0.633) and TrkB/β-III-tubulin (t(40) = 0.375, p = 
0.710). 
 
 
Figure 5-7: Mean (± SEM) ratios TrkB/β-actin and TrkB/β-III- in the PSD fraction and co-IP 
PSD depending on psychotic symptoms. 
(A) Mean ratio TrkB/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB/β-III-tubulin 
after co-IP of the PSD fraction. 
 
Student's t-test analysis was also carried out to determine whether the expression of 
TrkB is different in groups of individuals that had death by suicide. This study was 
carried out with and without the group control and WB experiments (see Figure 5-8 A 
and C) and co-IP experiments (see Figure 5-8 B and D) were compared.  
A B
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Figure 5-8: Mean (± SEM) ratios TrkB/β-actin and TrkB/β-III-tubulin in the PSD fraction and 
co-IP PSD depending on death by suicide. 
(A) Mean ratio TrkB/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio TrkB/β-actin after WB of the PSD fraction 
(without controls). (D) Mean ratio TrkB/β-III-tubulin after co-IP of the PSD fraction (without 
controls). 
 
Student's t-test did not reveal any difference between the groups with death by 
suicide or not for both TrkB/β-actin (t(27.91) = 0.505, p = 0.618) and TrkB/β-actin (t(42) 
= 1.217, p = 0.231) respectively with or without the control group. For the co-IP 
Student's t-test for both with (t(54) = 1.189, p = 0.240) or without (t(40) = 1.162, p = 
0.252) the control group showed no significant difference in the group with death by 
suicide for TrkB/β-III-tubulin. 
A B
C D
The glutamate post-synaptic density in schizophrenia 
182 
 
 
Figure 5-9: Mean (± SEM) ratios TrkB/β-actin and TrkB/β-III- in the PSD fraction and co-IP 
PSD depending on severity of substance and alcohol abuse. 
(A) Mean ratio TrkB/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB/β-III-tubulin 
after co-IP of the PSD fraction. (C) Mean ratio TrkB/β-actin after WB of the PSD fraction. (D) 
Mean ratio TrkB/β-III-tubulin after co-IP of the PSD fraction. Statistical test ANOVA with 
Bonferroni correction. Comparison with moderate, present substance abuse (* p<0.05). 
 
One-way ANOVA statistical test was performed to compare the means of the ratios 
TrkB/β-actin and TrkB/β-III-tubulin between each group with different severity of 
substance and alcohol abuse for both WB (see Figure 5-9 A and C) and co-IP (see Figure 
5-9 B and D) experiments. No significant difference was found between the groups 
with different severity of substance abuse for the ratio TrkB/β-actin (F(3, 48) = 0.579, p 
= 0.632) (see Figure 5-9 A) whereas a significant decrease of the mean of the ratio 
*
*
*
A B
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TrkB/β-III-tubulin was found for the groups "none/little" (F(4, 50) = 3.469, p = 0.029), 
"moderate past" (F(4, 50) = 3.469, p = 0.045) and "heavy present" (F(4, 50) = 3.469, p = 
0.042) compared to "moderate present" (see Figure 5-9 B). For the severity of alcohol 
abuse a trend towards a significant increase of the expression of TrkB (F(5, 48) = 2.175, 
p = 0.084) was revealed for the group "moderate present" compared to the group 
"social (1/2 drinks/day)" with WB experiments (see Figure 5-9 B). No significant effect 
of the severity of alcohol abuse (F(5, 50) = 0.292, p = 0.915) was observed with the co-
IP experiments (see Figure 5-9 D). 
 
Table 5-3: Correlational effects of demographic and peri-mortem factors on the ratios 
TrkB/β-actin and TrkB/β-III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
TrkB/β-actin (n=54) -0.048 -0.275* -0.075 0.108 0.088 
TrkB/β-III-tubulin (n=56) -0.257 -0.129 -0.053 -0.182 0.104 
*p<0.05 
 
Non-parametric correlation analysis of Spearman was performed in order to identify 
an eventual correlation between the expression of TrkB with the effect of the severity 
of substance and alcohol abuse. No correlation was found between the expression of 
TrkB and the severity of substance and acohol abuse either for WB (TrkB/β-actin: 
substance abuse: ρ(53) = 0.073; p = 0.604; alcohol abuse: ρ(54) = -0.099; p = 0.478) or 
co-IP experiments (TrkB/β-III-tubulin: substance abuse: ρ(55) = -0.007; p = 0.960; 
alcohol abuse: ρ(56) = -0.074; p = 0.586).  
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain for both TrkB/β-actin and TrkB/β-III-tubulin were examined with 
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non-parametric correlation analysis. A significant negative correlation was found 
between pH of the brain and expression of TrkB (ρ(54) = -0.275; p = 0.044) whereas 
age at death, mass of the brain, PMI and duration of storage of the brain were found 
to have no effect with WB experiments. Age at death, pH of the brain, mass of the 
brain, PMI and duration of storage of the brain were found to have no effect on the 
ratio TrkB/β-III-tubulin (see Table 5-3). 
 
Table 5-4: Correlational effects of demographic and peri-mortem factors on the ratios 
TrkB/β-actin and TrkB/β-III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
TrkB/β-actin (n=44) -0.084 0.056 -0.076 0.008 
TrkB/β-III-tubulin (n=42) -0.311* -0.124 -0.147 -0.044 
*p<0.05 
 
For the effects of age at death, age of onset of disease, duration of diseases and life 
time quantity of fluphenazine or equivalent for both TrkB/β-actin and TrkB/β-III-
tubulin the group control was removed. Non-parametric correlation analysis showed a 
significant negative correlation was found between age at death and the ratio TrkB/β-
III-tubulin (ρ(42) = -0.311; p = 0.045). Age of onset of disease, duration of diseases and 
life time quantity of fluphenazine or equivalent were found to have no effect on the 
expression of TrkB/β-III-tubulin. Age at death, age of onset of disease, duration of 
diseases and life time quantity of fluphenazine or equivalent were found to have no 
effect on the expression of TrkB/β-actin (see Table 5-4). 
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To summarise the expression of TrkB was significantly affected by demographic and 
peri-mortem factors for both WB and co-IP experiments. A decrease of the ratio 
TrkB/β-actin was correlated with an increase of the pH of the brain and the ratio 
TrkB/β-III-tubulin wasd affected by the effect of severity of substance abuse and the 
age at death. Consequently an ANCOVA statistical analysis was performed for both WB 
and co-IP experiments. ANCOVA revealed a trend towards an increase of the mean of 
the ratio TrkB/β-actin for the group with schizophrenia compared to the group control 
(F(3, 49) = 3.411, p = 0.078) and the group with bipolar disorder(F(3, 49) = 3.411, p = 
0.059) and significant difference for the ratio TrkB/β-III-tubulin (F(3, 49) = 0.391, p = 
0.760) between diagnosis groups. 
 
5.4.3 Expression of TrkB-T1 in the PSD fraction and within the PSD 
One-way ANOVA statistical test was used to compare the means of the ratios TrkB-
T1/β-actin and TrkB-T1/β-III-tubulin for both WB and co-IP experiments (see Figure 
5-10). One-way ANOVA statistical test was used to compare the means of the ratios 
TrkB-T1/β-actin and TrkB-T1/β-III-tubulin respectively for both WB and co-IP 
experiments (see Figure 5-10). For both WB and co-IP experiments no significant 
difference was revealed for the ratios TrkB-T1/β-actin (F(3, 46) = 1.888, p = 0.145) and 
TrkB-T1/β-III-tubulin (F(3, 52) = 1.957, p = 0.132) between diagnosis. The chart 
representing the mean of the ratio TrkB-T1/β-actin for each group of diagnosis showed 
an increase of the expression TrkB-T1 in the group with schizophrenia compared to the 
group control by WB (see Figure 5-10 A). Therefore a Student's t-test was performed to 
determinate whether the difference between the two groups was significant. A 
significant increase of the mean of the ratio TrkB-T1/β-actin (t(21) = 2.741, p = 0.012) 
was revealed using Student's t-test in the group with schizophrenia compared to 
control. For the co-IP experiments the chart representing the the difference of the 
means of TrkB-T1 between diagnosis showed a decrease of the ratio TrkB-T1 in the 
group with schizophrenia compared to the group control (see Figure 5-10 B). Student's 
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t-test revealed a significant decrease of the expression of TrkB-T1 for the group with 
schizophrenia compared to the group control (t(26) = 2.384, p = 0.025) and the group 
with bipolar disorder (t(20.60) = 2.101, p = 0.048). No significant difference of the 
mean of the ratio T-TrkB/β-III-tubulin was observed for the group with major 
depressive disorder compared to the group control or the group with bipolar disorder. 
 
 
Figure 5-10: Mean (± SEM) ratios TrkB-T1/β-actin and TrkB-T1/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on diagnosis. 
(A) Mean ratio TrkB-T1/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB-T1/β-III-
tubulin after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) major depressive 
disorder ; (con) control ; (scz) schizophrenia. An ANCOVA statistical analysis was performed 
with the pH of the brain and the age at death, PMI, death by suicide as co-variables 
respectively for TrkB/β-actin (see Table 5-5) and TrkB/β-III-tubulin (see Table 5-5 and Figure 
5-13 B), no significant differences were found between diagnosis. 
 
The expression of TrkB-T1 by gender was compared for both WB and co-IP 
experiments (see Figure 5-11 A and B). No significant difference of the expression of 
TrkB-T1 (t(48) = 0.910, p = 0.367) was observed by WB whereas a trend towards a 
significant decrease of the expression of TrkB-T1 (t(54) = 1.879, p = 0.435) in female 
was revealed with the co-IP experiment. Comparison of the mean of the ratios TrkB-
A B
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T1/β-actin (t(48) = 1.161, p = 0.252) and TrkB-T1/β-III-tubulin (t(54) = 1.050, p = 0.299) 
in the right or the left cerebral hemisphere did not reveal any cerebral laterisation of 
the expression of TrkB-T1 with both WB and co-IP experiments (see Figure 5-11 C and 
D). 
 
 
Figure 5-11: Mean (± SEM) ratios TrkB-T1/β-actin and TrkB-T1/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on gender and side of the cerebral hemisphere. 
(A) Mean ratio TrkB-T1/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB-T1/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio TrkB-T1/β-actin after WB of the PSD 
fraction. (D) Mean ratio TrkB-T1/β-III-tubulin after co-IP of the PSD fraction. 
 
A B
C D
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To determine whether the psychotic symptoms have an effect on the dependent 
variables TrkB-T1/β-actin and TrkB-T1/β-III-tubulin respectively for WB experiments 
(see Figure 5-12 A) and co-IP experiments (see Figure 5-12 B) Student's t-test analysis 
was performed. For this study the group control was removed from the analysis. No 
significant effect of psychosis was found for both ratios TrkB-T1/β-actin (t(36) = 1.150, 
p = 0.258) and TrkB-T1/β-III-tubulin (t(39) = 0.417, p = 0.679). 
 
 
Figure 5-12: Mean (± SEM) ratios TrkB-T1/β-actin and TrkB-T1/β-III- in the PSD fraction and 
co-IP PSD depending on psychotic symptoms. 
(A) Mean ratio TrkB-T1/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB-T1/β-III-
tubulin after co-IP of the PSD fraction. 
 
The expression of TrkB-T1 was measured for both groups death by suicide or not with 
both WB and co-IP experiments (see Figure 5-13). Student's t-test analysis revealed a 
trend towards a significant decrease of the mean of the ratio TrkB-T1/β-actin (t(48) = 
1.701, p = 0.095) in the group with death by suicide when the group control was 
included in the study (see Figure 5-13 A). A significant decrease of the mean of the 
ratio TrkB-T1/β-actin (t(26.55) = 2.745, p = 0.011) in the group with death by suicide 
when the group control was removed (see Figure 5-13 C). For the co-IP experiment a 
A B
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significant increase of the expression of TrkB-T1 in the group with death by suicide was 
found for both TrkB-T1/β-III-tubulin (t(54) = 2.528, p = 0.014) and TrkB-T1/β-III-tubulin 
(t(39) = 3.289, p = 0.002) respectively with (see Figure 5-13 B) or without (see Figure 
5-13 D) the group control. 
 
 
Figure 5-13: Mean (± SEM) ratios TrkB-T1/β-actin and TrkB-T1/β-III- in the PSD fraction and 
co-IP PSD depending on death by suicide. 
(A) Mean ratio TrkB-T1/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB-T1/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio TrkB-T1/β-actin after WB of the PSD 
fraction (without controls). (D) Mean ratio TrkB-T1/β-III-tubulin after co-IP of the PSD 
fraction (without controls). Statistical Student's t test (* p<0.05; ** p<0.01). 
 
*
A B
C D
*
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The effects of the severity of substance and alcohol abuse on the expression of TrkB-T1 
were assessed for both both WB (see Figure 5-14 A and C) and co-IP (see Figure 5-14 B 
and D) experiments with one-way ANOVA statistical test.  
 
 
Figure 5-14: Mean (± SEM) ratios TrkB-T1/β-actin and TrkB-T1/β-III-tubulin in the PSD 
fraction and co-IP PSD depending on severity of substance and alcohol abuse. 
(A) Mean ratio TrkB-T1/β-actin after WB of the PSD fraction. (B) Mean ratio TrkB-T1/β-III-
tubulin after co-IP of the PSD fraction. (C) Mean ratio TrkB-T1/β-actin after WB of the PSD 
fraction. (D) Mean ratio TrkB-T1/β-III-tubulin after co-IP of the PSD fraction. 
 
No significant difference was found for both TrkB-T1/β-actin (Substance abuse: F(4, 45) 
= 0.212, p = 0.931; Alcohol abuse: F(5, 44) = 0.654, p = 0.660) and TrkB-T1/β-III-tubulin 
A B
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(Substance abuse: F(4, 50) = 2.199, p = 0.083; Alcohol abuse: F(5, 50) = 0.500, p = 
0.775) neither for the effect of the severity of substance abuse (see Figure 5-14 A and 
B) nor the effect of the severity of alcohol abuse (see Figure 5-14 C and D). 
To identify a correlation between the expression of TrkB-T1/β-actin and TrkB-T1/β-III-
tubulin with the effect of the severity of substance and alcohol abuse a non-parametric 
correlation analysis of Spearman was performed. No significant correlation was 
observed between the severity of substance abuse and both ratios TrkB-T1/β-actin 
(ρ(50) = 0.018; p = 0.900) and TrkB-T1/β-III-tubulin (ρ(55) = -0.065; p = 0.639). Neither 
the ratio T-TrkB/β-actin (ρ(50) = 0.089; p = 0.538) nor the ratio TrkB-T1/β-III-tubulin 
(ρ(56) = -0.130; p = 0.340) were significantly correlated with an increase of the severity 
of alcohol abuse. 
 
Table 5-5: Correlational effects of demographic and peri-mortem factors on the ratios TrkB-
T1/β-actin and TrkB-T1/β-III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
TrkB-T1/β-actin (n=50) 0.072 -0.394** 0.029 -0.109 0.121 
TrkB-T1/β-III-tubulin 
(n=56) 
-0.305* 0.061 0.106 -0.315* -0.075 
*p<0.05; **p<0.01 
 
The effects of age at death, pH of the brain, mass of the brain, PMI and duration of 
storage of the brain for both TrkB-T1/β-actin and TrkB-T1/β-III-tubulin were examined 
with non-parametric correlation analysis. A significant negative correlation was found 
between the pH of the brain and the ratio TrkB-T1/β-actin (ρ(50) = -0.394; p = 0.005) 
whereas age at death, mass of the brain, PMI and duration of storage of the brain 
The glutamate post-synaptic density in schizophrenia 
192 
 
were found to have no effect. The pH of the brain, mass of the brain and duration of 
storage of the brain were found to have no effect on expression of TrkB-T1/β-III-
tubulin whereas a decrease of the expression of TrkB-T1 was significantly correlated 
with an increase of the age at death (ρ(56) = -0.305; p = 0.022) and the post-mortem 
interval (ρ(56) = -0.315; p = 0.018) (see Table 5-5). 
For the effects of age at death, age of onset of disease, duration of diseases and life 
time quantity of fluphenazine or equivalent on the expression of TrkB-T1 the group 
control was removed and were also examined with non-parametric correlation 
analysis. A significant negative correlation was found between age at death and the 
ratio TrkB-T1/β-III-tubulin (ρ(41) = -0.420; p = 0.009). Age of onset of disease, duration 
of diseases and life time quantity of fluphenazine or equivalent were found to have no 
effect on the ratio TrkB-T1/β-III-tubulin. Age at death, age of onset of disease, duration 
of diseases and life time quantity of fluphenazine or equivalent were found to have no 
effect on the the ratio TrkB-T1/β-actin (see Table 5-6). 
 
Table 5-6: Correlational effects of demographic and peri-mortem factors on the ratios T-
TrkB/β-actin and T-TrkB/β-III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
TrkB-T1/β-actin (n=38) 0.109 0.237 0.021 0.198 
TrkB-T1/β-III-tubulin 
(n=41) 
-0.420** -0.244 -0.082 0.015 
**p<0.01 
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To summarise the expression of TrkB-T1/β-III-tubulin was significantly affected by 
demographic and peri-mortem factors death by suicide, age at death and PMI for the 
co-IP experiments whereas for the expression of TrkB-T1/β-actin with the pH of the 
brain. Consequently an ANCOVA statistical analysis was performed to assess whether 
any significant difference of the mean of TrkB-T1/β-actin and TrkB-T1/β-III-tubulin for 
each diagnosis group would appear with the effect of demographic and peri-mortem 
factors as co-variables. No significant difference between diagnosis was found for 
TrkB-T1/β-actin (F(3, 45) = 1.470, p = 0.235) and for TrkB-T1/β-III-tubulin (F(3, 49) = 
2.209, p = 0.099) with the effect of demographic and peri-mortem factors as co-
variables. 
 
5.4.4 Expression of p75 within the PSD 
 
 
Figure 5-15: Mean (± SEM) ratio p75/β-III-tubulin co-IP PSD depending on diagnosis. 
Mean ratio p75/β-III-tubulin after co-IP of the PSD fraction. (bpd) bipolar disorder ; (mdd) 
major depressive disorder ; (con) control ; (scz) schizophrenia. 
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For the WB experiments the signal from p75 was not ditinguishable from the 
background of the membranes, consequently the analysis of the expression of p75 was 
only carried out using co-IP experiments. The mean of the ratio p75/β-III-tubulin was 
compared between each diagnosis groups using one-way ANOVA statistical test (see 
Figure 5-15). For the ratio p75/β-III-tubulin (F(3, 45) = 0.191, p = 0.902) no significant 
changes between diagnosis were found. 
 
 
Figure 5-16: Mean (± SEM) ratio p75/β-III-tubulin co-IP PSD depending on gender, side of the 
cerebral hemisphere and psychotic symptoms. 
(A) Mean of p75/β-III-tubulin after co-IP of the PSD fraction (gender). (B) Mean ratio p75/β-
III-tubulin after co-IP of the PSD fraction (cerebral hemisphere) (C) Mean ratio p75/β-III-
tubulin after co-IP of the PSD fraction (psychosis). 
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C
Expression of neurotrophin receptors in the premotor cortex in schizophrenia 
195 
 
The effects of gender (see Figure 5-16 A), the side of the cerebral hemisphere (see 
Figure 5-16 B) on the ratio p75/β-III-tubulin were examined with Student's T-test 
analysis. No significant effect of gender was found for both p75/β-III-tubulin (t(47) = 
1.141, p = 0.260). A trend towards a decrease of the ratio p75/β-III-tubulin (t(30.88) = 
1.707, p = 0.098) was found in the left side of cerebral premotor cortex. 
For the effect of psychotic symptoms the group control was removed from the analysis 
(see Figure 5-16 C). Student's t-test analysis did not show any significant effect of 
psychosis on the ratio p75/β-III-tubulin (t(34) = 0.686, p = 0.497). 
 
 
Figure 5-17: Mean (± SEM) ratio p75/β-III-tubulin co-IP PSD depending on death by suicide 
(co-IP). 
(A) Mean ratio p75/β-III-tubulin after co-IP of the PSD fraction. (B) Mean ratio p75/β-III-
tubulin after co-IP of the PSD fraction (without controls). 
 
For the effect of death by suicide on the ratio p75/β-III-tubulin (see Figure 5-17 A and 
B), a Student's t-test analysis was carried out with and without the group control. No 
significant effect of death by suicide was found for the ratio p75/β-III-tubulin (t(47) = 
1.651, p = 0.105) with the group control. Student's t-test for the ratio p75/β-III-tubulin 
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without the group control revealed a trend (t(19.18) = 1.888, p = 0.074) towards a 
significant decrease in the group without death by suicide. 
One-way ANOVA statistical test was performed to compare the mean of the ratio 
p75/β-III-tubulin between each severity of substance (see Figure 5-18 A) and alcohol 
(see Figure 5-18 B) abuse. No significant difference between the means of the ratio 
p75/β-III-tubulin either for effect of the severity of substance abuse (F(4, 43) = 0.941, p 
= 0.450) or the effect of the severity of alcohol abuse (F(5, 43) = 0.812, p = 0.548) was 
observed. 
 
 
Figure 5-18: Mean (± SEM) ratio p75/β-III-tubulin co-IP PSD depending on severity of 
substance and alcohol abuse. 
(A) Mean ratio p75/β-III-tubulin after co-IP of the PSD fraction (substance abuse). (B) Mean 
ratio p75/β-III-tubulin after co-IP of the PSD fraction (alcohol abuse). 
 
To identify an eventual correlation between the expression of p75 with the effect of 
the severity of substance and alcohol abuse a non-parametric correlation analysis of 
Spearman was performed. No correlation was found between the mean of the ratio 
p75/β-III-tubulin either for the effect of the severity of substance abuse (ρ(48) = 0.094; 
p = 0.524) or the effect of the severity of alcohol abuse (ρ(49) = -0.050; p = 0.735). 
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Table 5-7: Correlational effects of demographic and peri-mortem factors on the ratio p75/β-
III-tubulin. 
Spearman's correlation 
Age at 
death 
pH 
Mass of 
the brain 
PMI Storage 
p75/β-III-tubulin (n=49) -0.117 0.175 0.090 -.0173 -0.024 
 
The effects of the age at death, the pH of the brain, the mass of the brain, the PMI and 
the duration of storage of the brain for the p75/β-III-tubulin were examined with non-
parametric correlation analysis. No significant correlation was found between the ratio 
p75/β-III-tubulin and the demographic and peri-mortem factors (see Table 5-7). 
The effects of age at death, age of onset of disease, duration of diseases and life time 
quantity of fluphenazine or equivalent for both β-actin and p75/β-III-tubulin were also 
examined with non-parametric correlation analysis. No significant correlation was 
found between the ratio p75/β-III-tubulin and the demographic and peri-mortem 
factors (see Table 5-8). 
 
Table 5-8: Correlational effects of demographic and peri-mortem factors on the ratio p75/β-
III-tubulin (without controls). 
Spearman's correlation 
Age at 
death 
Age of 
onset of 
disease 
Duration 
of disease 
Life time quantity of 
fluphenazine or 
equivalent 
p75/β-III-tubulin (n=36) -0.253 -0.320 -0.063 -0.208 
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To summarise the expression of p75 was not significantly affected by any of the 
demographic and peri-mortem factors and subsequently no ANCOVA statistical 
analysis was performed. 
 
5.5 Discussion and conclusions 
 
This part of the thesis has established: 
1. That the expression of neurotrophic receptors involved in synaptic plasticity 
TrkB, T1-TrkB and p75 is not disturbed in any psychiatric disorder tested in 
this study compared to healthy control. 
2. That intra-post-synaptic expression of the neurotrophic receptor T1-TrkB is 
decreased in bipolar disorder and schizophrenia when only compared to 
healthy control. 
3. That extra-post-synaptic expression of the neurotrophic receptor T1-TrkB is 
increased schizophrenia when only compared to healthy control. 
 
Previous postmortem studies of TrkB have revealed a decrease in its expression in 
several regions of the brain in schizophrenia. One study assessed TrkB protein in the 
anterior cingulate cortex and hippocampus and found reduced expression in both 
regions (Takahashi et al., 2000). In another study, the distribution and localisation of 
TrkB in the hippocampal formation was assessed in schizophrenia. They immuno-
labelled TrkB-positive neurons showed a signet-ring like shape in the hippocampus of 
healthy individual brains whereas no such findings were observed in neurons from 
schizophrenic patient brains (Iritani et al., 2003). These studies indicate that TrkB 
function may be disturbed in patients with schizophrenia. However, a study using 
immunohistochemistry and immunoblotting to quantify protein expression of TrkB in 
the cerebellum found reductions in TrkB expression in bipolar disorder, but not 
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schizophrenia (Soontornniyomkij et al., 2011). This study suggests that the expression 
of TrkB may be disturbed in a regionally specific manner in schizophrenia. 
A study investigating TrkB mRNA expression suggested specific cell type disturbance in 
the DLPFC of patients with schizophrenia. The authors measured TrkB mRNA levels 
using in situ hybridisation. TrkB mRNAs were detected in large and small neurons in 
multiple cortical layers of the human DLPFC. They found significantly reduced 
expression of TrkB mRNA in large neurons in multiple cortical layers of patients with 
schizophrenia whereas the decrease of TrkB mRNA within the small neurons was not 
statistically significant (Weickert et al., 2005). Since neurons in the DLPFC integrate and 
communicate signals to various cortical and subcortical regions, these cell-type 
associated reductions in TrkB receptor may compromise the function and plasticity of 
the DLPFC and other areas of the brain in schizophrenia. A study reported a specific 
regional disturbance in the expression of TrkB mRNA within the hippocampus. Using in 
situ hybridisation in dentate gyrus, cornu ammonis subfields (CA1-4) subiculum and 
associated entorhinal cortex they found that the expression of TrkB mRNA was only 
reduced in CA4 in patients with schizophrenia compared with healthy subjects (Ray et 
al., 2011). Abnormal TrkB expression in specific region of the hippocampus of 
individuals with schizophrenia indicates that fundamental properties of hippocampal 
signalling transmission and plasticity may be affected in a specific neuronal network. 
In the present study our measurement of TrkB protein levels within the PSD using co-IP 
and WB did not show any significant changes in the expression of TrkB in the premotor 
cortex of patients with any psychiatric disorders (see section 5.4.2). However, a trend 
increase in the expression of TrkB in the premotor cortex of patients with 
schizophrenia was found compared to bipolar disorder (F(3, 49) = 3.411, p = 0.059) and 
healthy individuals (F(3, 49) = 3.411, p = 0.078). The difference between the results 
obtained by co-IP and WB may be due the presence of glial contaminants in the PSD 
fraction, as glial cells express TrkB (Frisen et al., 1993). Also, the fact that we did not 
find any significant change in the expression of TrkB in the premotor cortex may be 
due to disease-associated regionally specific expression changes.  
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The heterozygous reeler mouse has been used as an animal model for schizophrenia 
based on several neuropathological and behavioural abnormalities homologous to 
schizophrenia. A study showed that in these mice both mRNA and protein levels of 
TrkB-T1 were significantly higher in the PFC (Pillai and Mahadik, 2008). For TrkB-T1, 
postmortem studies have reported variable results in schizophrenia depending on the 
area of the brain studied. A study using qPCR reported increased expression of TrkB-T1 
mRNA in the DLPFC of patients with schizophrenia. In addition this study showed a 
significant decreases of the ratio TrkB/TrkB-T1 in schizophrenia for both mRNA and 
protein expression (Wong et al., 2011). This study suggests that an imbalance of the 
neurotrophin receptors may be implicated in the pathophysiology of schizophrenia. 
However, a recent study using formalin-fixed paraffin-embedded hippocampal sections 
and immunoautoradiography revealed no changes in TrkB-T1 expression in 
schizophrenia (Dunham et al., 2009). 
In the present study, neither co-IP nor WB of the PSD showed any significant change in 
the expression of TrkB-T1 for any of the psychiatric disorders (see section 5.4.3). 
However, using Student's t-test, co-IP of the PSD revealed that the expression of TrkB-
T1 was significantly reduced in schizophrenia compared to healthy individuals (t(26) = 
2.384, p = 0.025) and bipolar disorder (t(20.60) = 2.101, p = 0.048). By contrast for WB, 
a significant increase (t(21) = 2.741, p = 0.012) was revealed using Student's t-test for 
schizophrenia relative to healthy subjects. These results suggest that the expression of 
TrkB-T1 may be disturbed in schizophrenia and that the level of expression of TrkB-T1 
may differ depending on the sub-cellular localisation.  
No significant changes in expression levels for p75 were found in the heterozygous 
reeler mouse model of schizophrenia (Pillai and Mahadik, 2008). In addition, a 
postmortem study using immunoautoradiography showed no change of the expression 
of p75 in the hippocampus of patients with schizophrenia (Dunham et al., 2009). In the 
present study the expression of p75 was decreased in major depressive disorder and 
schizophrenia compared to healthy subjects (see section 5.4.4), however these did not 
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reach statistical significance. These results suggest that the expression of p75 is not 
altered in the premotor cortex of patients with schizophrenia. 
Taken together, previous studies and findings from the present study suggest that 
neurotrophin receptors may be disturbed in schizophrenia in a regional and/or cellular 
specific manner. In the premotor cortex none of the neurotrophin receptors tested 
was altered in schizophrenia relative to major depressive disorder, bipolar disorder 
and healthy controls. However the expression of TrkB-T1 was altered when the 
schizophrenia group was assessed separately relative to controls. This contributes to 
previous evidence that an imbalance between the neurotrphin receptor subtypes may 
occur in schizophrenia. 
 
  
 
6 General conclusions and future work 
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The aims of the studies presented in this thesis were to determine a possible change in 
the expression of proteins of the PSD involved in glutamatergic synaptic plasticity in 
premotor cortex in schizophrenia. Firstly, the method used to extract and purify the 
PSD was characterised using WB and TEM. Then protein expression studies were 
carried out using WB and co-IP. The ratio of NMDAR subunit NR2A, PSD-95, CaMKIIα, 
CaMKIIβ, NSF, TrkB, TrkB-T1 and p75 with β-actin and β-tubuin respectively for WB and 
co-IP was compared between schizophrenia, major depressive disorder, bipolar 
disorder and healthy controls. 
6.1 Extraction and characterisation of the PSD fractions 
6.1.1 Protocol of extraction of PSD 
The method based on sucrose gradient separation developed in the present study to 
extract the PSD from human premotor cortex may be used to the parallel identiﬁcation 
of compositional and post-transcriptional changes of proteins within the PSDs. Semi-
quantitative analysis of protein levels as well as post-transcriptional modiﬁcations such 
as phosphorylation between different protein mixtures may become a powerful tool 
for human postmortem studies of the diturbances of the glutamatergic system 
associated with psychiatric disorders. Indeed, a typical PSD preparation uses brain 
tissue in gram quantities (Carlin et al., 1980; Hahn et al., 2009) whilst the present study 
only uses a few milligrams. 
 
6.1.2 Characterisation of the PSD fractions 
 
 Transmission Electron Microscopy 
The presence of the PSDs from extracted PSD fractions was confirmed using TEM. The 
electron micrographs showed a heterogenic composition of the PSD. Indeed PSDs were 
detected, in addition to contaminants that resembled CaMKII clusters, mitochondria, 
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myelin and membrane vesicles. These results were in-line with previous studies using 
the same PSD isolation technique (Dosemeci et al., 2006).  
 
 Western Blotting 
The PSD-95, NR2A of the NMDAR, and subunits 2, 3 and 4 of AMPAR were all detected 
and enriched in the PSD fractions. Semi-quantitative analysis of the amount of PSD-95, 
NR2A and AMPAR subunits was carried out from six independent experiments of the 
isolation of the PSDs. The results showed a significant increase of the expression of 
PSD-95, NR2A and AMPAR in the PSD fractions compared to the total fractions. These 
results are in concordance with previous studies (Villasana et al., 2006; Hahn et al., 
2009). 
The presence of contaminants in the PSD fraction was also assessed. The pre-synaptic 
vesicle marker, synaptophysin, the cytoskeletal protein β-III-tubulin and a marker of 
astroglial cells, GFAP, were all immunodetected in the PSD fractions, similar to results 
obtained in previous studies (Dosemeci et al., 2006; Hahn et al., 2009), but 
contradictory with another study that used another type of PSD isolation (Villasana et 
al., 2006).  
The present study demonstrated that:  
1. PSDs can be isolated from frozen blocks of human premotor cortex in 
reasonable purity using the protocol developed by Dosemeci et al. 2006.  
2. The method used allowed us to use a minimal amount of human brain sample 
and obtain reasonable yield and purity of the PSD fraction. 
3. The application of the same strategy for the puriﬁcation of PSDs from 
hippocampal slices. While, as demonstrated, this highly puriﬁed preparation 
can be used in applications such as westerns for the quantiﬁcation of selected 
proteins, the very low yields are, at the present, incompatible with 
quantitative proteomic applications. 
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6.2 Expression of proteins of the PSD involved in synaptic plasticity 
Sixty human premotor cortex (BA 6) provided from the Stanley Consortium 
postmortem brain collection were used for the present study. PSD extraction was 
carried out using premotor cortex tissue from 15 patients with schizophrenia, 15 
patients with major depressive disorder, 15 patients with bipolar disorder and 15 non-
psychiatrically ill subjects. The expression of NR2A, PSD-95, CaMKIIα, CaMKIIβ, NSF, 
TrkB, TrkB-T1 and p75 was semi-quantified using WB and co-IP. Differences between 
WB and co-IP methods were found. Possibly due to differences in the abundance of 
proteins docked at the synapse versus those at extra-synaptic or intracellular locations; 
or due to improved purity of the PSD after co-IP. The results obtained by co-IP were 
considered more appropriated to study the expression of NMDAR subunit NR2A, PSD-
95, CaMKIIβ, NSF, TrkB, TrkB-T1 and p75 within the PSDs as discussed below. 
 
 Compared to healthy subjects the expression of NR2A, PSD-95, CaMKIIβ and 
TrkB-T1 were reduced in the premotor cortex of patients with schizophrenia 
using co-IP.  
 
6.2.1 Expression of NR2A 
 The expression of NR2A subunit is decreased in premotor cortex of patients 
with schizophrenia 
The NMDAR is a critical post-synaptic mediator of activity-dependent synaptic 
plasticity. Disturbance in the stochiometry of this ion channel may affect its Ca2+ 
permeability and the downstream signalling pathways. The NR1 subunit is associated 
with different intracellular signalling pathways (Bradley et al., 2006) and NR2A subunit 
confers different biophysical and pharmacologic properties to the channel (Lynch and 
Guttmann, 2001). NMDARs require postsynaptic depolarization to remove the Mg2+ 
ion that block the pore of the ionotropic receptor at resting membrane potential and 
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also require the binding of two agonists, glutamate (NR2 subunits), and either glycine 
or D-serine, at the glycine modulatory site (NR1 subunit) (Tsien, 2000).  
Imbalance in the stochiometry of the NMDAR subunits may disturb intracellular 
signalling pathways involved in synaptic plasticity (Greer and Greenberg, 2008; 
Wayman et al., 2008). NR2A and NR2B subunits confer distinct properties to NMDA 
receptors; heteromers containing NR1 plus NR2B mediate a current that decays three 
to four times more slowly than receptors composed of NR1 plus NR2A (Paoletti and 
Neyton, 2007). A decreased expression of NR2A at the PSD may lead to to a 
hypoactivity of the NMDAR as well as of the synaptic activity.  
 
6.2.2 Expression of PSD-95 
 The expression of PSD-95 is decreased in premotor cortex of patients with 
schizophrenia 
The MAGUK protein PSD-95, is a major scaffolding protein of the PSD (Cho et al., 
1992b) which contains several PDZ and protein-protein interaction domains that 
stabilise interactions between neurotransmitter receptors, synaptic adhesion 
receptors, and actin-associated scaffolding molecules (Ethell and Pasquale, 2005). 
Studies have shown that the density and size of dendritic spines is reduced in cultured 
neurons with knockdown of PSD-95 (Ehrlich et al., 2007). In addition stimuli that 
normally promote LTP in hippocampal slices instead lead to spine destabilization in 
PSD-95 knockdown neurons (Ehrlich et al., 2007). These studies emphasise the 
important role of PSD-95 in activity-dependent synapse stabilisation. The reduction of 
PSD-95 in the PSD of premotor cortex neurons in patients with schizophrenia may lead 
to a dysfunction in synaptic plasticity mechanisms.  
DISC1 has also been reported to be enriched in PSD fraction where it interacts with 
PSD-95 (Hayashi-Takagi et al., 2010). DISC1 also interacts with Kalirin-7, a GDP/GTP 
exchange factor for the small G protein Rac1, regulator of spine morphology and 
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plasticity (Hayashi-Takagi et al., 2010). Evidence suggests that DISC1 anchors Kal-7 to 
PSD-95, thereby sequestering Kal-7 to the PSD and preventing it from activating Rac1. 
This complex is modulated by neuronal activity, particularly NMDA receptor-
dependent activity, which regulates Rac-1 mediated changes in spine morphology. 
Therefore disturbances of the expression of NR2A and PSD-95 observed in this study 
suggest that the function and morphology of the synapses may be affected in the 
premotor cortex of patients with schizophrenia. 
 
6.2.3 Expression of CaMKIIα and CaMKIIβ 
 The expression of CaMKIIβ is decreased in premotor cortex of patients with 
schizophrenia 
CaMKII, a calcium-calmodulin protein kinase involved in synaptic plasticity (Colbran 
and Brown, 2004; Fink and Meyer, 2002; Hudmon and Schulman, 2002) consists mainly 
of CaMKIIα and CaMKIIβ isoforms in the CNS. CaMKIIβ is expressed during 
neurodevelopment and adulthood, whereas CaMKIIα is only expressed after birth (Fink 
et al., 2003; Lin and Redmond, 2008). The expression of CaMKIIα is correlated with the 
size of dendritic spines (Asrican et al., 2007) and the inhibition of CaMKIIα activity in 
mature neuronal cultures can reduce the activity-induced dendritic spine enlargement 
and stabilisation (Yamagata et al., 2009; Zha et al., 2009). In the present study we did 
not find any changes in the expression of CaMKIIα in the premotor cortex of patients 
with schizophrenia using WB. However this isoform could not be studied further using 
co-IP as the signal was indistinguishable from the heavy chain of the antibody used for 
the co-IP experiment. Cross-linking of the PSD-95 antibodies to the beads used to co-
immunoprecipitate the PSD may solve this issue and may revealed disturbances in the 
expression of CaMKIIα that were not observed using WB. 
The protein kinase CaMKIIβ contains a specific F-actin-binding domain that directly 
regulates F-actin and hence the stability of dendritic spines (Shen et al., 1998). A 
recent study revealed that knockdown of CaMKIIβ in hippocampal slices leads to a 
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significant loss of mature spines, transforming them into immature dendritic filopodia 
(Okamoto et al., 2007). Reduced expression of CaMKIIβ observed in our study suggests 
that dendritic spine stability may be affected in the premotor cortex of patients with 
schizophrenia. 
 
6.3 Expression of neurotrophic receptors involved in synaptic plasticity 
 The expression of TrkB-T1 is decreased in premotor cortex of patients with 
schizophrenia 
Tropomyosin receptor kinase B (TrkB) is the receptor for the neurotrophin BDNF. In 
humans, three major isoforms of TrkBs, the full-length receptor (TrkB) and two C-
terminal truncated receptors (TrkB-T1- and TrkB-Shc) are expressed in various tissues 
including in the CNS (Wong and Garner, 2012). These neurotrophin receptors activate 
different signalling pathways implicated in cell survival and cell differentiation 
mechanisms implicated in synaptic plasticity (Atwal et al., 2000). In the present study 
no changes in expression for the neurotrophin receptor TrkB, were found in the 
premotor cortex of patients with schizophrenia. TrkB is involved in BDNF -induced 
trafficking of AMPARs via interaction between NSF an ATPase and also stabilisation of 
surface AMPARs and the AMPAR subunit GluR2, important in different forms of 
synaptic plasticity (Narisawa-Saito et al., 2002). A recent study showed that 
disturbance of the interaction of NSF with the GluR2 subunit of AMPARs, promoted 
extensive loss of surface GluR2 in rat hippocampal neurons and decreased synaptic 
AMPAR current (Evers et al., 2010). Our study did not reveal any change of the 
expression of NSF in the premotor cortex of patients with schizophrenia. In summary, 
our results suggest that the NMDAR complex seems to be affected in the premotor 
cortex of patients with schizophrenia whereas the AMPAR complex may not. 
The neurotrphin receptor p75 which binds pro-neurotrophin factors is implicated in 
neural cell death and activates death signalling pathway mediated via one or more of 
the intracellular receptor binding partners (Itself, TrkB or other synaptic receptors), 
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resulting in c-jun kinase (JNK) activation, and subsequent p53, Bax-like proteins and 
caspase activation (Roux and Barker, 2002; Coulson et al., 2004). In our study no 
significant changes in the expression of p75 were found in the premotor cortex of 
patients with schizophrenia. 
In contrast with previous neurotrophin receptor studies, TrkB-T1 was downregulated 
in the premotor cortex of patients with schizophrenia in the present study. The role of 
the neurotrophin receptor TrkB-T1 is still unclear, however evidence is accumulating 
that it plays a role in synaptic plasticity. For example, knockdown of TrkB-T1 in mice 
was associated with increased anxiety and reduced length and complexity of neurites 
in the amygdala but not hippocampus. The authors also showed that TrkB-T1 regulates 
TrkB activity (Carim-Todd et al., 2009). Our findings suggest that the balance of 
neurotrophin receptors may be disturbed at the PSD of neurons and may affect 
neuronal synaptic plasticity in the premotor cortex of patients with schizophrenia. 
 
6.4 Expression of proteins implicated in synactic plasticity in 
schizophrenia compared to other psychiatric disorders 
 The expression of NR2A is decreased in premotor cortex of patients with 
schizophrenia and major depressive disorder but not bipolar disorder 
The expression of NR2A, PSD-95, CaMKIIα, CaMKIIβ, NSF, TrkB, TrkB-T1 and p75 was 
also assessed in major depressive disorder and bipolar disorder.  
Expression of the NR2A subunit of NMDAR was significantly decreased in major 
depressive disorder compared to healthy subject smilar to findings for schizophrenia. 
Furthermore, a significant decrease in the expression of NR2A was observed in 
schizophrenia compared to bipolar disorder.  
Dysfunction of glutamatergic function in major depressive disorder and bipolar has 
been recently suggested (Hashimoto, 2009; Chen et al., 2010). The present findings 
report a lack of changes in the abundance of glutamate-related PSD proteins in bipolar 
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disorder in the premotor cortex. In contrast, it appears that major depressive disorder 
may share common disturbances in NR2A and NMDAR function with schizophrenia. 
However, the additional decreases in PSD-95, CaMKIIβ and TrkB-T1 in schizophrenia, 
but not major depressive disorder, suggests that dysfunction of the glutamatergic 
system in the premotor cortex in schizophrenia is more severe. 
 
6.5 Conclusion 
In the present thesis, the studies revealed that extraction and co-IP were suitable 
techniques for the study of proteins of the PSD from postmortem brains samples and 
that function of the proteins involved in synaptic plasticity may be disturbed in the 
premotor cortex of patients with schizophrenia. In addition, the number of PSD 
proteins that were affected in schizophrenia was much greater than for the affective 
disorders. This provides further evidence to suggestions that dysfunction of the 
glutamatergic system is a core feature of the pathophysiology of schizophrenia. 
 
 The present findings demonstrate a significant alteration of specific molecular 
mechanisms implicated in synaptic plasticity in the premotor cortex of 
patients with schizophrenia. 
 
Despite the contribution this study has made to the already large literature of NMDAR 
function in schizophrenia, the understanding of the possible causes and consequences 
NMDAR and associated proteins remains only speculative. Such findings must be 
accompanied by more detailed investigation in other brain areas such as PFC, temporal 
cortex and cerebellum. Furthermore investigation of the expression of other proteins 
of the PSD such as Homer, GKAP1 and Shank and of the phosphorylation status of 
these proteins may provide further insights into the pathophysiological mechanisms of 
schizophrenia. 
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Appendix A : Pictures of the membranes obtained for the 
characterisation of the PSD fractions 
A.1 Detection of PSD-95, tubulin and actin 
 
Figure A-1: Digital pictures of the membranes after detection of PSD-95, tubulin and actin. 
(A-F) Experiment 1 (A)  to experiment 6 (F). (L) ladder (KDa); (T) Total fraction; (C) Cytosolic 
fraction; (S) Sucrose 0.32 M fraction; (M) Myelin/light membranes fractions; (W1) wash 1 
fraction; (W2) wash 2 fraction; (W3) wash 3 fraction; (P) PSD fraction. 
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A.2 Detection of NR2A (control) 
 
 
Figure A-2: Digital picture of the membrane after detection of NR2A (control). 
(L) ladder (KDa); (T) Total fraction; (C) Cytosolic fraction; (S) Sucrose 0.32 M fraction; (M) 
Myelin/light membranes fractions; (W1) wash 1 fraction; (W2) wash 2 fraction; (W3) wash 3 
fraction; (P) PSD fraction. 
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A.3 Detection of NR2A 
 
Figure A-3: Digital pictures of the membranes after detection of NR2A. 
(A-F) Experiment 1 (A)  to experiment 6 (F). (L) ladder (KDa); (T) Total fraction; (C) Cytosolic 
fraction; (S) Sucrose 0.32 M fraction; (M) Myelin/light membranes fractions; (W1) wash 1 
fraction; (W2) wash 2 fraction; (W3) wash 3 fraction; (P) PSD fraction. 
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A.4 Detection of synaptophysin 
 
Figure A-4: Digital pictures of the membranes after detection of synaptophysin. 
(A-F) Experiment 1 (A)  to experiment 6 (F). (L) ladder (KDa); (T) Total fraction; (C) Cytosolic 
fraction; (S) Sucrose 0.32 M fraction; (M) Myelin/light membranes fractions; (W1) wash 1 
fraction; (W2) wash 2 fraction; (W3) wash 3 fraction; (P) PSD fraction. syn: synaptophysin 
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A.5 Detection of AMPAR and GFAP 
 
Figure A-5: Digital pictures of the membranes after detection AMPAR and GFAP. 
(A-F) Experiment 1 (A) to experiment 6 (F). (L) ladder (KDa); (T) Total fraction; (C) Cytosolic 
fraction; (S) Sucrose 0.32 M fraction; (M) Myelin/light membranes fractions; (W1) wash 1 
fraction; (W2) wash 2 fraction; (W3) wash 3 fraction; (P) PSD fraction. 
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Appendix B : Pictures of the membranes obtained for the co-IP 
of the PSD fractions 
 
B.1 Detection of PSD-95, NSF and actin 
 
Figure B-1: Digital pictures of the membranes after detection of PSD-95, NSF and actin. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
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B.2 Detection of PSD-95, NSF and actin 
 
 
Figure B-2: Digital pictures of the membranes after detection PSD-95, NSF and actin. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60 
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
 
 
 
A B
C
250
150
100
75
50
37
250
150
100
75
50
37
250
150
100
75
50
37
Psd-95
NSF
HAB
actin
Psd-95
NSF
HAB
actin
Psd-95
NSF
HAB
actin
The glutamate post-synaptic density in schizophrenia 
222 
 
B.3 Detection of tubulin 
 
 
Figure B-3: Digital pictures of the membranes after detection tubulin. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
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B.4 Detection of tubulin 
 
 
Figure B-4: Digital pictures of the membranes after detection tubulin. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60 
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
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B.5 Detection of NR2A 
 
 
Figure B-5: Digital pictures of the membranes after detection of NR2A. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
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B.6 Detection of NR2A 
 
 
Figure B-6: Digital pictures of the membranes after detection of NR2A. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60 
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
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B.7 Detection of p75 
 
 
Figure B-7: Digital pictures of the membranes after detection of p75. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
Ladder in KDa 
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B.8 Detection of p75 
 
 
Figure B-8: Digital pictures of the membranes after detection of p75. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60 
Ladder in KDa 
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B.9 Detection of TrkB, TrkB-T1 and CaMKIIβ 
 
 
Figure B-9: Digital pictures of the membranes after detection of TrkB, TrkB-T1 and CaMKIIβ. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
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B.10 Detection of TrkB, TrkB-T1 and CaMKIIβ 
 
 
Figure B-10: Digital pictures of the membranes after detection of TrkB, TrkB-T1 and CaMKIIβ. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60 
HAB: Heavy chain of the antibody used for co-IP 
Ladder in KDa 
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Appendix C Pictures of the membranes obtained for the WB of 
the PSD fractions 
 
C.1 Detection of PSD-95, NSF, tubulin and actin 
 
Figure C-1: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 1 to 3 (Duplicate); (B) Samples 4 to 6 (Duplicate); (C) Samples 7 to 9 (Duplicate); 
(D) Samples 10 to 12 (Duplicate). 
Ladder in KDa 
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C.2 Detection of PSD-95, tubulin and actin 
 
 
Figure C-2: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 13 to 15 (Duplicate); (B) Samples 16 to 18 (Duplicate); (C) Samples 19 to 21 
(Duplicate); (D) Samples 22 to 24 (Duplicate). 
Ladder in KDa 
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C.3 Detection of PSD-95, tubulin and actin 
 
 
Figure C-3: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 25 to 27 (Duplicate); (B) Samples 28 to 30 (Duplicate); (C) Samples 31 to 33 
(Duplicate); (D) Samples 34 to 36 (Duplicate). 
Ladder in KDa 
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C.4 Detection of PSD-95, tubulin and actin 
 
 
Figure C-4: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 37 to 39 (Duplicate); (B) Samples 40 to 42 (Duplicate); (C) Samples 43 to 45 
(Duplicate); (D) Samples 46 to 48 (Duplicate). 
Ladder in KDa 
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C.5 Detection of PSD-95, tubulin and actin 
 
 
Figure C-5: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 49 to 51 (Duplicate); (B) Samples 52 to 54 (Duplicate); (C) Samples 55 to 57 
(Duplicate); (D) Samples 58 to 60 (Duplicate). 
Ladder in KDa 
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C.6 Detection of PSD-95, tubulin and actin 
 
 
Figure C-6: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
Ladder in KDa 
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C.7 Detection of PSD-95, tubulin and actin 
 
 
Figure C-7: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60. 
Ladder in KDa 
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C.8 Detection of NR2A 
 
 
Figure C-8: Digital pictures of the membranes after detection of NR2A. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
Ladder in KDa 
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C.9 Detection of NR2A 
 
 
Figure C-9: Digital pictures of the membranes after detection of NR2A. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60.  
Ladder in KDa 
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C.10 Detection of TrkB, TrkB-T1, CaMKIIα and CaMKIIβ 
 
 
Figure C-10: Digital pictures of the membranes after detection of TrkB, TrkB-T1, CaMKIIα and 
CaMKIIβ. 
(A) Samples 1 to 9; (B) Samples 10 to 18; (C) Samples 19 to 27; (D) Samples 28 to 36.  
Ladder in KDa 
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C.11 Detection of TrkB, TrkB-T1, CaMKIIα and CaMKIIβ 
 
 
Figure C-11: Digital pictures of the membranes after detection of TrkB, TrkB-T1, CaMKIIα and 
CaMKIIβ. 
(A) Samples 37 to 45; (B) Samples 46 to 54; (C) Samples 55 to 60.  
Ladder in KDa 
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C.12 Detection of TrkB, TrkB-T1 and actin 
 
 
Figure C-12: Digital pictures of the membranes after detection of TrkB, TrkB-T1 and actin. 
(A) Samples 3 to 9; (B) Samples 10 to 18; (C) Samples 19 to 25; (D) Samples 26 to 34.  
Ladder in KDa 
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C.13 Detection of TrkB, TrkB-T1 and actin 
 
 
Figure C-13: Digital pictures of the membranes after detection of TrkB, TrkB-T1 and actin. 
(A) Samples 35 to 43; (B) Samples 44 to 51; (C) Samples 52 to 56; (D) Samples 57 to 60.  
Ladder in KDa 
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C.14 Detection of TrkB, TrkB-T1 and actin 
 
 
Figure C-14: Digital pictures of the membranes after detection of TrkB, TrkB-T1 and actin. 
(A) Samples 3 to 11; (B) Samples 12 to 19; (C) Samples 20 to 27; (D) Samples 28 to 36.  
Ladder in KDa 
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C.15 Detection of TrkB, TrkB-T1 and actin 
 
 
Figure C-15: Digital pictures of the membranes after detection of TrkB, TrkB-T1 and actin. 
(A) Samples 37 to 45; (B) Samples 46 to 52; (C) Samples 53 to 60.  
Ladder in KDa 
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C.16 Detection of CaMKIIα and CaMKIIβ 
 
 
Figure C-16: Digital pictures of the membranes after detection of CaMKIIα and CaMKIIβ. 
(A) Samples 3 to 11; (B) Samples 12 to 19; (C) Samples 20 to 27; (D) Samples 28 to 36.  
Ladder in KDa 
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C.17 Detection of CaMKIIα and CaMKIIβ 
 
 
Figure C-17: Digital pictures of the membranes after detection of CaMKIIα and CaMKIIβ. 
(A) Samples 37 to 45; (B) Samples 46 to 52; (C) Samples 53 to 60.  
Ladder in KDa 
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C.18 Detection of CaMKIIα and CaMKIIβ 
 
 
Figure C-18: Digital pictures of the membranes after detection of CaMKIIα and CaMKIIβ. 
(A) Samples 3to 10; (B) Samples 11 to 18; (C) Samples 19 to 26; (D) Samples 27 to 35.  
Ladder in KDa 
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C.19 Detection of CaMKIIα and CaMKIIβ 
 
 
Figure C-19: Digital pictures of the membranes after detection of PSD-95, NSF, tubulin and 
actin. 
(A) Samples 36 to 43 (B) Samples 44 to 49; (C) Samples 50 to 55; (D) Samples 56 to 60.  
Ladder in KDa 
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